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ABSTRACT 
Mechanisms of variability in CYP2D6 metabolism: the contributions of polymorphisms, 
copy number variations and microRNA 
Anuradha Ramamoorthy 
 
Cytochrome P450 2D6 (CYP2D6) is an important drug metabolizing enzyme that 
is involved in the metabolism of 20-25% of commonly prescribed drugs.  There is 
interindividual variability in CYP2D6 enzyme activity and this leads to compromised 
metabolism of many drugs.  Genetic and environmental factors explain only a part of the 
interindividual variability; the other factors that contribute to this variability are largely 
unknown.  Hence, it becomes important to study CYP2D6 to understand the endogenous 
and exogenous factors that control its activity. 
The specific objective of this research was to determine the contribution of genetic 
and epigenetic factors in the regulation of CYP2D6 expression and activity.  The specific 
aims were: (1) to identify the common CYP2D6 polymorphisms in Vietnamese and 
Filipino women with breast cancer and evaluate its association with plasma 
concentrations of endoxifen (an active metabolite of the breast cancer therapeutic drug, 
tamoxifen); (2) to identify the CYP2D6 copy number variations (CNVs) in these women 
and evaluate their association with endoxifen concentration; and (3) to identify 
microRNAs (miRNAs) that regulate the expression of CYP2D6 directly or indirectly.   
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The results of this study indicated that: (1) in Vietnamese and Filipino women, the 
reduced function allele CYP2D6*10 was frequent (~55%) and it was significantly 
associated with reduced endoxifen concentration; (2) in these women, only 39% carried 
two copies of the CYP2D6 gene, the rest had a genomic imbalance for CYP2D6, 
primarily involving the CYP2D6(*36)n-*10 allele.  However, carrying multiple copies of 
CYP2D6*36 allele did not significantly affect CYP2D6 activity, suggesting that multiple 
copies of a gene does not always translate to additive effects; and (3) microRNAs were 
identified to target HNF4A, a transcriptional factor that regulates CYP2D6 expression.  
These miRNAs are likely to play an important role in the indirect regulation of CYP2D6.   
Taken together, these results emphasize on the role of polymorphisms, CNVs and 
possibly miRNAs in the regulation of CYP2D6.  These clinically important biomarkers 
will help to improve the efficacy and reduce the side effects of many CYP2D6 substrate 
drugs and thus contribute to personalization of drug therapy.   
 
David A. Flockhart, M.D., Ph.D., Chair 
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CHAPTER ONE 
Introduction and Literature Review 
 
Pharmacogenetics of interindividual variability in drug response 
 Genetic polymorphisms in drug metabolizing enzymes (DMEs), drug receptors 
and drug transporters influence an individual‟s ability to metabolize and eliminate drugs.  
These pharmacogenetic variations contribute to interindividual variability in drug 
metabolism and response.  Among the DME genes, the greatest impact is due to 
polymorphisms in drug metabolizing Cytochrome P450s (CYP450s) such as CYP2A6, 
CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, and CYP2D6.  Of these CYP450s, 
polymorphisms in CYP2D6 gene have been extensively studied because of its clinical 
importance, especially in treating patients with drugs such as antidepressants, 
antipsychotics, anticancer agents, etc.  For many CYP2D6 substrate drugs, screening an 
individual‟s CYP2D6 genetic makeup and tailoring drug therapy based on that 
information can decrease the adverse events and increase both clinical and economic 
benefits (Laika et al., 2009). 
 
The cytochrome P450 drug metabolizing enzyme family 
 The cytochrome P450 is a superfamily of heme-thioloate monooxygenase 
enzymes (EC 1.14.14.1) that is involved in the oxidative metabolism of a number of 
endogenous and exogenous compounds like steroids, drugs, carcinogens and mutagens.  
In humans, 57 functional CYP450 genes and 58 pseudogenes have been described 
(Nelson et al., 2004; Guengerich, 2008).  The functional CYP450 genes are expressed in 
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the endoplasmic reticulum of a number of tissues (Nelson et al., 2004).  The liver 
expressed CYP450s include many non-drug and drug metabolizing enzymes (Figure 1.1 
A).  Of the drug metabolizing CYP450s, the clinically important ones include phase I 
DMEs like CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, 
CYP3A4, CYP3A5 and CYP2D6 (Figure 1.1 B).   
  
Figure 1.1 A-B: The liver expressed Cytochrome P450s and their contribution to 
drug metabolism. 
 
 
 
 
 
 
Note: (A) Physical abundance of CYP450 enzymes in the human liver; (B) Percentage of 
clinically important drugs metabolized by the various CYP450 enzymes in the human 
liver.  Source: redrawn from www.pharmacy.wsu.edu/courses/PharS541/Docs/ 
541.05.IV.Role %20of%20Induction%20 &%20Inhibition.htm.   
 
 The drug metabolizing CYP450s are responsible for the metabolism of 40-45% of 
all marketed drugs and 70-80% of all phase I dependent drug metabolism (Ingelman-
Sundberg and Rodriguez-Antona, 2005; Guengerich, 2008).  The activity of these 
CYP450 enzymes determine: (1) the rate of biotransformation of a parent drug into active 
(A) (B) 
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and/or inactive metabolites, (2) the concentration of the drug and/or its metabolites that 
will be achieved in the body, and (3) the rate of elimination of the drug and its 
metabolites. 
 The activity of the drug metabolizing CYP450 enzymes, especially that of 
CYP2D6 is highly variable among individuals (Ingelman-Sundberg, 2005).  Some of this 
variability is due to environmental (including drug-drug interactions) and genetic factors.  
These two factors lead to poor risk/benefit ratio for a number of CYP2D6 substrate drugs 
and can result in unexpected drug effects including, therapeutic failure and adverse drug 
reactions (Rau et al., 2004).  Hence, for practical clinical purposes, it is important to 
understand the factors that contribute to variability in CYP2D6 mediated drug 
metabolism. 
 
CYP2D6 and its role in drug metabolism  
 Cytochrome P450 2D6 (CYP2D6) is a member of the CYP450 superfamily that is 
involved in the metabolism and bioactivation of a number of xenobiotics.  CYP2D6 
accounts for only ~3% of all CYP450 expression in the liver (Figure 1.1 A), but it is 
responsible for the metabolism of about 20-25% of commonly prescribed drugs 
(Ingelman-Sundberg, 2005; Figure 1.1 B).  These include drugs such as antidepressants, 
neuroleptics, opiates, antiarrythmics and antihypertensive agents (Table 1.1).   
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Table 1.1: Major CYP2D6 drug substrates and inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: Redrawn from Cytochrome P450 drug interaction table 
(http://medicine.iupui.edu/clinpharm/ddis/table.asp).   
 
 There is considerable interindividual variability in CYP2D6 enzyme activity 
(Ingelman-Sundberg, 2005).  Based on the enzyme activity, an individual can be 
classified as: (1) ultrarapid metabolizer (UM) with increased enzyme activity, (2) 
extensive metabolizer (EM) with „normal‟ enzyme activity, (3) intermediate metabolizer 
(IM) with decreased enzyme activity, or (4) poor metabolizer (PM) with negligible 
enzyme activity (Figure 1.2).  
SUBSTRATES INHIBITORS 
Beta-blockers 
S-metoprolol 
propafenone 
propranolol 
carvedilol 
timolol 
 
Antidepressants 
clomipramine 
amitriptyline 
nortriptyline 
venlafaxine 
desipramine 
imipramine 
paroxetine 
fluoxetine 
 
SERM 
tamoxifen  
 
Opioids 
oxycodone 
codeine 
Antipsychotics 
zuclopenthixol 
perphenazine 
thioridazine 
haloperidol 
risperidone  
 
Others 
dextromethorphan 
chlorpheniramine 
chlorpromazine 
promethazine 
amphetamine 
debrisoquine 
fluvoxamine 
phenacetin 
bufuralol 
lidocaine 
sparteine 
tramadol 
Strong 
bupropion 
paroxetine 
fluoxetine 
quinidine 
 
Moderate 
terbinafine 
duloxetine 
sertraline 
 
Weak 
amiodarone 
cimetidine 
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Figure 1.2: CYP2D6 genotype-phenotype correlation and nortriptyline dose 
adjustment for the different metabolizer groups. 
 
Note: Fully functional CYP2D6 alleles are denoted by red boxes, decreased function 
alleles by orange boxes, null alleles by yellow boxes, and gene deletion by a dashed line.  
The associated phenotypes were determined by the urinary metabolic ratio (MR) of 
debrisoquine to 4-hydroxy-debrisoquine (interpreted as an in vivo index of CYP2D6 
activity).  MR = 12.6 is the cutoff point between subjects with „poor metabolism‟ and 
subjects with intermediate or extensive metabolism.  Source: modified from Myers, U.A., 
2004.   
 
 This variability in enzyme activity can affect drug metabolism and consequently, 
therapeutic response.  For example, individuals who have increased CYP2D6 enzyme 
activity (UM) due to multiple copies of the functional gene can have therapeutic failure 
due to rapid drug metabolism.  Hence, therapeutic plasma concentrations will not be 
achieved at ordinary drug dosages (Hedenmalm et al., 1997; Ingelman-Sundberg, 2004).  
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For example, when treating with the antidepressant drug, nortriptyline, the UMs require a 
much higher dose than the EMs, who in turn require a higher dose than the PMs (Figure 
1.2).  On the other hand, individuals who lack CYP2D6 enzyme activity (PM) due to lack 
of the functional copies of CYP2D6 gene have either: (1) therapeutic failure due to 
decreased bioactivation of the prodrugs (e.g., tamoxifen), or (2) increased side effects due 
to slower clearance of CYP2D6 substrate drugs (e.g., desipramine, fluvoxamine, 
fluoxetine, citalopram, etc.; Ingelman-Sundberg et al., 1999; Ingelman-Sundberg, 2004). 
 
CYP2D6 gene structure 
CYP2D6 belongs to the CYP2D gene family.  The CYP2D gene cluster which is 
located on chromosome 22q13.1 (Kimura et al., 1989) consists of three genes: (1) 
CYP2D6, a „functional‟ gene; (2) CYP2D8, a pseudogene that arose by gene conversion; 
and (3) CYP2D7, a nonfunctional gene that arose by gene duplication (Figure 1.3).  In the 
CYP2D family, CYP2D6 is the only gene that encodes a functional enzyme (Gaedigk et 
al., 2005).  The wild type CYP2D6 gene is ~4.4 kb long.  It is composed of 9 exons and a 
1491 bp long open reading frame (ORF) that translates into a protein with 497 amino 
acids (GenBank Accession No. M33388.1; Kimura et al., 1989).  Many alternatively 
spliced transcript variants that encode different isoforms have also been reported (source: 
Entrez Gene - http://www.ncbi.nlm.nih.gov/gene/1565).  The CYP2D6 gene is highly 
polymorphic; these polymorphisms affect the pharmacokinetics, metabolism, safety, and 
efficacy of drugs that are metabolized by it (Ingelman-Sundberg, 2005; Figure 1.3). 
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Figure 1.3: Human CYP2D gene family and common variants in the CYP2D6 gene. 
 
Note: In the CYP2D6 gene, the brown boxes represent the exons and the white boxes 
represent the untranslated regions (UTRs).  Some of the CYP2D6 representative variants 
are also shown; del denotes deletion; > denotes conversion. 
 
The CYP2D6 gene is not highly conserved across species.  The rat and mouse 
orthologs equivalent to human CYP2D6 are cyp2d1 and cyp2d22, respectively.  Among 
these three species, the drug metabolism profile is very different; they exhibit variability 
in substrate specificity and also enzyme inhibition (Bogaards et al., 2000).  Among rats 
and mice, there is also considerable interstrain difference in the metabolic profile 
(Corchero et al., 2001).  For example, debrisoquine, a CYP2D6 substrate drug, is 
metabolized to 4-hydroxydebrisoquine by humans and Sprague-Dawley rats, but not by 
Dark Agouti rats, or by C57BL/6, DBA/2 and ddY strains of mice (Al-Dabbagh et al., 
1981; Masubuchi et al., 1997).  Hence, model organisms are generally considered to be 
inadequate for preclinical studies of CYP2D6 substrate drugs.  However, a humanized 
CYP2D6 transgenic mouse model is now available and has been shown to be a good 
experimental model resembling the human extensive metabolizer phenotype for some 
drugs, including debrisoquine (Corchero et al., 2001). 
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CYP2D6 expression 
The CYP2D6 protein is expressed primarily in the endoplasmic reticulum and 
accounts for ~3% of the total CYP450 protein content in the human liver (Hakkola et al., 
1994; Rodriguez-Antona et al., 2000; Figure 1.1 A).  CYP2D6 mRNA and/or protein are 
also expressed at variable levels in extra-hepatic tissues including the circulating 
peripheral blood mononuclear cells, kidney, placenta, heart, brain, breast, lung and 
intestine (Romkes-Sparks et al., 1994; Carcillo et al., 1996; Guidice et al., 1997; 
McFayden et al., 1998; Siegle et al., 2001; Miksys et al., 2002).  However, when 
compared to hepatic CYP2D6 expression, the extra-hepatic expression level is very low.  
Though in vitro studies have suggested a role for brain expressed CYP2D6 in the 
metabolism of endocannabinoids (Snider et al., 2008), the role of other tissues in 
CYP2D6 mediated drug metabolism is still not clear and is generally considered to be 
negligible.   
The CYP2D6 mRNA and protein expression do not appear to be induced by drugs 
and xenobiotics (Eichelbaum et al., 1986).  CYP2D6 mRNA and protein expression 
appears to be mainly under genetic control, i.e., CYP2D6 gene polymorphisms and gene 
copy numbers.  However, CYP2D6 enzyme activity is induced by drugs like rifampin 
and dexamethasone (source: Cytochrome P450 drug interaction table: 
http://medicine.iupui.edu/clinpharm/ddis/table.asp) and also by pregnancy (Wadelius et 
al., 1997).  The detailed mechanism underlying the induction during pregnancy is 
unclear.  It was thought that the placenta or fetal liver may contribute to this metabolic 
induction.  However, it has been shown that in the fetus, even though CYP2D6 mRNA is 
detectable, CYP2D6 protein expression is mostly undetectable.  The CYP2D6 protein 
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concentration rises only a few days after birth (Treluyer et al., 1991).  The mechanisms 
that trigger post-natal expression of CYP2D6 are still not known.  Hence, it is possible 
that the developmental regulation of CYP2D6 expression may be due to posttranslational 
regulation by microRNAs.   
 
Transcriptional regulation of CYP2D6 expression by HNF4A 
 The hepatic expression of CYP2D6 is critical for the metabolism of the substrate 
drugs.  This hepatic CYP2D6 gene expression is primarily regulated through liver-
enriched transcription factors (LETF) such as hepatic nuclear factor 4α (HNF4α; 
HNF4A; NR2A1; Corchero et al., 2001).  Mutations in HNF4A have been shown to 
regulate CYP2D6 expression, and consequently affect CYP2D6 enzyme activity (Lee et 
al., 2008).  HNF4A is considered to be a „master regulator‟ that regulates the expression 
of many genes involved in drug metabolism like phase I enzymes (including CYP2D6), 
phase II enzymes, transporters and other transcriptional factors that regulate the CYP450 
genes (Kamiyama et al., 2007; Figure 1.4).  Apart from the regulation of drug 
metabolizing enzymes, HNF4A regulates several genes that are involved in other hepatic 
functions including, fatty acid and cholesterol metabolism, glucose metabolism, urea 
biosynthesis and liver differentiation (Kamiyama et al., 2007).  Thus, regulation of 
HNF4A will affect many genes that are involved in important liver functions.   
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Figure 1.4: HNF4A is a master transcriptional regulator of drug metabolizing 
enzymes. 
 
Note: Dashed line indicates that only some of the Phase II enzymes and transporters are 
specifically regulated by PXR and/or CAR. 
 
 Most of the data on CYP2D6 transcriptional regulation has been obtained from 
transient transfection of CYP2D6 in hepatoma cell lines.  This is because the CYP2D6 
enzyme expression is quickly lost in freshly isolated hepatocytes, and is neither 
maintained nor inducible in hepatoma cell lines (Cairns et al., 1996). 
 
CYP2D6 mediated drug metabolism 
CYP2D6 is responsible for the metabolism of about 20-25% of commonly 
prescribed drugs (Ingelman-Sundberg, 2005).  Some of these drugs include (Table 1.1): 
beta-blockers, antiarrhythmics, tricyclic antidepressants, selective serotonin reuptake 
inhibitors (SSRIs), opioids, antihypertensives, antitussives, antipsychotics and selective 
11 
 
estrogen receptor modulators (SERMs; e.g., tamoxifen).  While, some of these CYP2D6 
substrate drugs (e.g., nortriptyline) are metabolized into inactive metabolites, the other 
drugs (e.g., codeine and tamoxifen) are bioactivated into active metabolites. 
 
Tamoxifen as an endocrine therapy for breast cancer 
Tamoxifen is a clinically important drug that is metabolized by CYP2D6.  
Tamoxifen is primarily used in the hormonal therapy in breast cancer.  Additionally, it is 
also used in the treatment of infertility, retroperitoneal fibrosis, gynecomastia and bipolar 
disorder.  It is a selective estrogen receptor modulator (SERM) that has been repeatedly 
shown to improve the survival rate in breast cancer patients (Osborne, 1998).  In breast 
cells, tamoxifen acts as an antagonist and competes with estradiol to bind to the estrogen 
receptors (ER) and induces conformational changes that inhibit the transcription of 
estrogen regulated genes (Figure 1.5).  However, it is not a pure antagonist; it exhibits 
mixed agonist/antagonist activity in different tissues.  In case of tissues that are weakly 
estrogenic (e.g., cardiovascular tissues and bone), it has some protective effect (Chang et 
al., 1996).  But, in case of tissues that are strongly estrogenic (e.g., endometrium), it can 
lead to rare adverse side effects like endometrial cancer.  Despite the common and rare 
side effects, the risk/benefit ratio is still favorable for tamoxifen therapy (Bonanni et al., 
2007).  
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Figure 1.5: Mechanism of action of tamoxifen in breast cancer cells. 
 
Note: Estradiol binds to the estrogen receptor (ER) and results in changes that bring about 
cellular proliferation.  Tamoxifen is anti-estrogen that competes with estradiol for binding 
with the ER and blocks the proliferation.  Source: modified from www.pharmgkb.org/. 
 
Worldwide, tamoxifen is the most commonly used hormonal therapy for breast 
cancer.  Tamoxifen is still heavily used, even though some postmenopausal patients are 
now taking aromatase inhibitors (AIs) instead of tamoxifen (American Society of Clinical 
Oncology guidelines; Winer et al., 2005).  In the U.S. alone, in 2007, ~1.6 million 
tamoxifen prescriptions were issued (source: www.drugtopics.com).  Some of the reasons 
for the heavy use of tamoxifen include: (a) it is the standard endocrine therapy for 
premenopausal breast cancer, since AIs are not given to premenopausal women, (b) it is 
the most common endocrine therapy used for breast cancer risk reduction, (c) it is the 
only FDA approved endocrine therapy for the treatment of ductal carcinoma in situ 
(DCIS), (d) it is the only hormonal therapy approved for male breast cancer, (e) it is used 
in the treatment of patients who are intolerant or resistant to AI treatment, and (f) in the 
13 
 
USA and around the world, its low cost makes it affordable to many women who cannot 
afford the AIs.  
Although tamoxifen is a very effective therapy, the pharmacodynamic response to 
tamoxifen varies considerably between individuals (Lonning et al., 1992; Ingle et al., 
1999).  This variability is seen in both its effectiveness as well as its side effects 
(Osborne, 1998).  Some of the side effects include hot flashes, mood disturbances, 
vaginal discharge and bleeding, invasive endometrial cancer and deep vein thrombosis.  
These side effects can be severe enough to cause discontinuation of the therapy.  About 
30-50% of women do not complete the recommended 5 years of therapy (Barron et al., 
2007); one of the common reasons for discontinuation is the side effects (Rae et al., 
2009).  Consequently, a better understanding of the variability in the occurrence of these 
side effects would help to improve the compliance of this life saving drug.  
 
Metabolism of tamoxifen by CYP2D6 
Tamoxifen is heavily metabolized by several of the cytochrome P450 drug 
metabolizing enzymes (Desta et al., 2004; Figure 1.6).  CYP3A is involved in the 
metabolism of tamoxifen to N-desmethyltamoxifen (NDM).  NDM is subsequently 
metabolized to a more active metabolite, endoxifen, by the polymorphic enzyme 
CYP2D6.  Tamoxifen is also hydroxylated by a number of CYP450s (CYP3A,
 
CYP2C9, 
CYP2C19, CYP2B6, and CYP2D6) to form 4-hydroxytamoxifen (4-OH-tam) which is 
further metabolized by CYP3A to endoxifen.  Phase II drug metabolizing enzyme like 
UDP glucuronosyltransferase 2B7 (UGT2B7) may be involved in the subsequent 
clearance of these metabolites (Sun et al., 2007; Blevins-Primeau et al., 2009).  
14 
 
Figure 1.6: Metabolism of tamoxifen by Phase I and II drug metabolizing enzymes. 
  
Note: Size of the arrow indicates the relative size of the pathway.  Source: modified from 
Borges, et al., 2006. 
 
Endoxifen is considered to be the most active metabolite of tamoxifen and is 
primarily generated by the activity of CYP2D6 (Desta et al., 2004; Johnson et al., 2004).  
Compared to the parent drug, tamoxifen, endoxifen is ~30-100-fold more potent in 
estrogen receptor binding, regulation of estrogen dependent gene expression and 
inhibition of breast cancer cell growth (Johnson et al., 2004).  Endoxifen is similar to the 
extensively studied tamoxifen metabolite, 4-hydroxytamoxifen (4-OH-tam; Lim et al., 
2005; Lim et al., 2006), but in breast cancer patients, it reaches ~10-fold higher 
concentration than 4-OH-tam (Stearns et al., 2003).  However, there is over 10-fold 
interindividual variability in the concentration of this potent metabolite in breast cancer 
patients (Stearns et al., 2003; Jin et al., 2005).  A part of this variability is due to CYP2D6 
gene variants and due to concurrent use of drugs that inhibit CYP2D6 enzyme activity 
(Figure 1.7; Stearns et al., 2003; Jin et al., 2005; Borges et al., 2006).  Hence, 
15 
 
comprehensive CYP2D6 genotyping, identification of CYP2D6 gene copy numbers and 
evaluation of co-medication for CYP2D6 inhibitors are essential to account for the 
variability in plasma endoxifen concentrations.  However, there is considerable 
unexplained variability in the endoxifen concentrations even after correcting for these 
genetic and environmental factors. 
 
Figure 1.7: CYP2D6 gene polymorphisms and concomitant use of CYP2D6 
inhibitors are associated with plasma endoxifen concentration. 
Note: Blood samples were collected after 4 months of tamoxifen treatment for identifying 
CYP2D6 genotype and for the measurement of plasma endoxifen concentrations.  Solid 
circles represent the individual plasma endoxifen concentrations; vertical bars represent 
the mean plasma endoxifen concentration for each group.  Source: modified from Jin, et 
al., 2005. 
 
The CYP2D6 polymorphisms that reduce endoxifen concentration are also 
associated with reduced side effects and poorer clinical outcomes.  A number of studies 
 
16 
 
performed primarily in Caucasian women (Goetz et al., 2005; Bonanni et al., 2006; Goetz 
et al., 2007; Gonzalez-Santiago et al., 2007; Schroth et al., 2007; Schroth et al., 2009) and 
a relatively few studies in Asian women (Lim et al., 2007; Kiyotani et al., 2008; Xu et al., 
2008) have suggested that CYP2D6 PM or IM allelic status is associated with poorer 
outcomes in prevention, adjuvant and metastatic settings (Figure 1.8; Table 1.2).  
 
Figure 1.8: CYP2D6 genotype is associated with clinical outcomes. 
 
Note: Kaplan-Meier estimates of (A) relapse-free time; (B) disease-free survival; and (C) 
overall survival for patients with CYP2D6*4/*4 genotype (PM) and CYP2D6*Wt/*4 (IM) 
when compared to the wildtype CYP2D6*1/*1 genotype (EM).  Source: modified from 
Goetz, et al., 2005. 
 
Not all studies have confirmed the association between CYP2D6 variant genotype 
and poor clinical outcomes (Nowell et al., 2005; Wegman et al., 2005; Wegman et al., 
17 
 
2007; Okishiro et al., 2009; Table 1.3).  Two of these studies (Wegman et al., 2005; 
Wegman et al., 2007) have reported that the PMs have a better outcome when compared 
to the EMs.  One of the possible explanations is that the PMs (who generally have fewer 
side effects) continued with their tamoxifen therapy, while the EMs (who generally have 
more side effects) discontinued the therapy.  Two other studies (Nowell et al., 2005; 
Okishiro et al., 2009) have reported a lack of association between CYP2D6 gene variants 
and clinical outcome, i.e., CYP2D6 PMs and IMs have the same outcome as the EMs.  
None of these studies have no data on drug compliance.  About 30-50% of women do not 
complete the 5-year tamoxifen regimen (Barron et al., 2007); one of the reasons for 
discontinuation is increased side effects in the EMs when compared to the PMs (Rae et 
al., 2009).  Another possible explanation for the differences in the results is that the 
variability in other related pathways may also be important.  For example, plasma 
endoxifen concentration is dependent not only on its formation by CYP2D6 but also on 
its clearance by phase II enzymes like UGT2B7 (Blevins-Primeau et al., 2009).  A 
missense mutation in UGT2B7 (His268Tyr; UGT2B7*2) results in decreased enzyme 
activity and consequently slower drug clearance (Sun et al., 2007).  Hence, it is 
conceivable that UGT2B7 alone or in combination with CYP2D6 contributes to 
variability in tamoxifen response.  Similarly, a polymorphism in the drug transporter 
ABCC2 has been shown to be associated with poor clinical outcome, even though it is not 
associated with plasma concentrations of tamoxifen and its metabolites (Kiyotani et al., 
2010).  Hence, it is likely that other genes in related pathways may also account for some 
of the interindividual variability in drug metabolism and response. 
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Interindividual variability in CYP2D6 enzyme activity and CYP2D6 mediated drug 
metabolism 
 There is considerable interindividual variability in CYP2D6 enzyme activity and 
this leads to variability in metabolism and disposition of the substrate drugs (Ingelman-
Sundberg, 2005).  Based on CYP2D6 allelic make up and enzyme activity, an individual 
can be classified into one of the four different phenotype groups: poor (PM), intermediate 
(IM), extensive (EM), and ultrarapid (UM) metabolizer.  In these four different 
phenotype groups, for a number of drugs, one drug dose size does not fit all.  For 
example, for a number antidepressants (e.g., imipramine, paroxetine, nortriptyline, etc.), 
the dosing required to achieve the same plasma concentration can differ by 10-30 fold 
between individuals due to their CYP2D6 metabolizer status (Figure 1.9; Kirchheiner et 
al., 2004; Ingelman-Sundberg and Rodriguez-Antona, 2005).  
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Figure 1.9: CYP2D6 mediated quantitative influences on pharmacokinetics of 
selected antidepressant drugs. 
 
Note: CYP2D6 mediated quantitative influences on pharmacokinetics of selected 
antipsychotic drugs expressed as percent dose adjustments.  White bars represent 
CYP2D6 poor metabolizer (PM), light gray – intermediate metabolizer (IM), dark gray – 
extensive metabolizer (EM), black – ultrarapid metabolizers (UM).  Source: modified 
from Kirchheiner et al., 2004.  
 
Causes of variability in CYP2D6 enzyme activity 
 The primary factors that are currently known to cause interindividual variability 
in CYP2D6 enzyme activity include environmental and genetic factors. 
 
1. Environmental factors 
 Environmental factors like diet (Aklillu et al., 2002) and drug-drug interactions  
(Lam et al., 2002) can influence CYP2D6 enzyme activity.  Many clinically important 
drugs are CYP2D6 enzyme inhibitors (Table 1.1) and consequently affect the metabolism 
of other CYP2D6 substrate drugs.  In vivo and in vitro studies using the CYP2D6 probe 
drug dextromethorphan have shown that certain selective serotonin reuptake inhibitors 
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(SSRIs; e.g., fluoxetine and paroxetine) can act as CYP2D6 enzyme inhibitors.  These 
CYP2D6 inhibitor drugs can convert extensive metabolizers into poor metabolizers (Lam 
et al., 2002).  In breast cancer patients taking tamoxifen, these SSRIs were routinely co-
prescribed to treat depression and to alleviate hot flash symptoms.  This results in lower 
plasma endoxifen concentration because these SSRIs inhibit CYP2D6 activity and thus 
interfere with tamoxifen metabolism (Jin et al., 2005).  Thus, these inhibitors convert a 
CYP2D6 extensive metabolizer to a phenotypic poor metabolizer, thus creating a 
phenocopy of a poor metabolizer (Figure 1.7).  The concurrent use of some of the SSRIs 
(e.g. paroxetine) during tamoxifen therapy is associated with increased risk of death from 
breast cancer (Kelly et al., 2010). 
 So far, there are no known xenobiotics or drugs that have been shown to induce 
the expression of CYP2D6 messenger RNA (mRNA) and/or protein (Eichelbaum et al., 
1986). 
 
2. Genetic factors 
 CYP2D6 enzyme expression appears to be mainly under genetic control, i.e., gene 
polymorphisms and copy number variations (CNVs).  These variants can affect CYP2D6 
enzyme expression and activity. 
 
a. CYP2D6 gene polymorphisms 
CYP2D6 is a highly polymorphic gene.  So far, more than 78 alleles and allelic 
subvariants have been identified (Human Cytochrome P450 Allele Nomenclature 
Committee: www.cypalleles.ki.se/cyp2d6.htm).  
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These alleles can be classified as: 
i. Functional alleles, with „normal‟ enzyme activity (e.g., CYP2D6*1, *2, *35, etc.) 
ii. Reduced functional alleles, with decreased enzyme activity (e.g., CYP2D6*9, *10, 
*17, *29, *37, *41, etc.), and 
iii. Nonfunctional alleles, with negligible enzyme activity (e.g., CYP2D6*3-*8, *11-
*16, *18-*20, *36, *38, *40, *42, etc.). 
 A CYP2D6 star-allele represents either a single genetic variant or a „haplotype‟ 
that results in: amino acid substitution, post-transcriptional modification, post-
translational modification, alteration in transcription, splicing, or translation (Robarge et 
al., 2007).  CYP2D6*1 is the wildtype reference sequence to which all the variants are 
compared.  As new nucleotide variants (either a single variant or a combination of 
variants) are identified, a unique number is assigned (e.g., CYP2D6*2, *4, *10, etc.; 
Figure 1.10).  Different combinations of nucleotide changes within a named star-allele 
are defined by additional letters.  For example, CYP2D6*2A is characterized by the 
following nucleotide changes: -1584C>G, -1235A>G, -740C>T,   -678G>A, gene 
conversion with CYP2D7 in intron 1, 1661G>C, 2850C>T and 4180G>C; the subvariant 
CYP2D6*2B is characterized by 1039C>T, 1661G>C, 2850C>T, 4180G>C and the 
subvariant CYP2D6*2C is characterized by 1661G>C, 2470T>C, 2850C>T, and 
4180G>C.  That is, CYP2D6*2A-C share key mutations, but are further distinguished 
based on the additional mutations that they do not share.   
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Figure 1.10: Polymorphisms in selected CYP2D6 alleles.
 
Note: X represents single nucleotide polymorphisms (SNP) that are used for genotyping; 
x represents some of the representative SNPs present in the given CYP2D6 star-allele 
haplotype. 
 
 These polymorphisms can affect CYP2D6 enzyme expression and activity.  For 
example, individuals with CYP2D6*1/*10 and CYP2D6*10/*10 genotypes had 3-fold 
lower CYP2D6 protein in their liver microsomes when compared to CYP2D6*1/*1 
individuals (Shimada et al., 2001).  In vitro expression studies have shown that 
CYP2D6*10 enzyme had 50-100 fold lower efficiency in metabolizing 
dextromethorphan and fluoxetine when compared to CYP2D6*1 (Yu et al., 2002).  
Consequently, these polymorphisms affect pharmacokinetics, metabolism, safety and 
efficacy of CYP2D6 substrate drugs.  Based on the CYP2D6 allelic make up, an 
individual can be classified into different categories such as ultrarapid (UM), extensive 
(EM), intermediate (IM) or poor (PM) metabolizer (Table 1.4). 
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Table 1.4: Consequences of selected CYP2D6 gene polymorphisms.  
CYP2D6 
allele 
Mutation 
a
 
Consequence of 
mutation 
Enzyme 
b
 
Metabolizer 
status 
*1 None None Normal EM 
*2 4180G>C Amino acid change Normal EM 
*17 1023C>T Amino acid change Unstable  IM 
*41 2988G>A Splicing defect Unstable  IM 
*10 100C>T Amino acid change Unstable  IM 
*36 
100C>T, gene 
conversion in exon 9 
Amino acid changes Inactive  PM 
*3 A2549del Frameshift Inactive  PM 
*4 1846G>A Splicing defect Inactive  PM 
*5 Gene deletion No enzyme No enzyme PM 
*6 T1707del Frameshift Inactive  PM 
Note: Some of the frequent CYP2D6 alleles in the Caucasian, Asian and African 
populations are represented here.  
a
 mutation that is used for genotyping the 
corresponding CYP2D6 allele; 
b
 in vivo enzyme activity (source: 
www.cypalleles.ki.se/cyp2d6.htm); PM - poor metabolizer; IM - intermediate 
metabolizer; EM - extensive metabolizer.   
 
 There are considerable differences in the frequencies of CYP2D6 gene 
polymorphisms in different ethnic populations (Figure 1.11).  For example, CYP2D6*4, 
CYP2D6*3, CYP2D6*5 and CYP2D6*6 are present at a combined frequency of 20-30% 
in Caucasians (Bradford, 2002; Sistonen et al., 2007) and are the primary cause of poor 
metabolism in this population.  However, in Asians and Africans, CYP2D6*3-*6 alleles 
are present in less than 7% frequency (Bradford, 2002).  In Asians, the primary cause for 
reduced enzyme activity is CYP2D6*10, an intermediate metabolizer allele that is present 
at a frequency of 40-60% (Veiga et al., 2009).  However, in both Caucasians and 
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Africans, CYP2D6*10 is present at a frequency of less than 5% (Bradford, 2002).  In 
Africans, the primary cause of reduced enzyme activity are CYP2D6*17 and 
CYP2D6*29.  Both these alleles are present in less than 3% frequency in both Caucasian 
and African populations (Bradford, 2002; Sistonen et al., 2007). 
 
Figure 1.11: Frequencies of selected CYP2D6 alleles in different ethnic populations.
 
Source: data from Veiga et al., 2009, Sachse et al., 1997 and Wennerholm et al., 1999. 
 
 For practical clinical purposes, CYP2D6 enzyme activity is predicted based on the 
CYP2D6 genotype scoring system (Table 1.5).  Each of the nonfunctional CYP2D6 allele 
which codes for either no protein (CYP2D6*5) or for protein with no enzyme activity 
(e.g., CYP2D6*3, *4, *6, etc.) is given a score of 0.  A reduced function allele (e.g., 
CYP2D6*9, *10, *17, *41, etc.) which codes for protein with decreased enzyme activity 
is given a score of 0.5.  A fully functional allele (e.g., CYP2D6*1, *2, *35, etc.) which 
codes for protein with normal enzyme activity is given a score of 1.  An individual‟s 
CYP2D6 genotype score is the summation of the individual allelic scores. 
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Table 1.5: CYP2D6 enzyme activity scores based on CYP2D6 alleles and copy 
number variations. 
CYP2D6 allele 
Metabolizer 
status 
CYP2D6 
allele score 
*3-*8, *11-*16, *18-*20, *36, *38, *40, *42, *44, 
*56, *4xN PM 0 
*10, *17, *37, *9, *29, *41, *45, *46 IM 0.5 
*41xN, *45xN EM
 a
 1 
*1, *2, *33, *35 EM 1 
*1xN, *2xN, *35xN UM 2 
Note: This is an arbitrary scoring system based on the CYP2D6 alleles present.  A score 
of 0.5 does not mean that an allele has one-half or one-fourth the enzyme activity when 
compared to an allele with a score of 1 or 2, respectively.  PM - poor metabolizer;         
IM - intermediate metabolizer; EM - extensive metabolizer; UM - ultrarapid metabolizer; 
a
 considered to be UM by other publications (Zanger et al., 2004; Zineh et al., 2004).  
Source: redrawn from Borges, S., et al., 2010.   
 
 New CYP2D6 alleles and diplotype combinations are continuing to be reported; 
this adds to the complexity of CYP2D6 genotype-guided drug dosage decisions in the 
clinic.  Co-medication with CYP2D6 inhibitors also adds to the discordance.  Hence, 
genotype-phenotype based scoring systems have been developed to help clinicians to 
individualize drug therapy (Zanger et al., 2004; Gaedigk et al., 2008; Borges et al., 2010).  
Potential confounders in implementing these scoring systems include some of the poorly 
understood factors like pregnancy that affect CYP2D6 enzyme activity. 
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b. CYP2D6 copy number variations (CNVs) 
 Although CYP2D6 gene polymorphisms contribute to a large portion of 
interindividual variability in CYP2D6 enzyme activity, CYP2D6 gene copy number 
variations (CNVs) also contribute to this variability (Weinshilboum, 2003; Eichelbaum et 
al., 2006; Yu and Shao, 2009).  Copy number variation is defined as the variation in the 
number of copies of a gene (or sequences of DNA) from the normal two copies in the 
genome of a specific individual.  The CYP2D6 gene often undergoes gene deletion or 
multiplication resulting in CNVs.  The frequencies of these CNVs vary considerably 
among different ethnic populations (Bradford, 2002; Sistonen et al., 2007).  For example, 
the frequency of the CYP2D6 whole gene deletion (CYP2D6*5) ranges from 1-7% in 
Caucasians, Africans and Asians populations (Bradford, 2002).  Similarly, CYP2D6 
whole gene multiplication ranges from 0-13% in Caucasians and Africans (Bradford, 
2002; Sistonen et al., 2007), while in Asians, CYP2D6 gene multiplication is as high as 
54% in Asians (Figure 1.12; Hosono et al., 2009).  The genetics of CYP2D6 CNV is 
further complicated by the variety of CYP2D6 alleles that exist as multiple copies.  
While, the functional CYP2D6*1 and *2 duplications are frequent among all ethnicities 
(Bradford, 2002; Sistonen et al., 2007),  the nonfunctional CYP2D6*4 is more common 
among Caucasians (Bradford, 2002) and the reduced function CYP2D6*36-*10 allele 
multiplications are common in Asians (Johansson et al., 1994; Hosono et al., 2009).   
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Figure 1.12: CYP2D6 gene copy number variations in the Japanese and Chinese 
Coriell diversity panel. 
  
Source: data from Hosono et al., (Hosono et al., 2009).  
 
 The phenotypic consequence of CNVs depend on the CYP2D6 allele involved in 
duplication (Table 1.6).  For example, based on the metabolism of the CYP2D6 probe 
drug dextromethorphan, it has been shown that individuals with CYP2D6*2 duplications 
have increased enzyme activity when compared to carriers of a single copy of CYP2D6*2 
allele (Aklillu et al., 1996).  However, individuals with CYP2D6*10 duplications have 
similar enzyme activity as the individuals with a single copy of CYP2D6*10 allele 
(Ishiguro et al., 2004).  Thus, the carriers of multiple copies of functional CYP2D6 alleles 
(*1xN, *2xN) are classified as UMs, the carriers of *10x2 are still considered to be IMs 
and carriers of nonfunctional *4x2 are still PMs (Table 1.6).  Little is known about the 
phenotypic consequence of other multiple copy arrangements including *36-*10-*10 or 
*36-*36-*10, etc.  Hence, the total number of CYP2D6 copies detected by the CNV 
assays cannot reasonably be used to estimate the phenotypic consequence, without 
identifying the CYP2D6 allele involved in the duplication. 
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Table 1.6: Consequences of CYP2D6 gene copy number variations. 
Variation CYP2D6 allele 
Enzyme 
activity  
Phenotype 
group 
Ethnicity 
Gene deletion *5 None  PM AA, CA, As 
Gene 
multiplication 
*4xN None PM CA 
*1xN, *2xN, *35xN Increased  UM AA, CA, As 
*41xN, *45xN Increased  EM 
a
 CA, AA 
*36-*10 Decreased  IM As, AA 
(*36)n-(*10)n Unknown Unknown As 
Note: PM - poor metabolizer; IM - intermediate metabolizer; EM - extensive metabolizer; 
UM - ultrarapid metabolizer; AA - African Americans; CA - Caucasians; As - Asians;      
a 
considered to be UM in some publications (Zanger et al., 2004; Zineh et al., 2004) and 
EM in others (Borges et al., 2010).  Source: www.cypalleles.ki.se/cyp2d6.htm. 
 
 The determination of CYP2D6 gene copy numbers is complicated by the presence 
of two highly homologous pseudogenes, CYP2D7 and CYP2D8.  It is also complicated 
by the presence of CYP2D6-CYP2D7 fusion genes.  For example, CYP2D6*36 includes 
the 5‟ end of the CYP2D6 gene fused with the 3‟end of the CYP2D7 gene due to gene 
recombination.  The genome wide association study (GWAS) arrays have relatively few 
CYP2D6 probes and therefore are inefficient for accurate identification of allele specific 
CYP2D6 CNVs.  Furthermore, because of the large sizes of gene deletion and 
duplications, the CYP2D6 copy number estimation commonly involves relatively difficult 
techniques like long-template PCR and southern blotting (Meijerman et al., 2007).   
 Recently, several qRT-PCR assays have been reported (Schaeffeler et al., 2003; 
Meijerman et al., 2007; Hosono et al., 2009).  Commercial qRT-PCR assays have also 
become available; however, since the exact positions of the target sequences are not 
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provided for these assays, their ability to distinguish between specific alleles and fusion 
genes must be determined experimentally.  For example, when CYP2D6 gene copy 
number was estimated in 32 Asian individuals from the Coriell Japanese-Chinese human 
diversity DNA panel using four different qRT-PCR copy number assays, not all the 
assays yielded concordant results (Ramamoorthy et al., 2010).  These copy number 
assays targeted different regions of the CYP2D6 gene: (i) 5‟-flanking region (5‟flank) 
assay and (ii) intron 2 (Int2) assay, both available commercially from Applied 
Biosystems (Foster City, CA, USA), (iii) intron 6 (Int6) assay and (iv) exon 9 (Ex9) 
assay, both assays reported previously in the literature (Hosono et al., 2009).  Three of 
the CYP2D6 CNV assays (5‟-flank, Int2, and Int6) estimated CYP2D6 copy numbers that 
were concordant for all 32 subjects (Figure 1.13).  However, the Ex9 assay results were 
concordant in only 10 of 32 samples.  The 10 concordant samples did not contain any 
CYP2D6*36 alleles and the 22 discordant samples contained at least one CYP2D6*36 
allele.  Also, the Ex9 assay accurately quantified all of the non-CYP2D6*36 alleles in all 
samples.  The specific target site of the Ex9 assay was verified by sequencing the PCR 
amplicon and the result indicated that the assay targets a region of CYP2D6 exon 9 that 
undergoes partial gene-conversion in the CYP2D6*36 allele.  These results indicate that 
the CYP2D6 CNV assays can be specific for subsets of CYP2D6 alleles and the decision 
of which CNV assays to use must include consideration of the alleles that are being 
targeted.  In conclusion, all copy number assays may not yield similar results and have to 
be selected based on the region of the gene that they target.  This will likely also be 
important for other genes as the genomic structure of the gene copies are being 
elucidated. 
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 The presence of many copies of CYP2D6 gene and the involvement of the 
different alleles (e.g., CYP2D6*1, *2, *10, *35, etc.) makes it difficult to accurately infer 
the diplotypes present in the two homologous chromosomes.  In order to predict the 
complex haplotypes within a chromosome, bioinformatic algorithms like CNV phaser 
(Kato et al., 2008) can used.  This program uses data from genotyping assays and gene 
copy number assays, that is, CYP2D6 alleleic status and CYP2D6 copy units, to predict 
the CYP2D6 diplotype combinations.   
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 A number of other genes involved in drug metabolism also exhibit CNVs - 
UGT2B17 and UGT2B28 (McCarroll et al., 2006), SULTA1 (Hebbring et al., 2007), 
GSTT1 and GSTM1 (Bolt and Thier, 2006).  In fact, CNVs are more common than 
originally thought before the human genome project (Iafrate et al., 2004; Sebat et al., 
2004).  In the human genome, there are thousands of copy number variable regions 
(CNVRs) that range from 100 bp to several Mb (Redon et al., 2006).  Studies have 
suggested an increasing role for CNVs in many diseases including cancer, developmental 
diseases, mental illness, autoimmune diseases and infectious diseases (Shrestha et al., 
2009; Wain et al., 2009).  However, though a recent genome-wide association study 
identified an association between gene CNVs and eight common human diseases (e.g., 
Crohn‟s disease, rheumatoid arthritis, type 1 diabetes and type 2 diabetes), it concluded 
that CNVs are unlikely to contribute greatly to the genetic basis of common human 
diseases (Craddock et al., 2010).  The researchers speculated that SNPs rather than CNVs 
may be associated with the pathogenesis of these diseases.  That is, even though CNVs 
are present frequently in individuals, their phenotypic consequence may depend on the 
sequence of the DNA that is duplicated.  
 
3. Epigenetic factors 
 Genetic and environmental factors only explain a part of the variability in 
CYP2D6 enzyme activity.  Epigenetic factors like DNA methylation and microRNAs 
may explain some of this unexplained interindividual variability.  For example, there is a 
lack of statistically significant correlation between CYP2D6 mRNA and protein 
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expression in human livers, even with the same CYP2D6 genotype group (e.g., 
CYP2D6*1/*1; Figure 1.14; Borges et al., unpublished).   
 
Figure 1.14: Lack of association between CYP2D6 mRNA and protein expression in 
the human livers.
 
Note: The CYP2D6 mRNA level was not correlated with the protein level in CYP2D6 
wildtype (*1/*1) livers (N = 11) in a panel of 54 human livers.  The CYP2D6 and 18s 
mRNA levels were measured by specific RT-PCR assays and the ratio was multiplied by 
10
6
 to simplify
 
data presentation.  The protein levels were quantified by western blots 
using CYP2D6 specific antibody.  Source: Borges et al., unpublished. 
 
 This poor correlation between CYP2D6 mRNA and protein suggests that 
CYP2D6 mRNA may be post-transcriptionally regulated by factors like p-bodies (sites in 
the cytoplasm where mRNA is sequestered until translation or degradation), or 
microRNAs, etc.  Recent studies have shown that a number of CYP450 enzymes as well 
as some of their transcriptional factors are regulated by microRNAs (Tsuchiya et al., 
2006; Takagi et al., 2008; Pan et al., 2009).  However, the role of miRNAs in the 
regulation of CYP2D6 is still not known. 
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Introduction to microRNAs  
 MicroRNAs (miRNAs) are small (18-25 nucleotides), noncoding RNAs that bind 
typically to the 3‟-UTR of a messenger RNA (mRNA) and negatively regulate gene 
expression.  These miRNAs regulate gene expression by one of the two following 
mechanisms: by blocking protein translation or by degrading the messenger RNA (Olsen 
and Ambros, 1999; Ambros et al., 2003; Figure 1.15).  So far, 940 mature miRNAs have 
been reported in the human genome (miRBase Registry; version 15.0; Griffiths-Jones et 
al., 2006).  These miRNAs are estimated to control 20-90% of the human genes (Lewis et 
al., 2005; Miranda et al., 2006).  Each miRNA can regulate multiple protein coding 
genes; therefore, having hundreds of miRNAs offers an enormous potential for post-
transcriptional regulation. 
 
MicroRNA gene processing  
 The initial steps of miRNA gene processing are similar to that of the protein 
coding genes; however, there are many differences in the later stages of processing.  In 
the nucleus, genes encoding miRNAs are transcribed primarily by the RNA polymerase 
II enzyme to form pri-miRNA transcripts (200-300 bp precursors) that have a 5‟ cap and 
a 3‟ poly-A tail.  These are then processed by the RNase III enzyme complex, Drosha-
Pasha/DGCR8, to form 70-80 bp long pre-miRNAs (Gregory et al., 2004; Han et al., 
2004).  These pre-miRNAs are then exported by exportin5 to the cytoplasm (Lund et al., 
2004) where they are processed by another RNase III enzyme, Dicer, to form double 
stranded, mature miRNA (18-25 bp).  One strand of the mature miRNA is then 
incorporated into a RNA-induced silencing complex (RISC; Du and Zamore, 2005).  This 
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RISC complex then targets the miRNA complementary regions within the mRNA 3‟-
UTR.  This results in translational repression either by direct mRNA degradation or more 
commonly by blocking protein synthesis (Figure 1.15).  
 
Figure 1.15: Gene processing and mechanisms of action of microRNAs.
 
Source: modified from He and Hannon, 2004. 
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Functions of microRNAs 
 MicroRNAs are involved in a wide range of biological activities (John et al., 
2004) including: cell differentiation, cell death, noncancerous diseases (diabetes, viral 
infection) and cancer (breast cancer, colon cancer, glioblastoma, etc.).  MiRNAs can act 
as oncogenes or tumor suppressor genes and hence play an important role in 
tumorigenesis (Esquela-Kerscher and Slack, 2006).  Amplification or loss of miRNA 
genes has been reported in a number of cancers subtypes; these altered miRNA 
expression patterns affect cell cycle and
 
survival (Calin and Croce, 2006).  Aberrant 
miRNA expression patterns act as „signatures‟ and allow for better classification of tumor 
type, progression and prognosis (Chen and Stallings, 2007).   
As more miRNAs are being identified and studied, newer functions are being 
recognized.  Previously, miRNAs were thought to function by binding to the mRNA 3‟-
UTR and regulating gene expression by either mRNA degradation or by blocking protein 
synthesis (Bartel, 2004).  New evidence now indicates that miRNAs are also involved in 
induction of gene expression.  For example, hsa-miR-373 can bind to a highly 
complementary region in E-cadherin promoter sequence and readily induce gene 
expression (Place et al., 2008).  Similarly, mmu-miR-10a can interact with the 5‟-UTR of 
mRNAs encoding ribosomal proteins to enhance their translation (Orom et al., 2008).  It 
has now been shown that miRNAs can also bind to coding regions and repress gene 
expression (Duursma et al., 2008); this mechanism may explain some of the differential 
expression seen in mRNA splice variants.   
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Pharmacological relevance of microRNAs  
 An important role for miRNAs in drug metabolism and drug resistance is 
beginning to emerge.  For example, ATP-binding cassette xenobiotic transporter ABCG2 
(To et al., 2008), cytochrome P450 1B1 (Tsuchiya et al., 2006), cytochrome P450 3A4 
(Pan et al., 2009) and the transcription factor pregnane X receptor (Takagi et al., 2008) 
have been shown to be regulated by miRNAs.  This miRNA regulation of DMEs may 
explain some of the interindividual variability that is seen in drug response (Ingelman-
Sundberg et al., 2007).   
Cytochrome P450 1B1 (CYP1B1) is a member of the CYP450 superfamily that is 
constitutively expressed in many tissues including breast and ovary.  In the estrogen 
target tissues, CYP1B1 catalyzes
 
the biotransformation of 17β-estradiol to 4-
hydroxyestradiol that causes DNA damage.  In a number of cancers, including breast 
cancer, there is an increased
 
expression of CYP1B1 protein.  Recently, CYP1B1 has been 
shown to be post-transcriptionally
 
regulated by hsa-miR-27b by blocking protein 
synthesis (Tsuchiya et al., 2006).  This was the first CYP450 that was shown to be 
regulated by miRNAs. 
 Pregnane X receptor (PXR; NR1I2) is a transcription factor that regulates the 
expression of a number of DMEs and drug transporters.  PXR expression is regulated by 
hsa-miR-148a post-transcriptionally by blocking protein synthesis (Takagi et al., 2008).  
This down-regulation in PXR expression affected both constitutive and inducible 
expression of Cytochrome P450 3A4 (CYP3A4).  Even though bioinformatic analyses 
predicted that hsa-miR-148a can directly regulate CYP3A4, the in vitro experiments did 
not support the bioinformatic predictions.  Hence, hsa-miR-148a appears to regulate 
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CYP3A4 expression not directly, but indirectly through the transcription factor, PXR.  
This miRNA regulation of CYP3A4 may explain some of the interindividual variability 
seen in response to CYP3A4 substrate drugs. 
CYP3A4 is a member of the CYP450 superfamily of DMEs that is involved in the 
metabolism of a number of clinically important drugs (e.g., antiarrhythmics, 
benzodiazepines, HIV antivirals, calcium channel blockers, etc.; Source: 
http://medicine.iupui.edu/flockhart/table.htm).  Both CYP3A4 mRNA and protein 
expression is regulated by hsa-miR-27b (Pan et al., 2009).  Vitamin D receptor 
(VDR/NR1I1), a transcriptional factor that regulates CYP3A4 expression is also post-
transcriptionally regulated by hsa-miR-27b, thus contributing to an increased repression 
of CYP3A4 protein.  This direct and indirect miRNA regulation of CYP3A4 may also 
explain some of the CYP3A4 mediated interindividual variability seen in drug response. 
Apart from drug metabolizing enzymes and their transcriptional factors, a number 
of other pharmacologically important targets have been shown to be regulated by 
miRNAs.  For example, estrogen receptor alpha (ERα; ESR1), a target of several drugs, 
has been shown to be regulated by hsa-miR-206 (Adams et al., 2007).  Hsa-miR-206 
binds to the 3‟-UTR of ERα and reduces its expression post-transcriptionally.  The 
expression of hsa-miR-206 was also inhibited by ERα agonists suggesting the 
involvement of a mutually inhibitory feedback loop.  This miRNA is also expressed at a 
higher level in ERα negative breast cancers (Iorio et al., 2005).   
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Drug induced changes in microRNAs 
 MicroRNAs are influenced by drug or xenobiotic treatment.  For example, 
treatment with carbon tetrachloride and acetaminophen caused changes in the expression 
of  a number of miRNAs in rat liver (Fukushima et al., 2007).  MiRNAs have also been 
shown to play an important role in drug response and in the development of resistance or 
sensitivity to drugs.  For example:  
(1) Suppressing the expression of hsa-miR-21 in a cholangiocarcinoma cell line increased 
its sensitivity to the chemotherapeutic agent gemcitabine (Meng et al., 2006).  
(2) Hsa-miR-221 and hsa-miR-222 target ERα (Zhao et al., 2008) and p27Kip1 (Miller et 
al., 2008) and confer in vitro resistance to tamoxifen.  
(3) MiRNA expression profile is different between fulvestrant-resistant vs. -sensitive 
MCF7 cells and this may contribute to development of drug resistance (Xin et al., 2009).  
(4) A parental gastric cancer cell line (BCL2), when compared to its multidrug resistant 
progeny had altered expression profile for a small set of miRNAs (Xia et al., 2008).  
When some of those miRNAs (e.g., hsa-miR-15b and hsa-miR-16) were over expressed 
in the multidrug resistant progeny cells, they became sensitized to anticancer drugs, while 
inhibition of those miRNAs made the parental cell line multidrug resistant.   
 
Polymorphisms affect mRNA-miRNA interactions 
MicroRNA SNPs (miRSNPs) are SNPs that occur either in the miRNA or their 
target site on the mRNAs.  These miRSNPs can interfere with mRNA-miRNA interaction 
by destroying a miRNA target site or by creating a new miRNA target site.  Such loss or 
gain of miRNA targeting by miRSNPs can result in the development of drug resistance.  
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For example, dihydrofolate reductase (DHFR), an important enzyme involved in the 
intracellular folate metabolism has been shown to be differentially regulated in vitro by a 
miRSNP (Mishra et al., 2007).  In cancer chemotherapeutics, DHFR is a target of the 
drug methotrexate (MTX).  Wildtype DHFR is regulated by hsa-miR-24 through a target 
site in the DHFR mRNA 3‟-UTR.  A SNP (829C>T) that occurs near the miRNA target 
site interferes with the normal pairing of hsa-miR-24 with DHFR mRNA.  This results in 
DHFR over-expression and consequently, methotrexate resistance.  Similarly, a SNP in 
the hsa-miR-206 target site in the ERα mRNA contributes to increased repression ERα 
protein (Adams et al., 2007).  Such miRSNPs may have great clinical application (Mishra 
et al., 2007).   
MiRSNPs can thus act as a loss or gain of function mutation that result in loss of 
target repression or gain of illegitimate repression, respectively.  This can in turn lead to 
the development of drug resistance.  The regulation of the CYP450s by these miRSNPs 
may explain some of the interindividual variability seen in drug response.  A number of 
bioinformatic algorithms including PolymiRTS (Bao et al., 2007) and Patrocles (Georges 
et al., 2006) databases have been developed to identify the physiological effect of 
miRSNPs in the mRNA 3‟-UTR.   
 
Bioinformatic algorithms predict mRNA-microRNAs interactions 
 A number of bioinformatic algorithms are available for predicting mRNA-
miRNA interactions.  Most of these prediction algorithms have some common rules.  
These include: (1) „Seed sequence‟ - perfect or near perfect complementarity of 7 bases 
(base pair 2-8 in the 5‟ region of the miRNA) between mRNA and miRNA, (2) restricted 
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sequence searches of the 3‟-UTRs of mRNAs, and (3) homology between two or three 
animal genomes.  
Some of the important bioinformatic programs include:  
1. miRanda: miRanda algorithm (John et al., 2004) is based on sequence 
complementarity and uses position-specific rules for the identification of mRNA-miRNA 
target pairs.  This program requires strict conservation across species (human, mouse and 
rat; target position within ±10 residues of each other); it filters out the predicted target 
sites that are not well conserved.  The program also places emphasis on combinatorial 
regulation of one mRNA by many miRNAs.   
2. miRBase Targets: miRBase Targets (Griffiths-Jones et al., 2006) looks for 
complementarity between mRNA and miRNAs starting at the 5‟ end of the miRNA.  It 
requires strict complementarity in the „seed region‟ and does not predict alignments that 
have more than one mismatch in this region.  Species conservation is important; the 
target site in the 3‟-UTR has to be conserved and detected at the same position by a 
specific miRNA in at least two orthologous species.  
3. TargetScan: In order to predict the miRNA targets, TargetScan program 
(Lewis et al., 2003) relies on „seed region‟ identification, energy of binding between the 
RNA heteroduplex, and mRNA conservation across species (human, mouse and rat).  
Earlier versions of the program required strict species conservation.  However, the later 
version allows the users to choose the type of conservation: (1) highly conserved, (2) 
conserved, and (3) poorly conserved.  
4. PicTar: PicTar algorithm (Krek et al., 2005) predicts miRNAs based on 
evolutionary conservation of the 3‟-UTR sequences across related species.  The minimal 
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number of species is user defined.  The CYP450 genes do not appear to be a part of this 
program‟s database probably because they are not highly conserved.  
5. RNA22: RNA22 (Miranda et al., 2006) is a pattern-based program that first 
identifies the miRNAs target sites in a user defined RNA sequence and then identifies the 
corresponding miRNA(s).  Unlike other programs, RNA22 does not look for species 
conservation.  Hence, it also identifies the miRNA binding sites that are not conserved 
across species.  Also, as the input sequence is user defined, hence this program offers the 
flexibility of identifying miRNAs that target other regions of a gene – promoter, 5‟-UTR, 
or coding region. 
The differences in these algorithms are due to the approaches that are used to deal 
with the „loop-outs‟ that are formed by non-complementary regions, non-Watson and 
Crick base pairing and the stringency of conservation across species.  Four of these 
programs (miRanda, miRBase Targets, TargetScan and PicTar) use evolutionary 
conservation parameter.  The use of the evolutionary conservation parameter might 
decrease the noise, but may potentially fail to identify a lot of „true‟ mRNA-miRNA 
interaction because of the stringent species conservation requirement (Miranda et al., 
2006).  This can be overcome by supplementing with a program like RNA22 that does 
not require phylogenetic conservation.  Because of these inherent differences, different 
programs often predict different miRNAs to target the same mRNA.  Hence, using many 
programs in conjunction and applying a filter to select miRNAs will result in a 
comprehensive list of predicted miRNAs that can be tested in vitro. 
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Summary  
 CYP2D6 is a key drug metabolizing enzyme that is involved in the metabolism of 
a number of clinically important drugs.  There is considerable interindividual variability 
in CYP2D6 enzyme activity that leads to compromised drug metabolism, which in turn 
affects the clinical outcome.  This variability is due in part to CYP2D6 gene variants and 
due to drug-drug interactions that results in CYP2D6 enzyme inhibition.  Although these 
factors explain part of the interindividual variability in CYP2D6 enzyme activity, 
substantial unexplained variability still remains.  Post-transcriptional regulatory factors 
like microRNAs may explain some the variability; very little is known about the factors 
contributing to post-natal and post-transcriptional regulation of CYP2D6. 
 
Research aims and significance 
a. Research aims 
 Cytochrome P450 2D6 (CYP2D6) enzyme is involved in the metabolism of 20-
25% of drugs commonly used in the clinics, including tamoxifen (Ingelman-Sundberg, 
2005).  There is considerable interindividual variability in CYP2D6 enzyme activity; 
between different individuals, the CYP2D6 metabolic activity can vary up to a 1000-fold 
(Dahl et al., 1992).  This results in substantial variability in both beneficial and adverse 
side effects of CYP2D6 metabolized drugs.  Part of this variability can be explained by 
environmental factors and genetic factors.  The environmental factor includes diet and 
drug-drug interactions.  Many clinically important drugs are CYP2D6 enzyme inhibitors 
(Table 1.1) and consequently affect the metabolism of other CYP2D6 substrate drugs.  
The genetic factors include both polymorphisms and copy number variations in the 
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CYP2D6 gene.  CYP2D6 is a highly polymorphic gene with more than 78 allelic and 
allelic subvariants reported so far (www.cypalleles.ki.se/cyp2d6.htm).  These allelic 
variants result in proteins with no enzyme activity (PM), reduced enzyme activity (IM), 
„normal‟ enzyme activity (EM), or, increased enzyme activity (UM).  Deletion and 
multiplication of CYP2D6 gene has been reported; the phenotypic consequence of these 
CNVs will depend on the CYP2D6 alleles involved.  There is considerable variability in 
the frequencies of both CYP2D6 polymorphisms and gene copy numbers between 
different ethnicities.   
 The genetic and environmental factors only explain a part of the interindividual 
variability; the other factors that contribute to variability in CYP2D6 enzyme activity are 
largely unknown.  Hence, it becomes important to study CYP2D6 to understand the 
endogenous and exogenous factors that control its activity. 
 The overall hypothesis is that genetic and epigenetic factors contribute to the 
variability seen in CYP2D6 mediated drug response.  The specific objective of this 
research is to determine the contributions of CYP2D6 genotype, copy number 
polymorphism and microRNA to the variability in CYP2D6 mediated drug metabolism.  
Since hepatic CYP2D6 activity determines the therapeutic exposure to several commonly 
used drugs (including tamoxifen), a better understanding of the regulation of this enzyme 
will help explain the variable efficacy and side effects.  The specific objective will be 
tested through the following specific aims: 
Specific aim 1: To identify common CYP2D6 genetic variants in Vietnamese 
and Filipino women with breast cancer and to test the association of these variants 
with plasma endoxifen concentrations.  The working hypothesis is that in Vietnamese 
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and Filipino women on tamoxifen therapy, genetic polymorphisms in the CYP2D6 gene 
are associated with reduced plasma endoxifen concentration. 
Specific aim 2: To identify CYP2D6 gene copy number variations in 
Vietnamese and Filipino women with breast cancer and to test the association of 
these copy number variants with plasma endoxifen concentrations.  The working 
hypothesis is that high CYP2D6 copy number polymorphisms exist in Vietnamese and 
Filipino women and the presence of these CNVs is associated with altered CYP2D6 
enzyme activity and consequently changes in plasma endoxifen concentration.  
Specific aim 3: To identify microRNAs that target CYP2D6.  The working 
hypothesis is that the variability in the enzyme activity within a genotype may be due to 
direct or indirect miRNA regulation of CYP2D6.  That is, in subjects with the same 
CYP2D6 genotype, miRNAs regulate CYP2D6 expression by suppressing CYP2D6 
mRNA translation and thus contribute to the interindividual variability in CYP2D6 
expression. 
 
b. Significance 
 Published literature has shown that there is interindividual variability in CYP2D6 
enzyme activity.  A part of the interindividual variability in drug response is due to 
environmental and genetic factors.  However, the cause of much of the variability 
remains unknown.  This CYP2D6 mediated interindividual variability has clinical 
consequences.  While some individuals that poorly metabolize (PM) CYP2D6 substrate 
drugs have increased risk of adverse side effects from the parental drug, other individuals 
that metabolize these drugs faster (UM) show poor therapeutic response or increased 
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toxicity due to high concentration of the metabolites.  It has been estimated that the cost 
of treating patients with extreme CYP2D6 enzyme activity (UM and PM) is on average 
$4,000-6,000 per year greater than the cost of treating patients in the EM and IM groups 
(Chou et al., 2000). 
This research project aims to understand the contributions of genetic 
polymorphisms, copy number variations and microRNAs in the regulation of CYP2D6 
enzyme activity.  Upon completion of the first and second specific aims, the contribution 
of CYP2D6 polymorphisms and copy number variations to CYP2D6 enzyme activity and 
consequently tamoxifen metabolism in Vietnamese and Filipino women with breast 
cancer can be determined.  This is important because considerable interethnic variability 
in CYP2D6 variants have been reported; the phenotypic consequence of CYP2D6 gene 
variants has not been studied in these two Asian populations.  Also, tamoxifen is more 
commonly used than AIs in many developing countries in Asia.  Hence, these results 
obtained in the Vietnamese and Filipino population will help to personalize tamoxifen 
therapy.  Upon completion of the third specific aim, the role of microRNAs in the 
regulation of CYP2D6 would be elucidated for the first time.   
 The rationale for undertaking these studies is that a better understanding of the 
factors that regulate CYP2D6 will help to better predict the interindividual variability in 
CYP2D6 mediated drug metabolism.  This in turn, will lead to improvements in safety 
and efficacy of drugs metabolized by CYP2D6, including tamoxifen therapy for breast 
cancer.  Ultimately, the new information generated from this research, when added to 
already existing literature on CYP2D6 pharmacogenetics, will contribute to the 
personalization of drug therapy.  
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CHAPTER TWO 
Cytochrome P450 2D6 Variants Predict Endoxifen Concentration in Vietnamese 
and Filipino Breast Cancer Patients. 
The work presented in this chapter has been prepared in part for submission as 
„Cytochrome P450 2D6 and UDP-Glucoronosyl transferase 2B7 genetic variants predict 
tamoxifen active metabolite, endoxifen, in Vietnamese and Filipino breast cancer 
patients‟ by Zereusenay Desta, Anuradha Ramamoorthy, Todd Skaar, Michael Daum, 
Faouzi Azzouz, Lang Li, David Flockhart, Richard Love, et al. 
 
 
Abstract 
 Tamoxifen is a hormonal therapy that is used globally in the treatment and 
prevention of breast cancer.  Tamoxifen is metabolized to a more active metabolite, 
endoxifen, by the drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6).  Genetic 
polymorphisms in CYP2D6 reduce the enzyme activity and consequently reduce 
endoxifen concentration.  These CYP2D6 variants are also associated with poor clinical 
outcome.  There is considerable interethnic variability in the frequencies of CYP2D6 
gene polymorphisms.  In 93 Vietnamese and 144 Filipino premenopausal women 
diagnosed with breast cancer, the association between CYP2D6 genotype and endoxifen 
concentration was analyzed at 4 months after initiation of tamoxifen therapy (20 mg/day 
orally).  In the combined Vietnamese and Filipino cohort, the reduced function allele 
CYP2D6*10 was the most common allele with a frequency of 55.8%.  To evaluate the 
correlation between CYP2D6 polymorphisms and tamoxifen metabolism, these women 
were divided into four groups based on their CYP2D6 genotype score.  In these four 
different score groups: (1) EM/EM, (2) EM/IM, (3) IM/IM or EM/PM, and (4) IM/PM, 
the mean (±SD) plasma endoxifen concentrations were 145±139, 106±71, 66±63 and 
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61±31 nM, respectively and the endoxifen/N-desmethyltamoxifen ratios were 0.53±1.61, 
0.17±0.11, 0.09±0.14 and 0.06±0.02, respectively.  Both the endoxifen concentration and 
endoxifen/N-desmethyltamoxifen ratio were significantly different (p < .005) among 
these four groups in the combined population.  In conclusion, CYP2D6 gene variants are 
associated with lowered plasma concentration of endoxifen in the Vietnamese and the 
Filipino populations.  
 
Introduction 
 Tamoxifen is a selective estrogen receptor modulator (SERM) that is used 
globally in the hormonal therapy of estrogen receptor (ER) positive breast cancers in both 
pre- and post-menopausal women.  It has been repeatedly shown to improve both the 
disease-free and overall survival in breast cancer patients (Osborne, 1998; Clarke, 2006).  
Although tamoxifen is a very effective therapy, the pharmacodynamic response to 
tamoxifen varies considerably between individuals (Lonning et al., 1992; Ingle et al., 
1999).   
 Tamoxifen is metabolized by several of the cytochrome P450 (CYP450) enzymes 
into a number of metabolites with varying pharmacological activities (Desta et al., 2004).  
Of these enzymes, CYP2D6 is primarily responsible for the generation of one of the more 
active metabolite, endoxifen (Desta et al., 2004).  Endoxifen is ~30-100 fold more potent 
than the parent drug tamoxifen (Johnson et al., 2004).  It is equipotent to another 
metabolite, 4-hydroxytamoxifen, but it is present in much higher plasma concentration 
(Lee et al., 2003; Stearns et al., 2003; Johnson et al., 2004; Jin et al., 2005; Borges et al., 
2006).  Endoxifen is now being developed as a new therapeutic drug for breast cancer.  
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Pre-clinical study using cancer cell lines and rodent models has shown that endoxifen can 
act as a standalone drug and inhibit cellular proliferation (Ahmad et al., 2010); human 
clinical trials have not been reported yet. 
 In breast cancer patients undergoing tamoxifen therapy, the plasma concentration 
of endoxifen is affected by polymorphisms in the CYP2D6 gene (Stearns et al., 2003; Jin 
et al., 2005; Borges et al., 2006).  CYP2D6 is a highly polymorphic gene (Ingelman-
Sundberg, 2005); more than 78 alleles and allelic subvariants have been described so far 
(Human Cytochrome P450 Allele Nomenclature Committee: 
www.cypalleles.ki.se/cyp2d6.htm).  The frequencies of many of the CYP2D6 alleles vary 
with ethnicity (Bradford, 2002; Sistonen et al., 2007).  In Caucasians, the primary cause 
of poor metabolizer (PM) status is the CYP2D6*4 allele, followed by other alleles 
including CYP2D6*3, *5 and *6; the combined frequency of these alleles is about 20-
30% (Bradford, 2002; Sistonen et al., 2007).  However, in Asians, CYP2D6*3-*6 alleles 
are present in about 5-6% (Bradford, 2002; Sistonen et al., 2007).  In Asians, the primary 
cause of reduced CYP2D6 activity is the CYP2D6*10 allele.  The frequency of the 
CYP2D6*10 allele is 40-60% in the Asians, but is less than 1% in the Caucasians 
(Bradford, 2002; Sistonen et al., 2007).   
 The CYP2D6 gene polymorphisms that lead to reduced (IM) or poor (PM) 
enzyme activity are associated with reduced plasma endoxifen concentration (Stearns et 
al., 2003; Jin et al., 2005; Borges et al., 2006) and poor clinical outcomes (Goetz et al., 
2005; Bonanni et al., 2006; Goetz et al., 2007; Gonzalez-Santiago et al., 2007; Schroth et 
al., 2007; Schroth et al., 2009).  Published data on CYP2D6 genotype-endoxifen 
concentration or CYP2D6 genotype-outcome is largely from Caucasian populations.  To 
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date, little information is available from the different Asian populations (Wain et al., 
2009).  Studies performed in Korea (Lim et al., 2007), Japan (Kiyotani et al., 2008) and 
China (Xu et al., 2008) have suggested that CYP2D6*10 is associated with poorer clinical 
outcome.  Not all studies have confirmed these findings in both Caucasian and Asian 
populations (Nowell et al., 2005; Wegman et al., 2005; Wegman et al., 2007; Okishiro et 
al., 2009). 
 This study is set up as a prospective clinical trial for breast cancer patients 
undergoing adjuvant tamoxifen therapy in two Asian countries - Vietnam and the 
Philippines in order to study the association of CYP2D6 gene polymorphism, tamoxifen 
metabolism and clinical outcome.  As a part of the initial analyses, the association 
between CYP2D6 genetic variants and the concentrations of tamoxifen and its 
metabolites were determined. 
 
Results 
Patient characteristics:  
 The breast cancer patient cohort consisted of 93 Vietnamese and 144 Filipino 
premenopausal women.  These women were diagnosed with clinical stage II-III hormone 
receptor positive breast cancer by biopsy.  They were treated with surgical oophorectomy 
and tamoxifen.  There were no statistically significant difference in demographic 
characteristics between different the CYP2D6 genotype groups (Table 2.1).    
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CYP2D6 variants and allele frequencies  
 Genotyping was performed for 7 different CYP2D6 alleles including those that 
are common in Asian and Caucasian population, CYP2D6*2-*6, *10, and *41.  The 
CYP2D6 alleles that did not carry any of the variations mentioned above were designated 
as CYP2D6*1.  The functional CYP2D6 alleles (CYP2D6*1 and *2) were designated as 
extensive metabolizers (EM), reduced function alleles (CYP2D6*10 and *41) were 
designated as intermediate metabolizers (IM), and nonfunctional alleles (CYP2D6*4 and 
*5) were designated as poor metabolizers (PM).   
 The CYP2D6 allele frequencies for both the Vietnamese and the Filipino 
populations are listed in Table 2.2.  The most frequent allele present in both the 
populations was the IM allele, CYP2D6*10.  The CYP2D6 poor metabolizer alleles that 
are frequent in Caucasians, CYP2D6*3, *4, *6 were absent in both the populations.  Most 
of the allelic frequencies, except CYP2D6 *2 in the Filipino population, were in 
accordance with the Hardy-Weinberg equilibrium (Table 2.2).  The frequencies of the 
genotype combinations, along with their predicted metabolizer phenotype and score are 
given in Table 2.3.   
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Table 2.2: CYP2D6 allele frequencies in the Vietnamese and Filipino breast cancer 
patients.  
CYP2D6 allele 
Frequency (%) 
Vietnamese 
cohort 
Filipino 
cohort 
Combined 
cohort 
*10 59.1 53.6 55.8 
*1 25.3 30.0 28.1 
*2 9.7 12.1 
a
 11.2 
a
 
*5 4.8 2.1 3.2 
*41 1.1 2.1 1.7 
*4 0 0 0 
*3 0 0 0 
*6 0 0 0 
Note: 
a
 CYP2D6 allele not in Hardy-Weinberg equilibrium (HWE).  The HWE was not 
calculated for CYP2D6*1 and other alleles (CYP2D6*3, *4 and *6) that were not present 
in the Vietnamese and/or Filipino populations.  
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Table 2.3: CYP2D6 genotypes in Vietnamese and Filipino breast cancer patients. 
Note: EM – extensive metabolizer with CYP2D6 functional allele; IM – intermediate 
metabolizer with CYP2D6 reduced function allele; PM – poor metabolizer with CYP2D6 
null allele; Undetermined – failure to make a CYP2D6 genotype call. 
 
Association between CYP2D6 variants and plasma tamoxifen metabolites  
 CYP2D6 genotype and tamoxifen metabolite concentration data was available for 
88 individuals in the Vietnamese cohort and 138 individuals in the Filipino cohort.  Only 
these individuals were included for subsequent genotype to phenotype association 
analyses.   
CYP2D6 
metabolizer 
status 
Score 
CYP2D6 
genotype 
Frequency (%) 
Vietnamese 
cohort         
Filipino 
cohort        
Combined 
cohort       
EM/EM 2 
*1/*1  6.5 1.4 3.4 
*1/*2  3.2  8.6 6.4 
*2/*2  1.1  7.9 5.2 
EM/IM 1.5 
*1/*10  30.1  47.1 40.3 
*2/*10  12.9 0 5.2 
*1/*41  1.1  1.4 1.3 
EM/PM 1 
*1/*5  3.2 0  1.3 
*2/*5  1.1 0  0.4 
IM/IM 1 
*10/*10  34.4  26.4 29.6 
*10/*41  1.1  2.9 2.1 
PM/IM 0.5 *5/*10 5.4 4.3 4.7 
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 In the entire cohort of Vietnamese patients, the mean plasma concentrations (± 
SD) of tamoxifen was 385 ± 281 nM, N-desmethyltamoxifen (NDM) was 640 ± 459 nM, 
4-hydroxytamoxifen (4-OH-tam) was 4.4  ± 3.8 nM, and endoxifen was 80.9  ± 63.9 nM.  
Similarly, in the entire cohort of Filipino patients, the mean plasma concentrations (± SD) 
of tamoxifen was 617 ± 790 nM, NDM was 1059 ± 1249 nM, 4-OH-tam was 5.2 ± 4.4 
nM, and endoxifen was 105.5 ± 96.3 nM.   
 For the purpose of this analysis, individuals were classified into four predicted 
phenotypic groups based on their genotype score (Table 2.3): EM/EM (score = 2), 
EM/IM (score = 1.5), EM/PM and IM/IM (score = 1), and IM/PM (score = 0.5).  The 
association between the CYP2D6 score groups and tamoxifen and its metabolites 
concentrations were analyzed by ANOVA.  No significant associations were observed 
between the four CYP2D6 score groups and the concentrations of the parent drug 
tamoxifen, or two other metabolites, NDM and 4-OH-tam in the Filipino or the combined 
cohorts.  However in the Vietnamese cohort, significant association (p < .05) was 
observed between the four CYP2D6 score groups and 4-OH-tam concentrations, but not 
for the parent drug tamoxifen or NDM concentrations (Figure 2.1 A-C; Table 2.4 A-C).   
 The plasma concentration of endoxifen (p ≤ .001; Figure 2.1 D; Table 2.4 A-C) 
was significantly associated with CYP2D6 score groups in the Vietnamese and the 
combined cohort, but not in the Filipino cohort.  Similarly, the endoxifen/NDM ratio (p < 
.05; Figure 2.1 E; Table 2.4 A-C) were significantly associated with CYP2D6 score 
groups in the Vietnamese, Filipino and the combined Vietnamese and Filipino cohorts.  
The wildtype CYP2D6 alleles (*1 and *2; score group 2) had higher plasma endoxifen 
concentration and higher endoxifen/NDM ratio when compared to the other CYP2D6 
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score groups with one or more variant alleles.  However, there is still considerable 
interindividual variability in plasma endoxifen concentrations and endoxifen/NDM ratio 
even within the same CYP2D6 score group (Figure 2.1 D and E).  Based on the 
regression analyses, these CYP2D6 gene variants explain 15%, 8% and 10% of the 
variability in the endoxifen concentration, and 4%, 6% and 30% of the variability in the 
endoxifen/NDM ratio, in the Vietnamese, Filipino and the combined cohorts, 
respectively. 
  
Table 2.4 A-C: Plasma concentrations of tamoxifen and its metabolites in subjects 
with different CYP2D6 score. 
 (A) Vietnamese cohort 
 
  
CYP2D6 
score 
N 
Mean concentration, nM (± SD) 
tamoxifen 
N-desmethyl 
tamoxifen 
4-hydroxy 
tamoxifen 
endoxifen 
endoxifen/
NDM ratio 
2 10 349 ± 264 458 ± 403 6.3 ± 5.1 125.2 ± 90.1 1.27 ± 2.98 
1.5 40 406 ± 226 668 ± 393 4.8 ± 2.9 100.6 ± 62.2 0.18 ± 0.12  
1 34 336 ± 281 609 ± 502 3.1 ± 2.7 53.3 ±  47.5  0.12 ± 0.20  
0.5 4 562 ± 322 925 ± 434 4.8 ± 2.5 61.8 ± 23.5 0.07 ± 0.02 
p-value  . 88 .29 .01 
a
 .001 
a
 < .03 
a
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(B) Filipino cohort 
CYP2D6 
score 
N 
Mean concentration, nM (± SD) 
tamoxifen 
N-desmethyl 
tamoxifen 
4-hydroxy 
tamoxifen 
endoxifen 
endoxifen/
NDM ratio 
2 25 671 ± 788 1003 ± 1046 6.1 ± 5.5 152.2 ± 155.8 0.23 ± 0.14 
1.5 67 487 ± 477 818 ± 695 4.9 ± 3.3 109.0 ± 75.5 0.17 ± 0.11 
1 40 817 ± 1150 1487 ± 1908 5.3 ± 5.5 77.1 ± 72.4 0.07 ± 0.04  
0.5 6 519 ± 455 1141 ± 654 4.6 ± 2.9 61.1 ± 37.9 0.05 ± 0.01  
p-value  .45 .09 .58 .08 < .0001 
a
 
 
(C) Combined cohort 
CYP2D6 
score 
N 
Mean concentration, nM (± SD) 
tamoxifen 
N-desmethyl 
tamoxifen 
4-hydroxy 
tamoxifen 
endoxifen 
endoxifen/
NDM ratio 
2 35 579 ± 692 848 ± 937 6.1 ± 5.3 144.5 ± 139.4 0.53 ± 1.61 
1.5 107 456 ± 403 762 ± 602 4.8 ± 3.1 105.9 ± 70.7 0.17 ± 0.11 
1 74 596 ± 895 1083 ± 1501 4.3 ± 4.5 66.2 ± 63.0 0.09 ± 0.14  
0.5 10 536 ± 387 1005 ± 559 4.7 ± 2.6 61.4 ± 31.4 0.06 ± 0.02  
p-value  .63 .11 .06 < .0001 
a
 < .005 
a
 
Note: Mean plasma concentration ± SD for tamoxifen and its metabolites, N-
desmethyltamoxifen, 4-hydroxytamoxifen, endoxifen, endoxifen/NDM ratio in (A) the 
Vietnamese cohort (N = 88 individuals), (B) the Filipino cohort (N = 138 individuals), 
and (C) the combined cohorts (N = 226 individuals) based on the CYP2D6 score; a p-
value < .05 based on ANOVA. 
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Figure 2.1 A-E: Association between CYP2D6 gene score and tamoxifen and its 
metabolites concentrations.  
(A) Tamoxifen 
 
(B) N-desmethyltamoxifen 
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(C) 4-hydroxytamoxifen  
 
(D) Endoxifen  
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(E) Endoxifen/N-desmethyltamoxifen ratio 
 
 
Note: The effect of CYP2D6 score groups on tamoxifen and its metabolites concentration 
in Vietnamese (N = 88 individuals), Filipino (N = 138 individuals), and combined 
cohorts (N = 226 individuals) after tamoxifen therapy (20 mg/day) for four months.  The 
solid bars represent mean + SD of (A) tamoxifen; (B) N-desmethyltamoxifen; (C) 4-
hydroxytamoxifen; (D) endoxifen concentration in the Vietnamese (orange circle), 
Filipino (green triangle), combined cohort (brown diamond) based on the CYP2D6 score; 
(E) endoxifen/N-desmethyltamoxifen ratio (with one outlier removed) in the Vietnamese 
(orange diamond), Filipino (green triangle), and combined cohort (brown diamond); * 
indicates p < .05 on a pair-wise comparison with the CYP2D6 score group 2.0 (wildtype). 
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Discussion 
 Worldwide, tamoxifen is the standard endocrine therapy for estrogen receptor 
positive breast cancer.  However, efficacy and side effects of this therapy are not 
predictable for individual patients.  Recent data suggest that genetic differences among 
individuals in tamoxifen metabolizing enzymes, primarily, CYP2D6 may account for 
significant variability in response to this drug (Goetz et al., 2005; Bonanni et al., 2006; 
Goetz et al., 2007; Lim et al., 2007; Schroth et al., 2007; Kiyotani et al., 2008; Xu et al., 
2008; Schroth et al., 2009).  Most of CYP2D6 genotype-clinical outcome studies have 
been primarily focused on the Caucasian population poor metabolizer allele, CYP2D6*4 
(Goetz et al., 2005; Bonanni et al., 2006; Goetz et al., 2007; Schroth et al., 2007; Schroth 
et al., 2009).  These studies showed that when compared to EMs, the PMs had fewer 
adverse events but, increased frequency of cancer recurrence.  Similarly in Asian women, 
three studies have reported an association between the CYP2D6 intermediate metabolizer 
allele, CYP2D6*10 and poor clinical outcome (Lim et al., 2007; Kiyotani et al., 2008; Xu 
et al., 2008).  Together, these studies have suggested that in the prevention, adjuvant and 
metastatic settings, PMs and IMs have an increased rate of cancer recurrence and 
decreased rate of survival.  However, these results have not been confirmed by all the 
studies (Nowell et al., 2005; Wegman et al., 2005; Wegman et al., 2007; Okishiro et al., 
2009).  In these studies reporting a negative or a lack of association between CYP2D6 
genotype and clinical outcome, one reason for the discordant result may be that, the EMs 
discontinued the therapy while, the PMs continued with their therapy.  The EMs can have 
increased side effects when compared to the PMs and this may lead to discontinuation of 
therapy in the EM group (Rae et al., 2009).  However, this explanation cannot be 
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confirmed as these studies do not report data on drug compliance, side effects and 
concentrations of tamoxifen and its metabolites.  Hence, in order to understand the 
association between CYP2D6 gene variants, endoxifen concentration and the clinical 
outcome, controlled prospective trials are needed. 
 A prospective clinical trial is being conducted in Vietnamese and Filipino 
premenopausal women with breast cancer who are on adjuvant tamoxifen therapy.  In this 
study, the association between CYP2D6 polymorphisms and metabolism of tamoxifen 
was analyzed.  In this study population, the frequency of CYP2D6 intermediate 
metabolizers (IM) was higher than the other metabolizer groups (Table 2.1 and 2.2).  The 
reduced function allele CYP2D6*10 was the most frequent allele (54-59%) in both the 
populations.  The other alleles that are common in Caucasian population, CYP2D6*3, *4, 
*6 and *41 were present in less than 2% frequency (Table 2.1 and 2.2).  The frequency of 
these CYP2D6 allelic variants in our present study of Vietnamese and Filipino women 
were similar to the other Asian populations previously reported (Kubota et al., 2000; Cai 
et al., 2007; Kiyotani et al., 2008; Lee et al., 2009; Veiga et al., 2009).   
 Since the CYP2D6 polymorphisms influence the metabolism of tamoxifen to 
endoxifen in other populations (Stearns et al., 2003; Jin et al., 2005; Borges et al., 2006), 
the association of the CYP2D6 polymorphisms with plasma endoxifen concentration in 
the Vietnamese and Filipino populations was investigated.  The results suggested that the 
reduced function variants, primarily CYP2D6*10, were significantly associated with 
reduced metabolism of tamoxifen to its active metabolite, endoxifen (Figure 2.1 D and E; 
Table 2.4).  In the combined Vietnamese and Filipino cohorts, both endoxifen 
concentration and endoxifen/NDM ratio were significantly different (p < .005) between 
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the four CYP2D6 score based groups.  These results are consistent with our previous 
studies in Caucasian women (Stearns et al., 2003; Jin et al., 2005; Borges et al., 2006) 
and also studies reported by others in Caucasian (Gjerde et al., 2008) and Asian (Lim et 
al., 2007) women showing that CYP2D6 genetic variants are associated with reduced 
plasma endoxifen concentration.  The concentrations of both the parent drug tamoxifen 
and the metabolite NDM were not significantly different among the different score 
groups.  However, the concentration of another metabolite, 4-OH-tam was significantly 
different in the Vietnamese cohort.  This metabolite is generated in part, by the activity of 
CYP2D6 (Desta et al., 2004) and this result is consistent with another previous study 
reported in Korean population (Lim et al., 2007).  
  This study shows that plasma endoxifen concentration is associated with CYP2D6 
genotype; however there is still considerable variability within each CYP2D6 genotype 
group (Figure 2.1 D and E).  Based on the analyses, CYP2D6 variants explain 
approximately 8-15% of the variability in the endoxifen concentration, and 4-30% of the 
variability in the endoxifen/NDM ratio, in these two populations.  Although CYP2D6 
genotype appears to explain a fairly small amount of the variability, it is reproducible and 
it appears to be important in clinical outcomes.  In some cases, this interindividual 
variability may be explained by other rare CYP2D6 alleles or other genes involved in 
endoxifen clearance (e.g., UGT2B7) that were not analyzed.   
 In conclusion, this study provides the first comprehensive analysis of the 
association between CYP2D6 polymorphisms and the concentration of endoxifen in 
Vietnamese and Filipino women.  In many developing countries including Vietnam and 
the Philippines, tamoxifen is preferred over aromatase inhibitors (AI) because of its low 
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cost.  Hence, a better understanding of the interindividual variability in the benefits and 
side effects would help to improve the effectiveness and compliance of this life saving 
drug. 
 
Materials and Methods 
 Patients: Premenopausal women with breast cancer were recruited from Vietnam 
(Hanoi K Hospital; N = 93) and Philippines (Philippine General Hospital; N = 144).  
These women were newly diagnosed with clinical stage II-III hormone receptor positive 
breast cancer.  These women were treated with tamoxifen (20 mg/day orally) adjuvant to 
surgical oophorectomy.  Tamoxifen (Nolvadex) was supplied by AstraZeneca.  The study 
protocol was approved by the respective institutional review boards of all the 
participating institutions in three countries (Vietnam, Philippines and USA).  The patients 
gave their informed consent to participate in this study. 
 Sample processing: The blood samples were collected after four months of 
therapy.  Based on the half-life of tamoxifen, by four months, the plasma concentration is 
expected to reach the steady-state.  The collected specimen were centrifuged and 
separated under light-protected conditions into plasma, serum and leukocytes.  The 
specimens were stored at -70ºC and shipped in liquid nitrogen canisters to Indiana 
University, where the samples were analyzed for CYP2D6 genotype and plasma 
endoxifen concentrations.  
 DNA extraction and quantification: Genomic DNA was isolated from the 
leukocytes using the QIAamp DNA Blood Maxi Kit (Qiagen, Valencia, CA, USA) and 
stored at -80ºC until use.  The DNA concentrations were measured by Quant-iT DNA 
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Broad Range Kit (Invitrogen, Carlsbad, CA, USA).  The DNA was diluted to 10 ng/µl 
and used for performing the CYP2D6 genotyping assays.   
 Genotyping the CYP2D6 variants: CYP2D6 is a highly polymorphic gene with 
more than 78 different alleles and allelic subvariants.  In our patient population, the 
genotyping was performed for CYP2D6*2, *3, *4, *5, *6, *10 and *41 alleles.  These 
alleles were selected because they are expected to cover >95% of the known reduced 
functional and nonfunctional alleles in the Asian and Caucasian populations (Bradford, 
2002; Sistonen et al., 2007; Veiga et al., 2009).  Genotyping was performed for *2-*4, 
*6, *10 and *41 using the predeveloped TaqMan Genotyping Assays (Applied 
Biosystems, Foster City, CA, USA) following the manufacturer‟s instructions.  The 
dbSNP rs id and the assay catalog numbers are: rs1135840 (C__27102414_10), 
rs35742686 (C__32407232_50), rs3892097 (C__27102431_D0), rs1065852 
(C__11484460_40) and rs28371725 (C__34816116_20).  The CYP2D6*5 allele was 
assayed by using long range PCR (XL-PCR) as described previously (Gaedigk et al., 
2008).  Briefly, a 2.9 Kb PCR product for CYP2D6*5 was generated using the following 
primers: forward primer: 5‟CTCCAGCCTCCACCAGTCCAG and reverse primer: 
5‟CAGGCATGAGCTAAGGCACCCAGAC.  The wildtype CYP2D6 allele (i.e., one 
without any deletions) does not produce a PCR product for these primers.  A 3.8 kb IL-10 
(forward primer: 5‟GCATGCACAGCTCAGCACTGC and reverse primer: 
5‟GCCACCCTGATGTCTCAGTTTCG) was used as an internal control (present in all 
the samples) to assure that the DNA quality was sufficient to perform the long template 
PCR.  The long range PCR was carried out using JumpStart REDAccuTaq LA DNA 
polymerase (Sigma, St. Louis, MO, USA) in a 16 µl reaction volume containing 20 ng of 
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the genomic DNA.  The annealing temperature was 68ºC and extension time was 4.5 min.  
The PCR products (3 µl) were analyzed by 1% agarose gel electrophoresis.  For the 
purpose of this study, CYP2D6 alleles that did not carry any of the variations mentioned 
above were designated as CYP2D6*1.  The alleles were designated as CYP2D6*10 if 
they had the 100T variant, but not the 1846A mutation.  Although, 100T is present in 
CYP2D6*36, in this study, we did not distinguish between CYP2D6*10 and *36.  As a 
quality control measure, 10% of randomly selected samples were re-genotyped for each 
SNP.   
 CYP2D6 gene score: Based on the expected enzyme activity, the CYP2D6 alleles 
were assigned a score (Borges et al., 2010).  Fully functional CYP2D6 alleles (*1 and *2) 
were assigned a score of 1, alleles associated with reduced enzyme activity (*10 and *41) 
were assigned a score of 0.5 and the nonfunctional alleles (*3-*6) were assigned a score 
of 0.  The bi-allelic score for CYP2D6 genotype was the summation of the two individual 
alleles.  
 Assays of tamoxifen and metabolites: Tamoxifen and its metabolites 
concentrations were measured by Desta et al., using routine LC-MS/MS method, as a part 
of the collaborative ongoing study.  
 Statistical analysis: Chi-square tests were performed for the calculation of 
Hardy-Weinberg equilibrium for all the alleles.  The comparison between CYP2D6 gene 
score and the plasma concentrations of tamoxifen and its metabolites, N-
desmethyltamoxifen, 4-hydroxytamoxifen, endoxifen and the derivative endoxifen/NDM 
ratio was performed using ANOVA and regression analysis.  A p-value of < .05 was 
considered to be statistically significant.    
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CHAPTER THREE 
CYP2D6 Copy Number Variations in Vietnamese and Filipino Breast Cancer 
Patients and the Effect of CYP2D6*36 Allele on Endoxifen Concentration. 
The work presented in this chapter has been prepared in part for submission as „CYP2D6 
copy number variations in Vietnamese and Filipino breast cancer subjects: effect of 
CYP2D6*36 on tamoxifen metabolites‟ by Anuradha Ramamoorthy, Michael Daum, 
Zereusenay Desta, Faouzi Azzouz, David Flockhart, Richard Love, Todd Skaar, et al. 
 
Abstract 
 The cytochrome P450 2D6 (CYP2D6) is an important drug metabolizing enzyme 
that is involved in the metabolism of 20-25% of commonly prescribed drugs.  Copy 
number variations (CNVs) in the CYP2D6 gene can affect enzyme activity and 
consequently, metabolism of many drugs.  Multiple CYP2D6 alleles are involved in 
CNVs and the enzyme activity depends on the allele involved.  CNVs involving 
CYP2D6*10 and *36 alleles are common in Japanese and Chinese population; however, 
their frequencies in many other Asian populations are unknown.  To determine CYP2D6 
gene copy numbers, quantitative RT-PCR assays were performed in a clinical trial 
involving the Vietnamese (N = 93) and Filipino (N = 144) breast cancer patients 
undergoing tamoxifen therapy.  The results indicated that only 39% of the individuals had 
two copies of the CYP2D6 gene; 3.8% had only one copy and 57.2% had more than 2 
copies of the CYP2D6 gene.  The most common allele involved in CNV was 
CYP2D6*36-*10, with a frequency of 31.4%.  To determine the phenotypic consequence 
of these CYP2D6 CNVs, the plasma concentration of endoxifen in individuals with 
CYP2D6*10, CYP2D6*36-*10 and CYP2D6*36-*36-*10 alleles were compared.  The 
results suggest that there is a trend of decreased enzyme activity with increased numbers 
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of CYP2D6*36 copies.  However, the activity of CYP2D6(*36)n-*10 allele was not 
significantly different from that of the CYP2D6*10 allele.  The CYP2D6(*36)n-*10 allele 
does not appear to affect the metabolizer status of an individual, i.e., like the CYP2D6*10 
carriers, the individuals with CYP2D6(*36)n-*10 alleles can also be classified as 
intermediate metabolizers.  In conclusion, the Vietnamese and Filipino women have a 
high CYP2D6 CNV and this frequently involves the CYP2D6(*36)n-*10 allele.  This 
CYP2D6(*36)n CNV allele does not appear to reduce or increase the function of the 
adjacent CYP2D6*10 allele in these two Asian populations.   
 
Introduction 
 The cytochrome P450 2D6 (CYP2D6) is a member of the cytochrome P450 
superfamily of drug metabolizing enzymes that is involved in the metabolism of 20-25% 
of commonly prescribed drugs (Ingelman-Sundberg, 2005).  The CYP2D6 is a highly 
polymorphic gene; over 78 alleles and allelic subvariants have been described so far 
(Human Cytochrome P450 Allele Nomenclature Committee: 
www.cypalleles.ki.se/cyp2d6.htm).  These polymorphisms alter CYP2D6 enzyme 
activity and consequently, affect the pharmacokinetics, efficacy and side effects of drugs 
that are metabolized by it (Ingelman-Sundberg, 2005; Eichelbaum et al., 2006).  There is 
considerable interethnic variability in the population incidence of these polymorphisms 
(Bradford, 2002; Sistonen et al., 2007).  For example, in Caucasians, the polymorphisms 
that result in complete loss of activity (poor metabolizer - PM), CYP2D6*3-*6 are 
present at a relatively high frequency (20-30%) when compared to the Asians (5-6%) 
(Bradford, 2002; Sistonen et al., 2007).  In Asians, the most common allele is 
71 
 
CYP2D6*10, a reduced function allele (intermediate metabolizer - IM) that is present at a 
frequency of 40-60% (Johansson et al., 1994; Garcia-Barcelo et al., 2000).  Currently, the 
most widely used method (Fukuda et al., 1999; Xu et al., 2008) for genotyping 
CYP2D6*10 involves testing for the presence of the 100C>T variant.  However, the 100T 
nucleotide is also present in CYP2D6*36, a null allele (Chida et al., 2002; Gaedigk et al., 
2006; Sakuyama et al., 2008) which is also present in a high frequency in Asians 
(Hosono et al., 2009).  In fact, in Japanese, CYP2D6*36-*10 gene duplication 
arrangement was more frequent than *10 alone [30% vs. 6% (Soyama et al., 2006) and 
24% vs. 9% (Hosono et al., 2008)].  Since the CYP2D6*10 and *36 alleles have different 
functional activities, it is important to distinguish between these alleles for predicting an 
individual‟s CYP2D6 phenotype.   
 Although polymorphisms in CYP2D6 account for a large portion of the 
interindividual variability seen in CYP2D6 mediated drug metabolism, copy number 
variations (CNV) in the CYP2D6 gene also appear to be important contributors of 
variability (Weinshilboum, 2003; Eichelbaum et al., 2006; Yu and Shao, 2009).  These 
CYP2D6 CNVs are composed of both whole gene deletions and multiplications.  The 
frequencies of these CNVs also have considerable interethnic variability.  The 
frequencies of CYP2D6*5 gene deletion (1-7%), CYP2D6*1-*1 gene duplication (0.2-
13%) and *2-*2 gene duplication (0.5-8%) are comparable in Africans, Caucasians and 
Asians (Bradford, 2002; Sistonen et al., 2007).  However, there is considerable difference 
in cases of other CYP2D6 alleles.  For example, CYP2D6*4-*4, *35-*35 and *41-*41 
gene duplications are common (0.6-15%) in the Caucasians, while the CYP2D6*36-*10 
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and *10-*10 gene duplications are common (20-30%) in the Asians (Bradford, 2002; 
Soyama et al., 2006; Sistonen et al., 2007; Hosono et al., 2009).   
 These CYP2D6 gene CNVs have important phenotypic consequence.  For 
example, CYP2D6*5, i.e., gene deletion results in poor metabolizer (PM) status that 
severely compromises an individual‟s ability to metabolize CYP2D6 substrate drugs.  
However, the phenotypic consequence of the CYP2D6 multiple copies depends on the 
allele that is duplicated (source: www.cypalleles.ki.se/cyp2d6.htm).  For example: (a) the 
carriers of multiple copies of functional CYP2D6 alleles (*1xN, *2xN) have increased 
enzyme activity and are classified as ultrarapid metabolizers (UM); (b) the carriers of 
*36-*10 or multiple copies of *10x2 do not have increased enzyme activity when 
compared to the carriers of *10 and therefore are still considered to be intermediate 
metabolizers (IM); and (c) carriers of CYP2D6*36x2 and CYP2D6*4x2 have negligible 
enzyme activity and are still considered to be poor metabolizers (PM).  However, little is 
known about the phenotypic consequence of other multiple copy arrangements such as 
*36-*10-*10 and *36-*36-*10.   
 The CYP2D6 gene polymorphisms and copy number variations can affect enzyme 
activity and hence the metabolism of a number of CYP2D6 substrate drugs including 
tamoxifen.  Tamoxifen is used worldwide in the prevention and treatment of hormone-
receptor positive breast cancer.  There is considerable interindividual variability in 
tamoxifen metabolism and response (Lonning et al., 1992; Ingle et al., 1999).  Tamoxifen 
is metabolized into a more active metabolite, endoxifen by the activity of CYP2D6 
(Desta et al., 2004).  Polymorphisms and copy number variations in CYP2D6 gene are 
associated with reduced plasma endoxifen concentration (Stearns et al., 2003; Jin et al., 
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2005; Borges et al., 2006) and poor clinical outcomes (Goetz et al., 2005; Bonanni et al., 
2006; Goetz et al., 2007; Gonzalez-Santiago et al., 2007; Lim et al., 2007; Schroth et al., 
2007; Kiyotani et al., 2008; Xu et al., 2008; Schroth et al., 2009).  However, not all 
studies have confirmed the association between CYP2D6 genotype and clinical outcomes 
(Nowell et al., 2005; Wegman et al., 2005; Wegman et al., 2007; Okishiro et al., 2009).  
One of the possible explanations for the discordant results in these studies is that the PMs 
(who generally have fewer side effects) continued with their tamoxifen therapy, while the 
EMs (who generally have more side effects) discontinued the therapy.  About 30-50% of 
women do not complete the 5 year tamoxifen regimen (Barron et al., 2007); one of the 
reasons for discontinuation of the therapy is increased side effects in the EMs when 
compared to the PMs (Rae et al., 2009).  However, this cannot be confirmed as these 
studies do not have data on drug compliance and have not measured the plasma 
concentrations of tamoxifen and its metabolites.  Hence, prospective controlled trials are 
needed to understand the association between CYP2D6 gene variants, endoxifen 
concentration and the clinical outcome of tamoxifen therapy.  
 Currently, a prospective clinical trial is being conducted involving the Vietnamese 
and Filipino breast cancer patients undergoing adjuvant tamoxifen therapy.  This trial will 
ultimately be able to address the association between CYP2D6 variants and clinical 
outcomes.  For the first part of this study, the association between CYP2D6 gene variants 
and endoxifen concentration was previously determined (Chapter Two).  In that study, 
the most common allele was CYP2D6*10 (~55% frequency) and it was associated with 
lower plasma endoxifen concentration.   
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 In this current study, based on the evolutionary background of CYP2D6 in two 
other Asian populations – Chinese and Japanese (Hosono et al., 2009), the hypothesis 
was that the Vietnamese and Filipino women may also have frequent CYP2D6 copy 
number variations and this may affect the enzyme activity.  To date, little is known about 
the presence of CYP2D6 CNVs or CYP2D6*36 in the Vietnamese and Filipino 
population.  Hence, the objective of this study was to determine the presence of CNVs 
and the functional consequence of CYP2D6*36 CNVs in the Vietnamese and Filipino 
populations. 
 
Results 
Estimation of CYP2D6 gene copy number variations 
 In order to estimate the CYP2D6 gene copy numbers, CYP2D6 copy number 
assays were performed in 237 (N = 93 Vietnamese and N = 144 Filipino) breast cancer 
patients who were undergoing tamoxifen therapy.  Seventeen of these samples were not 
included in subsequent analyses because: (a) samples failed to amplify, or (b) failure to 
accurately estimate CYP2D6 gene copy numbers (e.g., ambiguous copy number reads, or 
lack of concordance in the CYP2D6 copy numbers estimated by 5‟flank and Int2 assays), 
or (c) failure to identify the allele involved in the copy number variation.  Reliable 
CYP2D6 allele and copy number information was available for 210 samples; only these 
were included in the subsequent analyses.   
 The results indicated that in our combined cohort, only 39% of the individuals had 
2 copies of the CYP2D6 gene.  The rest of the individuals carried a genomic imbalance 
for CYP2D6 gene; 3.8% of the individuals had only 1 copy due to gene deletion 
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(CYP2D6*5), 42.5% had 3 copies, 11.4% had 4 copies, and 3.3% had 5 or more copies of 
the CYP2D6 gene (Figure 3.1).  The frequencies of these CNVs were comparable for 
both Vietnamese and Filipino populations (Figure 3.1). 
 
Figure 3.1: Frequency of CYP2D6 gene copy number variations in Vietnamese and 
Filipino breast cancer patients. 
 
Note: CYP2D6 gene copy number was estimated using 5‟flank qRT-PCR CNV assay 
along with an internal control, RNase P TaqMan Copy Number Reference Assay.  For 
copy number estimation, each sample was analyzed in triplicate.  
 
Estimation of CYP2D6 alleles and diplotypes 
 The CYP2D6 diplotypes were estimated using the CNV phaser software (Kato et 
al., 2008).  Three different analyses were performed:  
(1) The Vietnamese population (N = 82) and the Filipino population (N = 128) were 
analyzed separately using the CNV phaser.  
(2) Because of CYP2D6 allelic and CNV frequencies were comparable between the 
Vietnamese and Filipino population, both the cohorts were combined (N = 210) for the 
second set of analysis using the CNV phaser. 
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(3) Since the CYP2D6 allelic and CNV frequencies in the Vietnamese and Filipino 
population were comparable to that of the Japanese and Chinese populations reported 
previously (Hosono et al., 2009), all the four populations were combined (N = 653) by 
extrapolating data from Hosono et al., (Hosono et al., 2009) for all the CYP2D6 alleles 
that were included in our genotype analysis (N = 443).   
 The results indicated that in the three different analyses, the probability scores for 
the different diplotypes were comparable with the exception of some very rare 
diplotypes.  Since the probability scores were similar, the results from only the combined 
cohort (N = 210) is reported here (Table 3.1 and 3.2).  The most frequent CYP2D6 alleles 
involved in copy number variations (Table 3.1) were *36-*10 (31.4%), *5 (3.6%) and 
*36-*36-*10 (2.4%).  The CYP2D6*36 allele was almost always present along with a 
copy of a *10 allele (99.8% of the cases).  Of the diplotypes with copy number variations 
(Table 3.2), *1/*36-*10 was the most frequent (24.3%), followed by *10/*36-*10 (11%) 
and *36-*10/*36-*10 (9%).   
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Table 3.1: CYP2D6 allelic frequencies in the different cohorts. 
CYP2D6 allele 
Frequency % 
Vietnamese 
cohort 
Filipino 
cohort 
Combined 
cohort 
*36-*10 
a
 32.9 30.5 31.4 
*1 27.4 28.5 28.1 
*10 17.7 21.9 20.2 
*2 9.1 11.7 10.7 
*5 
a
 4.9 2.7 3.6 
*36-*36-*10 
a
 4.3 1.2 2.4 
*41 1.2 2.0 1.7 
*36-*10-*10 
a
 0.6 0.4 0.5 
*1-*1 0.6 0.0 0.2 
*10-*10 
a
 0.0 0.4 0.2 
*2-*2 
a
 0.0 0.4 0.2 
*36-*36 
a
 0.6 0.0 0.2 
*36-*36-*36-*10 
a
 0.0 0.4 0.2 
*36-*36-*36-*36-*36-*10 
a
 0.6 0.0 0.2 
Note: 
a
 CYP2D6 alleles that are involved in copy number polymorphism. 
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Table 3.2: Frequencies of CYP2D6 diplotypes in the different cohorts. 
CYP2D6 diplotype 
Probability 
Score 
a
 
N (%) 
Vietnamese 
cohort 
Filipino 
cohort 
Combined 
cohort 
*1/*36-*10
 b
 1 14 (17.1) 37 (28.9) 51 (24.3) 
*1/*10 1 12 (14.6) 19 (14.8) 31 (14.8) 
*10/*36-*10
 b
 1 11 (13.4) 12 (9.4) 23 (11.0) 
*36-*10/*36-*10
 b
 0.88 7 (8.5) 12 (9.4) 19 (9.0) 
*1/*2 1 3 (3.7) 10 (7.8) 13 (6.2) 
*10/*10 1 1 (1.2) 9 (7.0) 10 (4.8) 
*2/*2 1 0 9 (7.0) 9 (4.3) 
*1/*1 1 5 (6.1) 2 (1.6) 7 (3.3) 
*2/*36-*10
 b
 1 7 (8.5) 0 7 (3.3) 
*36-*10/*36-*36-*10
 b
 0.95 5 (6.1) 0 5 (2.4) 
*5/*36-*10
 b
 1 1 (1.2) 3 (2.3) 4 (1.9) 
*1/*5
 b
 1 3 (3.7) 0 3 (1.4) 
*5/*10
 b
 1 1 (1.2) 2 (1.6) 3 (1.4) 
*10/*41 1 0 3 (2.3) 3 (1.4) 
*2/*10 1 3 (3.7) 0 3 (1.4) 
*1/*41 1 1 (1.2) 1 (0.8) 2 (1.0) 
*2/*5
 b
 1 1 (1.2) 1 (0.8) 2 (1.0) 
*1/*36-*36-*10
 b
 1 0 2 (1.6) 2 (1.0) 
*36-*10/*41
 b
 1 1 (1.2) 1 (0.8) 2 (1.0) 
*5/*36-*36-*10
 b
 1 1 (1.2) 1 (0.8) 2 (1.0) 
*1/*1-*1
 b
 1 1 (1.2) 0 1 (0.5) 
*1/*36-*36-*36-*36-*36-*36-*10
 b
 1 1 (1.2) 0 1 (0.5) 
*10/*10-*10
 b
 1 0 1 (0.8) 1 (0.5) 
*10/*36-*10-*10
 b
 1 0 1 (0.8) 1 (0.5) 
*2/*2-*2
 b
 1 0 1 (0.8) 1 (0.5) 
*2/*36-*36-*10
 b
 1 1 (1.2) 0 1 (0.5) 
*36-*10/*36-*36
 b
 0.93 1 (1.2) 0 1 (0.5) 
*36-*36-*36-*10/*36-*10
 b
 0.61 0 1 (0.8) 1 (0.5) 
*5/*36-*10-*10
 b
 1 1 (1.2) 0 1 (0.5) 
Note: 
a
 Probability score reported from the CNV phaser analysis of combined cohort (N = 
210); 
b
 CYP2D6 diplotypes that are involved in copy number polymorphisms. 
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Correlation between CYP2D6 allele copy numbers and the plasma concentration of 
tamoxifen and its metabolites 
 More than 50% of the samples had at least one copy of CYP2D6*36 allele (Table 
3.1and 3.2).  Hence, the association between CYP2D6*36 gene copy numbers and the 
plasma endoxifen concentration was determined.  Tamoxifen and its metabolite 
concentration between were compared in the following groups:  
(a) *1/*10, *1/*36-*10 and *1/*36-*36-*10,  
(b) *10/*10, *10/*36-*10, *36-*10/*36-*10 and *36-*10/*36-*36-*10, and  
(c) *5/*10, *5/*36-*10 and *5/*36-*36-*10.   
 For these comparisons, there was no significant difference in plasma endoxifen 
concentration or endoxifen/N-desmethyltamoxifen concentration ratio (Table 3 A-C; 
Figure 3.2 A and B).  These results suggest that CYP2D6*36 copy number variation is 
not significantly associated with increased or decreased CYP2D6 enzyme activity.  
Similarly, when the activity of CYP2D6*10 was compared with both *36-*10 and *36-
*36-*10 alleles combined together [i.e., CYP2D6(*36)n-*10], the results indicated that 
the activity of (*36)n-*10 was not significantly different from that of *10.  Similarly, the 
concentrations of the parent drug tamoxifen and the other metabolites 4-
hydroxytamoxifen and N-desmethyltamoxifen were not associated with CYP2D6 enzyme 
activity (Table 3.3 A-C).  
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Table 3.3 A-C: Plasma concentrations of tamoxifen and its metabolites in subjects 
with different CYP2D6 diplotypes involved in CYP2D6(*36)n copy number 
variations.  
 (A) Combined cohort 
  
CYP2D6 
diplotype 
a
 
N 
Mean concentration, nM (± SD) 
Tamoxifen 
N-desmethyl 
tamoxifen 
4-hydroxy 
tamoxifen 
Endoxifen 
Endoxifen/ 
NDM ratio 
*1/ 
*10 
34 463 ± 396 729 ± 531 5.1 ± 3.0 118.2 ± 74.1 0.19 ± 0.13 
*1/ 
*36-*10 
58 439 ± 355 790 ± 648 4.5 ± 2.9 95.6 ± 62.1 0.15 ± 0.06 
*1/ 
*36-*36-*10 
2 667 ± 40 943 ± 9 5.0 ± 1.3 117.9 ± 28.7 0.12 ± 0.03 
*10/ 
*10 
10 1038 ± 1228 1734 ± 1995 6.4 ± 6.3 95.7 ± 83.2 0.07 ± 0.02 
*10/ 
*36-*10 
21 602 ± 1128 1076 ± 20037 4.2 ± 5.7 65.2 ± 75.6 0.13 ± 0.26 
*36-*10/ 
*36-*10 
18 701 ± 908 1305 ± 1398 4.9 ± 3.9 67.7 ± 56.9 0.07 ± 0.04 
*36-*10/ 
*36-*36-*10 
5 325 ± 342 663 ± 571 3.2 ± 3.8 41.0 ± 37.6 0.06 ± 0.01 
*5/ 
*10 
3 652 ± 659 1309 ± 993 5.5 ± 3.5 78.4 ± 47.4 0.07 ± 0.02 
*5/ 
*36-*10 
4 446 ± 295 844 ± 322 3.6 ± 1.9 48.6 ± 20.9 0.06 ± 0.01 
*5/ 
*36-*36-*10 
2 567 ± 379 1057 ± 390 4.8 ± 4.2 62.4 ± 39.1 0.06 ± 0.02 
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(B) Vietnamese cohort  
CYP2D6 
diplotype
 a
 
N 
Mean concentration, nM (± SD) 
Tamoxifen 
N-desmethyl 
tamoxifen 
4-hydroxy 
tamoxifen 
Endoxifen 
Endoxifen/ 
NDM ratio 
*1/ 
*10 
15 459 ± 237 699 ± 313 5.6 ± 3.0 129.7 ±71.5 0.22 ± 0.17 
*1/ 
*36-*10 
20 367 ± 227 655 ± 480 4.1 ± 2.5 80.1 ± 49.8 0.15 ± 0.08 
*1/ 
*36-*36-*10 
0      
*10/ 
*10 
1 81 176 1.0 16.0 0.09 
*10/ 
*36-*10 
10 273 ± 147 480 ± 455 2.8 ± 1.9 59.9 ± 57.4 0.21 ± 0.36 
*36-*10/ 
*36-*10 
6 469 ± 506 763 ± 688 4.4 ± 4.5 51.6 ± 52.6 0.06 ± 0.02 
*36-*10/ 
*36-*36-*10 
5 325 ± 342 663 ± 571 3.2 ± 3.8 41.0 ± 37.6 0.06 ± 0.01 
*5/ 
*10 
1 138 329 2.6 32.8 0.10 
*5/ 
*36-*10 
1 788 907 2.7 64.6 0.07 
*5/ 
*36-*36-*10 
1 835 1333 7.8 90.1 0.07 
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(C) Filipino cohort  
CYP2D6 
diplotype
 a
 
N 
Mean concentration, nM (± SD) 
Tamoxifen 
N-desmethyl 
tamoxifen 
4-hydroxy 
tamoxifen 
Endoxifen 
Endoxifen/ 
NDM ratio 
*1/ 
*10 
19 466 ± 493 753 ± 662 4.7 ± 3.0 109.1 ± 76.7 0.17 ± 0.09 
*1/ 
*36-*10 
38 476 ± 405 860 ± 717 4.8 ± 3.1 103.8 ± 66.9 0.14 ± 0.05 
*1/ 
*36-*36-*10 
2 667 ± 40 943 ± 9 5.0 ± 1.3 117.9 ± 28.7 0.12 ± 0.03 
*10/ 
*10 
9 
1144 ± 
1252 
1907 ± 2035 7.0 ± 6.4 104.6 ± 83.1 0.07 ± 0.02 
*10/ 
*36-*10 
11 901 ± 1522 1617 ± 2676 5.4 ± 7.7 70.0 ± 91.8 0.06 ± 0.03 
*36-*10/ 
*36-*10 
12 817 ± 1056 1576 ± 1602 5.1 ± 3.7 75.8 ± 59.4 0.08 ± 0.05 
*36-*10/ 
*36-*36-*10 
0      
*5/ 
*10 
2 910 ± 686 1799 ± 729 7.0 ± 3.5 101.2 ± 37.0 0.06 
*5/ 
*36-*10 
3 333 ± 229 824 ± 392 4.0 ± 2.2 43.2 ± 21.9 0.05 ± 0.01 
*5/ 
*36-*36-*10 
1 299 781 1.9 34.8 0.04 
Note: (A) Combined cohort (N = 163); (B) Vietnamese cohort (N = 61); and (C) Filipino 
cohort (N = 102); 
a
 *1 is inclusive of both *1 and *2 alleles.  
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Figure 3.2: Correlation between CYP2D6 allele copy numbers with tamoxifen 
metabolism in the combined cohort. 
 (A) Endoxifen concentration
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(B) Endoxifen/NDM ratio 
 
Note: The effect of CYP2D6 score groups on endoxifen concentration in the Combined 
cohort (N = 157 individuals) after tamoxifen therapy (20 mg/day) for four months.  The 
solid bars represent mean + SD of (A) endoxifen concentration and (B) endoxifen/N-
desmethyltamoxifen ratio based on the CYP2D6 genotype and copy number variations.   
 
Discussion 
 The drug metabolizing enzyme cytochrome P450 2D6 (CYP2D6) is involved in 
the metabolism of 20-25% of commonly prescribed drugs (Ingelman-Sundberg, 2005).  
Both CYP2D6 gene polymorphisms and copy number variations (CNVs) are known to 
affect the enzyme activity and response to CYP2D6 substrate drugs (Ingelman-Sundberg, 
2005; Eichelbaum et al., 2006).  The CYP2D6 CNVs involve either deletion or 
multiplication of the entire gene.  These CYP2D6 CNVs are present in all ethnicities, but 
85 
 
the alleles involved in the CNV are different among the different ethnicities (Bradford, 
2002; Sistonen et al., 2007).  For example, CNVs involving CYP2D6*36-*10 allele has 
been reported to be present in a high frequency in Asians, specifically Japanese and 
Chinese (Hosono et al., 2009).  However, the prevalence of CYP2D6 CNV in the 
Vietnamese and Filipino populations is not known. 
 The most widely used method of genotyping CYP2D6*10 is by the presence of 
100T mutation (Fukuda et al., 1999; Xu et al., 2008).  However, this genotyping method 
does not distinguish between CYP2D6*10 and CYP2D6(*36)n-*10 as the 100T 
polymorphism is also present in CYP2D6*36.  This CYP2D6*36 allele is thought to have 
arisen from CYP2D6*10 that had undergone recombination with CYP2D7 pseudogene, 
specifically in the exon 9 region.  The CYP2D6*36-*10 allele was first described in the 
Chinese population as a tandem 44kb fragment by XbaI digestion (Johansson et al., 
1994).  This CYP2D6*36-*10 haplotype is different from the CYP2D6*10-*10 
duplication haplotype (Soyama et al., 2006).  In vitro studies using recombinant 
CYP2D6*36 (expressed singly and not in tandem as CYP2D6*36-*10) showed that the 
protein content was decreased and the enzyme activity was negligible suggesting that the 
CYP2D6*36 allele belonged to the PM group (Hanioka et al., 2006; Sakuyama et al., 
2008).  These in vitro studies have suggested that because CYP2D6*36 had extremely 
low enzyme activity, the enzyme activity of CYP2D6*36-*10 would be comparable to 
that of CYP2D6*10.  In vivo studies involving CYP2D6*36-*36 duplication allele in one 
Japanese (Chida et al., 2002) and CYP2D6*36 allele in one Asian and four African 
American (Gaedigk et al., 2006) individuals concluded that carriers of the CYP2D6*36 
allele were PMs.  Thus, the carriers of CYP2D6*36 and CYP2D6*36-*36 are considered 
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to be PMs, while the carriers of CYP2D6*36-*10 are considered to be IMs.  However, 
not much is known about the phenotypic consequence of other complex arrangements 
including the (*36)n-*10 allele.  Recent studies in Asian women from Korea (Lim et al., 
2007), China (Xu et al., 2008) and Japan (Kiyotani et al., 2008) who were on adjuvant 
tamoxifen therapy have suggested that the CYP2D6*10 allele is associated with poor 
clinical outcomes.  However, these studies did not distinguish between CYP2D6*10 and 
copy number variations involving CYP2D6(*36)n-*10, a CNV that is very common in 
Japanese and Chinese individuals (Hosono et al., 2009).   
 This study is the first comprehensive study to analyze: (1) the CYP2D6 CNVs in 
Vietnamese and Filipino population and (2) the functional consequence of CYP2D6*36 
copy number variations.  In a prospective clinical trial involving 93 Vietnamese and 144 
Filipino women on adjuvant tamoxifen therapy, the presence of CYP2D6 gene CNVs was 
investigated.  The results indicated that in the combined cohort, only 39% of the 
individuals carried 2 copies of the CYP2D6 gene.  Approximately 61% of the individuals 
had a genomic imbalance for CYP2D6 - 3.2% had a CYP2D6 gene deletion (CYP2D6*5) 
and 57.2% of the individuals had three or more copies of the CYP2D6 gene (Figure 3.1).  
These results are comparable to the CYP2D6 CNVs reported in Japanese and Chinese 
individuals (Hosono et al., 2009).   
 The results of the CNV phaser program (Kato et al., 2008) that was used to 
estimate the CYP2D6 diplotypes indicated that 34.2% of the individuals had allelic CNVs 
involving the CYP2D6(*36)n-*10 duplication alleles.  In most of these individuals 
(99.8% of the cases), the CYP2D6(*36)n allele was almost always present along with a 
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copy of a CYP2D6*10 allele (Table 3.1).  Diplotypes involving these CNV alleles were 
also fairly common with a frequency of about 50% (Table 3.2).   
 In order to determine the phenotypic consequence of these CNVs involving the 
CYP2D6(*36)n alleles, tamoxifen and its metabolite concentration between different 
alleles: *10 vs. *36-*10 vs. *36-*36-*10 and also *10 vs. (*36)n -*10 were compared.  
There was no significant difference in plasma endoxifen concentration or 
endoxifen/NDM ratio between the different groups indicating that CYP2D6*36 copy 
number variations were not significantly associated with increased or decreased CYP2D6 
enzyme activity (Table 3.3 A-C; Figure 3.2 A and B).  The enzyme activity of 
CYP2D6*36-*10 and CYP2D6*36-*36-*10 is comparable to that of CYP2D6*10.  That 
is, based on tamoxifen metabolism, these CYP2D6(*36)n CNV alleles are still null alleles 
and consequently, can be considered as poor metabolizers.  However, there appears to be 
a trend of decreased enzyme activity with an increase in the number of CYP2D6*36 
copies.  That is, in some cases, plasma endoxifen concentration and endoxifen/NDM ratio 
of *10 allele is greater than *36-*10 allele, which in turn is greater than that of *36-*36-
*10 allele (Table 3.3 A-C; Figure 3.2 A and B).  Further confirmation of these results in 
other Asian populations will add to the literature.  However, even after correcting for 
these copy number variations, there is considerable unexplained interindividual 
variability (Figure 3.2 A and B).   
 A number of genes involved in the metabolism of drugs and xenobiotics are also 
known to exhibit gene copy number variations - UGT2B17 and UGT2B28 (McCarroll et 
al., 2006), SULT1A1 (Hebbring et al., 2007), GSTT1 and GSTM1 (Bolt and Thier, 2006).  
These CNVs can have functional consequence; however, CNVs involving the SULT1A1 
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gene were not found to be associated with the concentration of tamoxifen or its 
metabolites (Gjerde et al., 2008).  
 In the human genome, copy number variations are fairly common (Iafrate et al., 
2004; Sebat et al., 2004).  Thousands of copy number variable regions (CNVR) that 
ranges from 100 bp to several Mb have been reported (Redon et al., 2006).  Recent 
studies have suggested an increasing role for CNVs in many diseases including cancer, 
developmental diseases, mental illness autoimmune diseases and infectious diseases 
(Shrestha et al., 2009; Wain et al., 2009).  However, our knowledge of the functional 
consequences of these CNVs is still very poor.  The phenotypic consequence of the 
individual copies of a gene within the CNVRs is not clearly elucidated.  The results of 
this study suggest that all copies of a gene are not created equal.  Multiple copies of a 
gene do not always translate to additive effects.   
 Overall, this study indicated that CYP2D6 gene copy number variations exist in a 
high frequency in the Vietnamese and Filipino populations.  These copy number 
variations primarily involve the CYP2D6(*36)n-*10 alleles.  This study is the first large 
scale study to report that based on the plasma endoxifen concentration, the 
CYP2D6(*36)n-*10 enzyme activity is not significantly different from that of 
CYP2D6*10.  Hence, in order to determine the phenotypic consequence, in addition to 
determining the total CYP2D6 copy numbers, it is important to determine which alleles 
have altered copy numbers.  The high frequency of CNVs involving the CYP2D6*36 null 
allele in these Asian populations raises some interesting questions about the evolution of 
such complex CYP2D6 gene rearrangements. 
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Materials and Methods 
 Estimation of CYP2D6 gene copy numbers and the presence of CYP2D6*36 
allele: The CYP2D6 gene copy numbers were estimated using a quantitative RT-PCR 
CNV assay - 5‟flank assay (Hosono et al., 2009) along with an internal control RNase P 
TaqMan Copy Number Reference Assay (ABI, Forest City, CA, USA).  For copy number 
estimation, each sample was analyzed in triplicate using the TaqMan Genotyping PCR 
Master Mix (ABI, Forest City, CA, USA), in a 15 µL reaction including 20 ng of 
genomic DNA (5 ng/µl) in a Step-One Plus PCR instrument (Applied Biosystems, Forest 
City, CA, USA).  The final concentrations of 5‟flank assay primers and hydrolysis probes 
were 900 nmol/L and 200 nmol/L, respectively.  The cycling conditions used were: 95ºC 
for 10 min for initial denaturation and enzyme activation, followed by 40 cycles each of 
95ºC for 15 s and 60ºC for 1 min.  The relative quantitation (RQ) was performed using 
the CopyCaller Software (Applied Biosystems, Forest City, CA, USA), following the 
comparative ∆∆CT method.  Two Coriell panel samples - NA18529 (2 copies) and 
NA18968 (3 copies) were used as internal controls for CYP2D6 gene CNVs (Hosono et 
al., 2009).  The assay was repeated in 10% of randomly selected samples to check for 
concordance and reproducibility.  Additionally, another qRT-PCR assay, Int 2 assay 
(Hosono et al., 2009) was performed in 20-30% of the samples to check for concordance 
with the 5‟flank assay.   
 Another copy number assay, Hs00010001_cn (Ex9; ABI, Forest City, CA, USA) 
was used to estimate the number CYP2D6*36 alleles.  This assay specifically targets 
exon 9 region of CYP2D6 gene.  Since the CYP2D6*36 allele undergoes gene conversion 
with CYP2D7 in exon 9, the Ex9 assay does not amplify CYP2D6*36 allele.  The 
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difference in copy numbers between the 5‟flank assay and this Ex9 assay was used to 
indirectly estimate the copy number of CYP2D6*36 allele.  This approach has been 
verified using 32 DNA samples from the Japanese and Chinese Coriell diversity panel 
(Ramamoorthy et al., 2010).  The assay was repeated using 10% of randomly selected 
samples to check for concordance and reproducibility.   
 Statistical analysis: In order to identify the CYP2D6 diplotypes, the CNV phaser 
software was used (Kato et al., 2008).  For this analysis, all the CYP2D6 alleles 
(CYP2D6*1, *2, *3, *4, *5, *6, *10, *36 and *41) were included.  As described 
previously (Hosono et al., 2009), the copy number data was rounded to an integer and the 
diplotypes with the highest diplotype probability score are reported.   
 The comparison between the different CYP2D6 diplotype groups and the plasma 
concentrations of tamoxifen and its metabolites, N-desmethyltamoxifen, 4-
hydroxytamoxifen, endoxifen and also endoxifen/NDM ratio were analyzed by ANOVA 
and Wilcoxon sum-rank test using the SPSS software (version 13.0; SPSS Inc, Chicago, 
IL, USA).  A p-value of < .05 was considered to be statistically significant. 
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CHAPTER FOUR 
In silico and In vitro Identification of microRNAs that Post-transcriptionally 
Regulate HNF4A Expression. 
The work presented in this chapter has been prepared in part for submission as „In silico 
and in vitro identification of microRNAs regulating hepatic drug metabolism: post-
transcriptional regulation of HNF4A by microRNAs‟ by Anuradha Ramamoorthy, Lang 
Li, David Flockhart and Todd Skaar. 
 
Abstract 
Cytochrome P450 2D6 (CYP2D6) enzyme activity is highly variable among 
individuals; this variability is not completely explained by known environmental and 
genetic factors.  To further understand this variability, the role of microRNAs (miRNAs) 
in the regulation of CYP2D6 expression was investigated.  MiRNA identification 
algorithms were used to predict the miRNAs that regulate CYP2D6 and its transcriptional 
factor, hepatic nuclear factor 4α (HNF4A).  The results suggested that both genes are 
targets of miRNAs.  Using these bioinformatic predictions, in vitro functional validation 
studies were performed.  For CYP2D6, none of the five miRNAs that were tested 
regulated its expression.  For HNF4A, five out of six miRNAs that were tested by 
luciferase assays, down-regulated its activity by 20-40%.  In HepG2 cells, two of the 
miRNAs (hsa-miR-34a and hsa-miR-449a) down-regulated HNF4A protein expression 
by 30-60%.  These two miRNAs did not reduce the levels of HNF4A mRNA, but did 
down-regulate the level a HNF4A down-stream target, pregnane X receptor (PXR) 
mRNA by 30-40%, suggesting that the miRNAs are blocking HNF4A protein synthesis.  
Of these miRNAs, the highest expressed miRNA in hepatocytes was hsa-miR-34a.  
Additionally, bioinformatic algorithms were used to identify polymorphisms in the 
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HNF4A mRNA 3‟-untranslated region (3‟-UTR) that might affect normal mRNA-
miRNA interaction.  In vitro luciferase assays validated this prediction for a SNP 
(rs11574744) in the HNF4A 3‟-UTR; the luciferase activity of the variant was two-fold 
higher than the wild-type.  These findings demonstrate a potential role for miRNAs in the 
regulation of genes involved in drug metabolism.  Identification of endogenous hepatic 
miRNAs that regulate CYP2D6 directly or indirectly should be useful for understanding 
the clinical interindividual variability in drug metabolism and efficacy.  
 
Introduction 
 The cytochrome P450 2D6 (CYP2D6) enzyme metabolizes 20-25% of commonly 
prescribed drugs including many antidepressants, beta-blockers and anticancer agents 
(Ingelman-Sundberg, 2005).  The CYP2D6 gene is highly polymorphic and these 
polymorphisms affect enzyme activity (Ingelman-Sundberg, 2005; Eichelbaum et al., 
2006).  However, even within the same CYP2D6 genotype group [e.g., extensive 
metabolizers (EM) or intermediate metabolizers (IM)], there is still unexplained 
interindividual variability (Borges et al., 2006).  A part of this variability may be due to 
co-medication with drugs that act as CYP2D6 inhibitors (Stearns et al., 2003; Jin et al., 
2005).  While genetic and environmental factors explain only a part of the interindividual 
variability in CYP2D6 enzyme activity, substantial unexplained variability still remains.  
Epigenetic mechanisms may also contribute to the variability (Ingelman-Sundberg et al., 
2007); however, little is known about which factors are important. 
MicroRNAs are small (18-25 nucleotides), noncoding RNAs that regulate gene 
expression post-transcriptionally.  In animals, miRNAs typically bind to the 3‟-
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untranslated region (3‟-UTR) of the messenger RNAs (mRNAs) and negatively regulate 
gene expression either by blocking protein translation or by degrading the mRNA (Olsen 
and Ambros, 1999; Ambros et al., 2003).  As more miRNAs are identified and studied, 
newer target sites and functions are being recognized.  For example, it has now been 
shown that miRNAs can also bind to coding regions and repress gene expression 
(Duursma et al., 2008); this mechanism may explain some of the differential expression 
seen in mRNA splice variants.  MiRNAs also appear to be involved in the induction of 
gene expression; this induction occurs through binding to complementary regions in the 
promoter (Place et al., 2008) and the 5‟-UTR (Orom et al., 2008).  
In the human genome, 940 mature miRNAs have been reported so far (miRBase 
Registry; version 15.0; Griffiths-Jones et al., 2006).  Bioinformatic programs predict that 
miRNAs can regulate 20-90% of the mRNA transcripts (Lewis et al., 2005; Xie et al., 
2005; Miranda et al., 2006).  Each miRNA can regulate multiple genes and each gene can 
be regulated by multiple miRNAs; therefore, these miRNAs form a broad and complex 
regulatory network. 
MicroRNAs are involved in a wide range of biological activities including cell 
differentiation, cell death, cancer and noncancerous human diseases (John et al., 2004).  
Emerging evidence indicates that these miRNAs also regulate genes involved in drug 
disposition.  Those studies have focused on genes such the ATP-binding cassette 
transporter ABCG2 (To et al., 2008), pregnane X receptor (PXR; Takagi et al., 2008), 
cytochrome P450 1B1 (CYP1B1; Tsuchiya et al., 2006) and cytochrome P450 3A4 
(CYP3A4; Pan et al., 2009).  Others have also speculated that interindividual variability in 
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CYP450 expression and drug response may be due to the action of miRNAs (Ingelman-
Sundberg et al., 2007).   
The activity of miRNAs can be affected by single nucleotide polymorphisms 
(SNPs) that occur either in the miRNA or in the miRNA target site on the mRNA.  Such 
SNPs are called miRSNPs (Mishra et al., 2007).  These miRSNPs can alter miRNA gene 
processing and/or the normal mRNA-miRNA interactions.  Thus, these SNPs can create 
new miRNA target sites or destroy old target sites.  Hence, these miRSNPs may also 
contribute to the interindividual variability in the CYP450 enzyme expression and 
activity.  
The overall goal of the present study was to investigate the role of miRNAs in the 
regulation of CYP2D6 enzyme expression.  The HNF4A gene was also included in this 
analysis as it regulates the expression of CYP2D6 (Cairns et al., 1996; Corchero et al., 
2001).  HNF4A is an important transcriptional „master regulator‟ that regulates the 
expression of a number of drug metabolizing genes including phase I enzymes, phase II 
enzymes, transporters and transcriptional factors that regulate the CYP450 genes 
(Kamiyama et al., 2007).  Thus, regulation of HNF4A by miRNAs would likely affect 
many genes that are involved in drug metabolism.  Hence, the substantial unexplained 
variability in CYP2D6 enzyme activity may be due to direct regulation of CYP2D6 by 
miRNAs, as well as indirect regulation of it through HNF4A. 
In this study, the central hypothesis is that endogenous miRNAs regulate the 
expression of CYP2D6 and its transcription factor HNF4A.  MiRNA regulation of 
HNF4A may explain some of the as yet unexplained variability in CYP2D6 expression.  
To test this hypothesis, bioinformatic analyses were first performed to predict miRNAs 
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that target CYP2D6 and HNF4A, followed by in vitro functional validation studies.  
Lastly, polymorphisms in the miRNA target sites on HNF4A 3‟-UTR that are predicted 
to alter the mRNA-miRNA interactions were identified.  Collectively, these results 
suggest that miRNAs are likely to play an important role in the regulation of drug 
metabolism.  
 
Results 
Bioinformatic predictions to identify miRNAs 
Six bioinformatic algorithms were used to identify miRNAs that are predicted to 
target CYP2D6 and HNF4A: the algorithms were miRanda (John et al., 2004), miRBase 
Targets (Griffiths-Jones et al., 2006), TargetScan (Lewis et al., 2003), PicTar (Krek et al., 
2005), RNA22 (Miranda et al., 2006) and PITA (Kertesz et al., 2007).  These algorithms 
predicted that both the genes were miRNA targets (Table 4.1).  There was considerable 
variability in the number of miRNAs that were predicted by the different programs to 
target CYP2D6 and HNF4A.  The CYP2D6 gene has a 75 bp long 3‟-UTR and was 
predicted to be targeted by 7 different miRNAs.  The HNF4A gene has a 1724 bp long 3‟-
UTR and was predicted to be targeted by 350 different miRNAs.  
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Table 4.1: MicroRNAs that are predicted to target the 3’-UTR of CYP2D6 and 
HNF4A.  
Genes and 
Reference 
id. 
a
 
3’-UTR 
length 
(bp) 
Bioinformatic Programs 
b, c
 
Total no. 
of unique 
miRNAs 
d
 
Overlap 
e
 
miRBase 
Targets 
miRNA 
-da 
Target
Scan 
RNA22 PITA 
CYP2D6 
(NM_ 
000106) 
75 5 0 3 1 2 7 4 
HNF4A 
(NM_ 
000457) 
1724 10 13 112 251 63 350 99 
Note: 
a
 RefSeq Gene id from UCSC Genome browser in parenthesis; 
b
 PicTar predictions 
are not included in the table as CYP2D6 and HNF4A do not appear to be a part of the 
program‟s database; c Versions of the bioinformatic programs (retrieved on 07/27/2008): 
(1) miRBase Targets using miRBase release 11.0, (2) miRanda and TargetScan version 
4.2 uses miRBase release 10.0, (3) miRBase Registry version 10.0 was used in RNA22 
algorithm, and (4) PITA uses miRBase release 9.0; 
d
 Total number of unique miRNAs 
predicted by all the programs; 
e
 Total number of
 
miRNAs predicted to target the genes by 
at least 2 programs.  
 
In vitro functional studies to test the bioinformatic predictions 
 In the first functional study, 3‟-UTRs of CYP2D6 and HNF4A genes were cloned 
into the 3‟-UTR of the luciferase gene of the pIS-0 luciferase reporter construct (Figure 
4.1).  These plasmids with CYP2D6 and HNF4A 3‟-UTR are referred to as pIS-2D6 and 
pIS-HNF4A, respectively. 
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Figure 4.1: Schematic representation of the pIS-2D6 and pIS-HNF4A vectors.
 
Note: In pIS-2D6 vector, 72 bp of the full length 75 bp CYP2D6 3‟-UTR was cloned and 
in pIS-HNF4A vector, 1448 bp of the full length 1724 bp HNF4A 3‟-UTR was cloned.  
 
 In the in vitro studies, both pIS-2D6 and pIS-HNF4A plasmids significantly 
reduced (p < .01) luciferase activity, relative to the pIS-0 (control) plasmid (Figure 4.2).  
The luciferase activities of pIS-2D6 and pIS-HNF4A plasmids were approximately 55% 
and 60 % lower than the pIS-0 control plasmid.  The effect of both the CYP2D6 and 
HNF4A 3‟-UTRs were consistent across three concentrations of transfected plasmids, but 
was not significantly different (Figure 4.2).  These results indicated that the 3‟-UTRs of 
both the CYP2D6 and HNF4A genes have repressive activities, possibly through miRNA 
targeting.   
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Figure 4.2: Regulatory elements in the 3’-UTR of CYP2D6 and HNF4A.  
 
Note: HeLa, a cervical cancer cell line was transfected with pIS-0 (control), or pIS-2D6, 
or pIS-HNF4A plasmids at three different concentrations (100, 200 and 400 ng per well).  
Renilla luciferase plasmid was used as an internal control.  Dual luciferase assays were 
performed 24 hours after transfection.  Data are expressed as the pIS-2D6 and pIS-
HNF4A luciferase activities corrected for Renilla luciferase and normalized to the pIS-0 
within each experiment (mean ± SEM; n = 3 independent experiments performed in 
triplicates).  
a
 indicates p < .01 in pIS-2D6 and pIS-HNF4A when compared to the control 
pIS-0. 
 
The next set of studies focused on testing the effect of individual miRNAs on the 
pIS-2D6, pIS-HNF4A and the control pIS-0 plasmids.  Candidate miRNAs were selected 
based on two criteria: (1) the miRNA predicted by two or more of the bioinformatic 
algorithms and (2) favorable energy of binding (∆G) between the miRNA and the target 
sequence on the mRNA.  Among those that fit these criteria were hsa-miR-493* 
(formerly referred to as hsa-miR-493-5p) and hsa-miR-137 which were predicted to 
target CYP2D6, and hsa-miR-34c-5p, hsa-miR-449a and hsa-miR-766 which were 
predicted to target HNF4A.  These miRNAs were selected for the initial in vitro analysis.  
These miRNAs were cotransfected with the pIS plasmids (pIS-0, or pIS-2D6, or pIS-
HNF4A).  None of these miRNAs reduced the pIS-2D6 luciferase activity (Figure 4.3).  
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However, relative to the negative control miRNA (cel-miR-67), hsa-miR-34c-5p and hsa-
miR-449a significantly reduced (p < .01) the luciferase activity of the pIS-HNF4A 
plasmid by 40% and 35%, respectively.  In contrast, hsa-miR-766 did not regulate the 
expression of pIS-HNF4A.  Hsa-miR-34c-5p and hsa-miR-449a caused a slight 
unexplained increase in the pIS-0 and pIS-2D6 plasmids (Figure 4.3).  
  
Figure 4.3: Regulation of pIS-2D6 and pIS-HNF4A by miRNAs.  
 
Note: HeLa cells were cotransfected with 4 µg of pIS-0, or pIS-2D6, or pIS-HNF4A 
luciferase plasmids, along with Renilla reporter plasmid for normalization.  These cells 
were also transfected with 30 nM of miRNA Mimics.  Data are expressed as the pIS-
HNF4A or pIS-2D6 luciferase activity corrected for Renilla luciferase and normalized to 
pIS-0 within each experiment (mean ± SEM; n = 3 independent experiments performed 
in triplicates).  
a
 indicates p < .05 when compared to the control the negative control (cel-
miR-67) transfection. 
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 In another set of transfections, three additional miRNAs (hsa-miR-140-3p, hsa-
miR-149 and hsa-miR-323-3p) that were predicted by TargetScan version 5.1 to regulate 
the expression of CYP2D6 were tested.  None of these miRNAs affected the pIS-2D6 
luciferase activity (Figure 4.4).   
 
Figure 4.4: Lack of regulation of pIS-2D6 by miRNAs.  
 
Note: HeLa cells were cotransfected with 4 µg of pIS-2D6 luciferase plasmids, along 
with Renilla reporter plasmid for normalization.  These cells were also transfected with 
30 nM of miRNA Mimics.  Data are expressed as the pIS-2D6 luciferase activity 
corrected for Renilla luciferase and normalized to negative control (cel-miR-67) within 
each experiment (mean ± SEM; n = 3 independent experiments performed in triplicates). 
 
 Similarly, three additional miRNAs were tested for interaction with pIS-HNF4A.  
These miRNAs were: hsa-miR-34a (same family as hsa-miR-34c-5p), hsa-miR-34b* 
(which is a part of a single large precursor miRNA transcript that makes hsa-miR-34c-5p 
and hsa-miR-34a) and hsa-miR-765.  When compared to the negative control miRNA 
(cel-miR-67), hsa-miR-34a, hsa-miR-34b* and hsa-miR-765 significantly reduced (p ≤ 
.05) the pIS-HNF4A luciferase activity by 23%, 22%, and 24%, respectively (Figure 4.5).  
Since multiple miRNAs can simultaneously interact with a target mRNA (Krek et al., 
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2005), hsa-miR-34c-5p was cotransfected with hsa-miR-34b* and hsa-miR-34c-5p was 
cotransfected with hsa-miR-765.  Even though these cotransfections significantly reduced 
the luciferase activity (p < .05), no additive or synergistic effects were observed by 
cotransfecting these miRNAs.  In the case of the cotransfection of hsa-miR-34c-5p with 
the hsa-miR-34b*, the lack of additional or synergistic effect may be because of 
competition, as they are predicted to share one target site in common.   
 
Figure 4.5: Regulation of pIS-HNF4A by miRNAs. 
 
Note: HeLa cells were cotransfected with 4 µg of pIS-HNF4A luciferase plasmid, along 
with Renilla reporter plasmid for normalization.  These cells were also transfected with 
miRNA Mimics individually (cel-miR-67, hsa-miR-34a, hsa-miR-34b*, or hsa-miR-765; 
30 nM) or together (hsa-miR-34b* + hsa-miR-34c-5p; or hsa-miR-34c-5p + hsa-miR-
765; 15 nM each).  All data are expressed as the pIS-HNF4A luciferase activity corrected 
for Renilla luciferase and normalized to negative control (cel-miR-67) within each 
experiment (mean ± SEM; n = 3 independent experiments performed in triplicates).           
a
 indicates p ≤ .05 when compared to the control the negative control (cel-miR-67) 
transfection.  
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MicroRNAs regulate HNF4A mRNA and protein expression in vitro 
 In order to investigate whether these miRNAs regulate HNF4A mRNA and 
protein expression, HepG2 (a liver cancer cell line) was transfected with hsa-miR-34a, 
hsa-miR-449a, hsa-miR-493* and the negative control, cel-miR-67.  Both hsa-miR-34a 
and hsa-miR-449a were predicted to target HNF4A at two positions and they both target 
the same locations: (1) positions 164-171, and (2) positions 254-260 of HNF4A 3‟-UTR 
corresponding to the miRNA seed sequence.  Hsa-miR-493* is not predicted to target 
HNF4A and hence was used as a control.  Small interfering RNAs (siRNA) for HNF4A 
and a negative control siRNA described previously (Iwazaki et al., 2008) were also used 
as process controls.  The results indicated that only HNF4A siRNA significantly reduced 
HNF4A mRNA expression by about 50% (p = .05), while none of the miRNAs down-
regulated HNF4A mRNA expression (Figure 4.6).   
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Figure 4.6: MicroRNAs do not regulate the expression of HNF4A mRNA 
expression. 
 
Note: HepG2 cells were transfected with miRNAs (hsa-miR-34a, hsa-miR-449a, hsa-
miR-493*, or the negative control cel-miR-67; 100 nM) or siRNAs (HNF4A siRNA, or 
negative control siRNA; 100 nM).  At 72 hours after transfection, RNA was isolated.  
RT-PCR assays were performed for HNF4A mRNA using glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) as the internal control.  MiRNA transfections were normalized 
to miRNA control cel-miR-67 and siRNA transfections were normalized to negative 
control siRNA.  The relative mRNA expression was calculated as 2
–(∆∆CT)
 (mean ± SEM; 
n = 3 independent experiments performed in triplicates).  
a
 indicates p = .05 when 
compared to the control the negative control siRNA transfection. 
  
 In contrast to the HNF4A mRNA expression, HNF4A protein expression was 
down-regulated by both the siRNA and miRNAs; HNF4A siRNA reduced the HNF4A 
protein expression by 40%, while hsa-miR-449a down-regulated the HNF4A protein by 
about 30%, and hsa-miR-34a by about 60% (Figure 4.7 A and 4.7 B).   
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Figure 4.7: Regulation of HNF4A protein by miRNAs.   
(A) 
 
(B) 
 
 
 
  
Note: HepG2 cells were transfected with miRNAs (hsa-miR-34a, hsa-miR-449a, hsa-
miR-493*, or the negative control cel-miR-67; 100nM) or siRNAs (HNF4A siRNA, or 
negative control siRNA; 100 nM).  At 72 hours after transfection, nuclear protein was 
isolated and western blot assays were performed.  Beta-actin (β-actin) was used as the 
internal control for noramlization.  MiRNA transfections were normalized to miRNA 
negative control cel-miR-67, and siRNA transfections were normalized to negative 
control siRNA.  (A) The blots were scanned and the band density was measured (mean ± 
SEM; n = 3 independent experiments); (B) Representative western blot performed using 
anti-HNF4A antibody and anti-β-actin antibody. 
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 To determine whether this down-regulation of HNF4A resulted in altered 
expression of downstream HNF4A target genes, PXR mRNA expression was measured.  
PXR is a target of HNF4A transcription factor that has been used as a marker of HNF4A 
activity (Iwazaki et al., 2008).  The expression of PXR mRNA was reproducibly down-
regulated by approximately 30% by hsa-miR-449a, by approximately 40% by both hsa-
miR-34a and HNF4A siRNA (Figure 4.8).  In contrast, hsa-miR-493* did not down-
regulate HNF4A mRNA, PXR mRNA, or HNF4A protein expression.  In HepG2 cells, 
CYP2D6 mRNA expression was barely detectable by RT-PCR and did not appear to be 
influenced by HNF4A expression, probably due to its low basal expression levels (data 
not shown). 
 
Figure 4.8: Regulation of PXR mRNA by miRNAs.   
 
Note: HepG2 cells were transfected with miRNAs (hsa-miR-34a, hsa-miR-449a, hsa-
miR-493*, or cel-miR-67; 100 nM) or siRNAs (HNF4A siRNA, or negative control 
siRNA; 100 nM).  At 72 hours after transfection, RNA was isolated.  RT-PCR assays 
were performed with GAPDH as the internal control.  MiRNA transfections were 
normalized to miRNA control cel-miR-67 and siRNA transfections were normalized to 
negative control siRNA.  The relative mRNA expression was calculated as 2
–(∆∆CT)
 (mean 
± SEM; n = 3 independent experiments performed in triplicates).  
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 In order to assess the transfection efficiency of the miRNA Mimics, quantitative 
RealTime-PCR were performed in HeLa cells transfected with the synthetic miRNAs for 
hsa-miR-34a and cel-miR-67.  The results indicated that transfection of hsa-miR-34a 
mimic resulted in approximately 900-fold increase in the concentration of mature miRNA 
when compared to the control (Figure 4.9). 
 
Figure 4.9: Transfection efficiency of synthetic miRNAs.   
 
Note: HeLa cells were transfected with synthetic Mimics and Inhibitors for hsa-miR-34a 
and negative control cel-miR-67.  Total RNA including the small RNAs was isolated and 
reverse transcribed using hsa-miR-34a, or hsa-miR-449a, or U6 small nuclear RNA 
(snRNA) specific primers.  RT-PCR experiments were performed as described under 
Methods section.  The relative expression of the miRNAs was normalized to U6 snRNA.  
The relative mRNA expression was calculated as 2
–(∆∆CT)
 (mean ± SEM; n = 3 
independent experiments performed in triplicates).   
 
Expression of miRNAs in human hepatocytes 
To determine if the miRNAs that appear to target HNF4A are expressed in 
hepatocytes, their expression in primary hepatocytes isolated from three individual 
subjects was measured.  Additionally, their expression in HeLa and HepG2 cells was also 
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measured.  Quantitative Real-Time PCR using specific TaqMan miRNA assays were 
performed using U6 small nuclear RNA (snRNA) as endogenous control.  Hsa-miR-34a 
was easily detectable in all 3 hepatocyte preparations, as well as in HeLa and HepG2 
cells (Figure 4.10 A).  The other three hsa-miRNAs (hsa-miR-34b*, hsa-34c-5p and hsa-
miR-449a) were also expressed in hepatocytes, although at an apparent lower level 
(Figure 4.10 B).  Neither hsa-miR-34b*, nor hsa-34c-5p were detectable in HeLa or 
HepG2 cells.  Hsa-miR-449a was expressed in HepG2, but not detectable in HeLa cells. 
 
Figure 4.10: Expression of mature miRNAs in human cell lines and hepatocytes.   
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(B) 
 
Note: Total RNA, including the small RNAs, was isolated from three different human 
hepatocytes preparations.  RT-PCR assays were performed with U6 snRNA as the 
internal control.  The relative miRNA expression was calculated as 2
–(∆CT)
.  Values were 
multiplied by 10
3
 to simplify
 
data presentation.  The values shown in the graph were 
obtained from triplicate assays in a single PCR experiment.  (A) Expression of hsa-miR-
34a; (B) Expression of hsa-miR-34b*, hsa-miR-34c-5p and hsa-miR-449a. 
 
SNPs in the miRNA target sites 
SNPs in the miRNA target sites on the mRNA 3‟-UTR can alter the normal 
miRNA-mRNA interactions.  The dbSNP database 
(www.ncbi.nlm.nih.gov/projects/SNP) was used to identify SNPs in the 3‟-UTRs of 
CYP2D6 and HNF4A genes.  The dbSNP database indicated that SNPs are present in the 
3‟-UTR of HNF4A gene.  Two programs, PolymiRTS (Bao et al., 2007) and Patrocles 
(Georges et al., 2006) were used to determine if any of these HNF4A 3‟-UTR SNPs that 
exist in miRNA target sites are predicted to affect the base-pairing between the HNF4A 
mRNA and the predicted miRNAs.  The results indicated the presence of 5 SNPs in the 
HNF4A gene that were predicted to alter miRNA targeting (Table 4.2).  The analysis 
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predicted that SNPs destroyed 3 miRNA target sites and created 2 new target sites for 
miRNAs.  
 
Table 4.2: HNF4A 3’-UTR SNPs predicted to destroy or create a miRNA target site. 
dbSNP rs id 
Minor allele 
frequency 
Seed sequence  
[Ancestral/ 
Derived allele] 
Old target 
destroyed 
New target 
created 
rs11574744 0-2.5 and 0-4.0% 
a
 AC[T/A]GCCA 
-34a, -34c, 
-449, -449b 
 
rs11574745 0-2.5% A[C/T]CTTCA -493-3p  
rs6130615 11-61% and 30% 
a
 TAATG[C/T]G  -323 
rs6103734 0% 
b
 GTCA[G/A]GA -378  
rs6103735 0% 
b
 TTAA[G/A]GA 
 
 
-302b* 
Note: 
a 
Seattle SNPs database was used in addition to dbSNP to identify the minor allele 
frequency (MAF); 
b 
The MAF appears to be 0% in over 200 individuals that have been 
genotyped for these 2 SNPs. 
 
Since there were no reported SNPs reported in the 3‟-UTR of the CYP2D6 gene 
(data from „Human Cytochrome P450 Allele Nomenclature Committee and dbSNP), the 
CYP2D6 3‟-UTR was resequenced in 48 Caucasian and 48 African American DNA 
samples from the Coriell diversity panel.  No polymorphisms were detected in the 
CYP2D6 3‟-UTR in these two populations.    
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In vitro validation of SNP predictions 
 In order to test the hypothesis that germline variations can alter the miRNA 
targeting of HNF4A, a SNP (rs11574744; T>A) in the HNF4A 3‟-UTR was selected for 
further in vitro validation (Figure 4.11).  This SNP was predicted by both PolymiRTS and 
Patrocles algorithms to destroy a miRNA binding site (Table 4.2).   
 
Figure 4.11: HNF4A 3’-UTR SNP predicted to destroy a miRNA binding site.   
 
Note: Predicted miRNA interaction with wildtype and variant (rs11574744; T>A) in the 
HNF4A 3‟-UTR. 
 
In the first functional study, the activities of pIS-0, pIS-HNF4A and pIS-
HNF4A_SNP plasmids were compared.  The luciferase activity from the plasmid with 
the variant HNF4A was two-fold higher than the wild type pIS-HNF4A plasmid (Figure 
4.12 A; p < .05).  In the second functional study, the plasmids (pIS-0 or pIS-HNF4A or 
pIS-HNF4A_SNP) were cotransfected with hsa-miR-34a, hsa-miR-449a and negative 
control (cel-miR-67).  In the pIS-HNF4A plasmid, when compared to the negative 
control miRNA (cel-miR-67), hsa-miR-34a, and hsa-miR-449a reduced the pIS-HNF4A 
luciferase activity by 25% and 28% respectively; while in the pIS-HNF4A_SNP plasmid, 
the luciferase activity was reduced by only 6% and 9%, respectively (Figure 4.12 B).  
The luciferase activity was significantly higher (p < .05) in the pIS-HNF4A_SNP plasmid 
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transfected cells, compared to the pIS-HNF4A, when transfected with either hsa-miR-34a 
or hsa-miR-449a (Figure 4.12 B). 
 
Figure 4.12: In vitro validation of SNP predictions.   
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(B) 
 
Note: (A) Transfection of HeLa cell line with 200 ng of control pIS-0 plasmid or pIS-
HNF4A or pIS-HNF4A_SNP constructs along with Renilla luciferase plasmid as internal 
control.  Dual luciferase assays were performed at 24 hours.  Data are expressed as the 
pIS-HNF4A and pIS-HNF4A_SNP luciferase activity corrected for Renilla luciferase and 
normalized to the pIS-0 within each experiment (mean ± SEM; n = 3 independent 
experiments performed in triplicates); (B) HeLa cells were cotransfected with 4 µg of 
pIS-0, pIS-HNF4A, or pIS-HNF4A_SNP luciferase constructs, along with Renilla 
reporter plasmid for normalization.  The cells were also transfected with miRNA Mimics 
(hsa-miR-34a or hsa-miR449a; 30 nM).  All data are expressed as the pIS-HNF4A or 
pIS-HNF4A_SNP luciferase activity corrected for Renilla luciferase and normalized to 
negative control (cel-miR-67) within each experiment (mean ± SEM; n = 3 independent 
experiments performed in triplicates).  
a
 indicates p < .05 when compared to the wildtype 
pIS-HNF4A plasmid. 
 
RNAFold program (Gruber et al., 2008) was used to determine if the rs11574744 
SNP changed the predicted mRNA secondary structure.  A 70 bp nucleotide flank on 
either side of the SNP (Kertesz et al., 2007) was included to assess the minimum folding 
energy and secondary structure.  The MFE was the same for both the wildtype and SNP 
sequences (Figure 4.13).  Similarly, no differences were observed when the flanking 
sequence was extended to 200 bp on either side of the SNP.  
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Figure 4.13: The SNP rs11574744 is not predicted to affect the local secondary 
structure of HNF4A mRNA.  
 
Note: Secondary structures of wildtype and variant (highlighted in blue) HNF4A mRNAs 
were predicted using RNAFold (Gruber et al., 2008).  A 70 bp flanking either side of the 
SNP (rs11574744) was used to assess the minimum folding energy and secondary 
structure.   
 
To determine the genotype frequency of this SNP in different ethnicities, a 
custom TaqMan assay (ABI, Forest City, CA, USA) was designed to genotype the Coriell 
human diversity panel comprising of Caucasian, African American and Asian DNA 
samples.  The results of our genotyping suggest that the SNP is present only in African 
American samples at a minor allele frequency (MAF) of ~3% (Table 4.3). 
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Table 4.3: Minor allele frequency of HNF4A 3’-UTR SNP, rs11574744. 
Ethnicity No of samples 
genotyped 
SNP present Minor allele 
frequency (%) 
Asian - Chinese 43 No - 
Asian - Japanese 44 No - 
Caucasian 94 No - 
African American 89 Yes 3.4 
 
Discussion 
Interindividual variability in drug metabolism remains a significant contributor to 
differences in drug efficacy and toxicity.  Some of this variability is due to known genetic 
variations and environmental factors that inhibit the enzymes or alter their expression 
levels.  However, the mechanisms that underlie much of the variability are yet unknown.  
The studies presented here are the first steps in determining the contribution of miRNA to 
the regulation of drug metabolizing enzymes and ultimately their contribution to 
variability in drug metabolism.   
The CYP2D6 enzyme metabolizes 20-25% of commonly prescribed drugs 
(Ingelman-Sundberg, 2005).  The CYP2D6 gene polymorphisms and CYP2D6 enzyme 
inhibiting drugs lead to variability in CYP2D6 enzyme activity and consequently, affect 
drug metabolism (Ingelman-Sundberg, 2005; Eichelbaum et al., 2006).  While, genetic 
and environmental factors explain only a part of the interindividual variability in 
CYP2D6 enzyme activity, substantial unexplained variability still remains.  For example, 
even within the same CYP2D6 genotype group (e.g., extensive metabolizers - EM, or 
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intermediate metabolizers - IM) there is still unexplained interindividual variability 
(Borges et al., 2006).  The hypothesis is that the substantial unexplained variability in 
CYP2D6 enzyme activity may be due to direct regulation of CYP2D6 by miRNAs, as 
well as indirect regulation of it through the regulation of the transcriptional factor, 
HNF4A. 
The results of the bioinformatic analyses suggested that CYP2D6 is likely to be 
regulated by miRNAs (Table 4.1).  In addition to directly targeting CYP2D6, the 
miRNAs were also predicted to target CYP2D6 indirectly by targeting one of its 
transcriptional regulators, HNF4A.  The HNF4A is an important transcriptional „master 
regulator‟ that regulates the expression of genes that metabolize drugs and xenobiotics; 
these genes include phase I enzymes, phase II enzymes, transporters and transcriptional 
factors (Kamiyama et al., 2007).  Thus, regulation of HNF4A by miRNAs would likely 
affect many genes involved in drug disposition.  HNF4A is also expressed in the kidney, 
intestine and pancreas; in those tissues, it controls lipid (Hayhurst et al., 2001) and 
glucose metabolism (Stoffel and Duncan, 1997).  Nine different isoforms of HNF4A have 
been reported (Harries et al., 2008).  Since the predominate isoform (isoform 2) 
expressed in the liver is a full length isoform with 3‟-UTR (Ihara et al., 2005), it is one 
that is likely to be regulated by miRNAs.  Recent studies have shown that PXR, another 
transcription factor that regulates the CYP450 gene expression, is also a target of 
miRNAs (Takagi et al., 2008).   
As with many bioinformatic predictions, there was substantial variability between 
different algorithms in the miRNAs that are predicted target both the genes (Table 4.1).  
Part of this variability may be due to the different miRBase Registry versions that are 
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used by each algorithm; they ranged from versions 9 to 11.  The variability may also be 
due to differences in the algorithms; these include differences in parameters such as, 
degree of complementarity, differences in UTR annotations and species conservation.  
For example, three of the programs (miRanda, miRBase Targets and PicTar) use 
evolutionary conservation parameter.  Since the CYP2D6 gene is not highly conserved 
across species (Nelson et al., 2004), this may contribute to the variability between the 
different algorithms.  The total number of miRNAs predicted by the algorithms will 
continue to change as more miRNAs are being discovered and as the prediction 
algorithms are fine-tuned.  The total number of miRNAs predicted is a starting point for 
subsequent analysis; expression of these miRNAs can also vary from tissue to tissue. 
Based on the in silico analyses, further in vitro studies were performed.  None of 
the five miRNAs that were predicted to target CYP2D6 affected the expression of pIS-
2D6 plasmid (Figure 4.3 and 4.4).  For HNF4A, five of the miRNAs regulated the pIS-
HNF4A luciferase plasmids (Figure 4.3 and 4.5), and at least two of those also regulate 
the HNF4A protein expression (Figure 4.7).  Since the miRNAs did not reduce the 
HNF4A mRNA levels (Figure 4.6), they are most likely to be regulating HNF4A 
expression by blocking HNF4A protein synthesis rather than degradation of mRNA.  
Since CYP2D6 is strongly regulated by HNF4A, the miRNAs that target HNF4A likely 
also affect the expression of CYP2D6 and other downstream HNF4A target genes.  This 
is supported by the results showing that the HNF4A targeting miRNAs suppressed the 
expression of another downstream target, PXR.  Although the bioinformatic analysis 
indicated that PXR may also be a direct target of these miRNAs, the targets contained 
several mismatches indicating that they are more likely to block PXR translation rather 
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than cause mRNA degradation.  There was no observable effect of those miRNAs on 
CYP2D6; the likely reason may be because CYP2D6 is expressed at very low levels in 
the HepG2 cell line and, consequently, not strongly regulated by HNF4A in these cells.  
Of the miRNAs that target HNF4A, hsa-miR-34a expression appears to be higher 
than the other miRNAs in the primary hepatocytes preparations.  It is possible that the 
miRNAs that target HNF4A may be down-regulated to allow full HNF4A expression 
during normal conditions and then specifically up-regulated when HNF4A needs to be 
repressed.  Additional studies will be required to determine if any of these miRNAs are 
regulated by environmental factors that control HNF4A and CYP450 gene expression.   
MicroRNA functions can be altered by genetic variants that affect the miRNA 
binding to the target mRNA; these variants are called miRSNPs (Mishra et al., 2007).  
MiRSNPs have been shown to alter miRNA function and hence enzyme activity.  This 
has been shown to be the case for genes such as dihydrofolate reductase (Mishra et al., 
2007) and the estrogen receptor α (Adams et al., 2007).  Genetic variants in the 3‟-UTRs 
of drug metabolizing genes have not typically been given high priority in functional 
studies; however, based on these analyses, they may contribute to interindividual 
variability in the expression of the drug metabolizing enzymes.  Some studies have 
reported on the SNPs in the 3‟-UTRs of CYP450 genes that may be associated with 
altered phenotypes; these include CYP19A1 (Dunning et al., 2004) and CYP2A6 (Wang 
et al., 2006).  It is conceivable that these SNPs may be a target of miRNAs.  In our 
analyses, few SNPs were identified in HNF4A gene 3‟-UTR that are predicted to alter the 
miRNA targets (Table 4.2).  The in vitro luciferase assay results for HNF4A suggest that 
such genetic variants can cause altered mRNA-miRNA interactions (Figure 4.12 A and 
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B).  Further functional studies will be required to determine the clinical phenotypic 
consequences of the miRSNPs.  Both the programs that were used (PolymiRTS and 
Patrocles) only predict an effect if the SNPs in the „seed‟ region of the miRNA target 
sites.  However, SNPs in „non-seed‟ regions can also affect miRNAs that bind either 
upstream or downstream to the SNP (Mishra et al., 2007).  Neither of these programs 
predict such loss or gain of such mRNA-miRNA interactions.  Similarly, SNPs in the 
mature miRNAs and pre-miRNA may also affect the mRNA-miRNA interaction.  Since 
very few of the miRNA genes have been resequenced in depth, the genetic variants in 
those genes are not well characterized.  Therefore, these SNPs were not included in this 
analysis.  There were no SNPs in the CYP2D6 3‟-UTR.  The absence of any SNPs in this 
region suggests that it is highly conserved and may be important for CYP2D6 mRNA 
regulation; however, the short length (75 bp) makes it impossible to draw any definite 
conclusions about the conservation.   
These findings confirm a potential role for miRNAs in the regulation of CYP450s 
involved in drug metabolism.  It is conceivable that other genes, including Phase II 
enzymes, drug targets, and other drug transporters are also targets of the miRNAs.  
Recent studies have shown that other proteins involved in drug metabolism (Tsuchiya et 
al., 2006; Takagi et al., 2008; To et al., 2008; Pan et al., 2009) are subject to miRNA 
regulation.  These results, taken together with previous findings suggest a complex 
regulatory mechanism for drug metabolizing enzymes by miRNAs.  The identification of 
the endogenous hepatic miRNAs that regulate CYP2D6 directly or indirectly should help 
us understand the variability in therapeutic efficacy and toxicity for patients to several 
commonly used drugs.  Further, identifying polymorphisms that alter the drug 
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metabolizing mRNA-miRNA interactions would likely be a clinically important 
biomarker for guiding the use of CYP2D6 metabolized drugs.  Ultimately, these novel 
biomarkers would help improve the efficacy and reduce the side effects of the commonly 
prescribed drugs.   
 
Materials and Methods 
 Cell culture: HeLa (a cervical cancer cell line) and HepG2 (a liver cancer cell 
line) that were used in our in vitro transfection assays were obtained from ATCC 
(American Type Culture Collection; Manassas, VA, USA).  All tissue culture reagents 
were purchased from Invitrogen (Carlsbad, CA, USA).  HeLa and HepG2 cells were 
cultured in Dulbecco‟s Modified Eagle‟s Medium (DMEM) supplemented with 10% fetal 
bovine serum and 1% Penicillin-Streptomycin.  The cells were maintained at 37°C in a 
humidified atmosphere containing 5% CO2.   
Generation of luciferase reporter gene constructs: The pIS-0 vector (Yekta et 
al., 2004; Addgene plasmid #12178) was used to study 3‟-UTR function.  The 3‟-UTR of 
CYP2D6 (72 bp of the full length 75 bp; nucleotides 5837-5908 of GenBank id 
M33388.1) was synthesized as an oligonucleotide with SacI and NheI restriction sites and 
subcloned into the pIS-0 vector using those restriction sites (GenScript, Piscataway, NJ, 
USA).  The 3‟-UTR of HNF4A (1448 bp of the full length 1724 bp; nucleotides 1558-
3005 of NM_000457) was amplified using genomic DNA from the Coriell panel using 
primers (Integrated DNA Technologies, Coralville, IA, USA) with NheI and SacI 
restriction sites (FP: 5‟GGTGTTGAGCTCCTAAGAGAGCACCTGGTGA and RP: 
5‟GGGTTTGCTAGCGGAGACCTGGGTTCAAG; the restriction sites are italicized and 
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the HNF4A sequence is underlined).  The PCR product was cloned into the TOPO TA 
vector (Invitrogen, Carlsbad, CA, USA) and the insert sequence was verified by DNA 
sequencing.  The sequencing data revealed that the clone had the “variant” rs322210 (C 
allele); since the reported frequency of this allele is 55% (dbSNP), it appears to be the 
more common allele.  Therefore, this clone was used.  The insert was then subcloned into 
pIS-0 vector using the NheI and SacI restriction sites and transformed into DH5α 
competent cells.  Colonies with the inserts were identified by restriction digestion and the 
sequence was verified by direct DNA sequencing.  Plasmids were purified using the 
Plasmid Maxi Kit (Qiagen, Valencia, CA, USA).  The DNA concentrations were 
determined using QuantIT DNA Broad Range kit (Invitrogen, Carsbald, CA, USA) and 
verified on the BioAnalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA).  The 
control vector is referred to as pIS-0 and the vectors with HNF4A and CYP2D6 3‟-UTR 
sequences inserted are referred to as pIS-HNF4A and pIS-2D6, respectively.   
A plasmid with the variant HNF4A 3‟-UTR (rs11574744) was created by site-
directed mutagenesis (GenScript, Piscataway, NJ, USA).  Presence of this mutation was 
confirmed by resequencing the plasmid.  This mutant plasmid is referred to as pIS-
HNF4A_SNP.  
Transfection: For luciferase assays, 0.9x10
5
 HeLa cells were seeded into each 
well of a 24 well plate.  The cells were transfected with one of the three pIS plasmids 
(pIS-0, or pIS-2D6, or pIS-HNF4A) at three different concentrations of the plasmids 
(100, or 200, or 400 ng each).  Renilla luciferase reporter plasmid pGL4.74 (hLuc-TK) 
was used as a transfection control; the ratio of pIS: pGL4.74 was 50:1.  Transfection was 
performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the 
121 
 
manufacturer‟s instructions using Opti-MEM (Invitrogen, Carlsbad, CA, USA) and 
culture media without any antibiotics.  At 24 hours after transfection, the cells were 
harvested and dual luciferase assays (Promega, Madison, WI, USA) were performed as 
per manufacturer‟s instructions.  Transfections for the site-directed mutagenesis 
experiments were performed using the same protocol using 200 ng of pIS-0, or pIS-
HNF4A, or pIS-HNF4A_SNP plasmids.   
For luciferase and miRNA cotransfection experiments, 1.5x10
6
 HeLa cells were 
seeded in a T-25 flask.  At 24 hours, the cells were then transfected with 4 μg of pIS-0, or 
pIS-2D6, or pIS-HNF4A plasmid, along with 80 ng of Renilla luciferase reporter plasmid 
as transfection control.  At 24 hours after transfection, the cells were trypsinized and 
counted using a Z1 Particle Coulter Counter (Beckman Coulter, Fullerton, CA, USA).  
Approximately 1x10
5
 cells were seeded into each well of a 24 well plate.  The cells were 
reverse transfected (that is, plated onto the well containing the transfection mix) with 
either 30 nM of the miRNA, or combinations of miRNAs or the negative control 
(miRIDIAN Mimics from Dharmacon, Lafayette, CO, USA) using Lipofectamine 2000 
transfection reagent (Invitrogen, Carlsbad, CA, USA).  At 24 hours post miRNA 
transfection, the cells were harvested and dual luciferase assays were performed.  
Cotransfections for the site-directed mutagenesis experiment were performed with the 
same protocol using the pIS-0, or pIS-HNF4A, or pIS-HNF4A_SNP plasmids and 
specific miRNAs.  All transfections and luciferase assays were performed in triplicates 
over three different days.   
In order to verify that the transfected synthetic miRIDIAN Mimics (Dharmacon, 
Lafayette, CO, USA) were efficiently taken up by the cells, HeLa cells (2x10
5
 cells per 
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well in 96-well plates) were transfected with 30nM of either hsa-miR-34a mimic or 
negative control mimic (cel-miR-67).  RNA isolation and reverse transcription was 
performed using microRNA Cell-to-Ct kit (ABI, Forest City, CA, USA) and specific 
TaqMan MicroRNA Assays (ABI, Forest City, CA, USA) for hsa-miR-34a, U6 snRNA 
(endogenous control) and hsa-miR-449a (a non-specific control) following the 
manufacturer‟s instructions.  Specific details of the PCR are in the „Quantification of 
miRNAs‟ section.  The relative quantities of miRNA were calculated using the ∆∆CT 
method using U6 snRNA and negative control (cel-miR-67) transfections as controls.  
The relative miRNA expressions are reported as 2
–(∆∆CT) 
(Kreuzer et al., 1999).  The 
miRNA transfections were replicated on three separate days and the RT-PCR was done in 
triplicates for each of the transfections.   
Bioinformatic analysis to predict microRNAs: Six different web-based 
bioinformatic programs were used to identify the miRNAs predicted to target CYP2D6 
and HNF4A.  The programs included miRanda (John et al., 2004), miRBase Targets 
(Griffiths-Jones et al., 2006), TargetScan (Lewis et al., 2003), PicTar (Krek et al., 2005), 
RNA22 (Miranda et al., 2006) and PITA (Kertesz et al., 2007).  The parameter settings 
were either default or those used in the publications describing the tools.  For RNA22, 
which is a downloadable program with user defined mRNA and miRNA sequences, 
CYP2D6 gene reference sequence id was identified from the Human Cytochrome P450 
Allele Nomenclature Committee (www.cypalleles.ki.se/cyp2d6.htm) and the 3‟-UTR 
sequence was identified using the UCSC Genome Browser (http://genome.ucsc.edu).  
The mature miRNA sequences (version 10.0) were downloaded from the miRBase 
Sequence database (Griffiths-Jones et al., 2006). 
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Identification of SNPs located in the 3’-UTR: SNPs from the 3‟-UTR were 
obtained from NCBI SNP database (dbSNP; www.ncbi.nlm.nih.gov/projects/SNP) and 
UCSC Genome Browser database.  The minor allele frequencies (MAF) were obtained 
from dbSNP database for CYP2D6 and HNF4A genes.  Additionally, Seattle SNPs 
database (http://pga.gs.washington.edu) was used for identifying the MAF for HNF4A. 
Bioinformatic analysis to predict the effect of SNPs on mRNA-miRNA 
interactions: Two programs - PolymiRTS (Bao et al., 2007) and Patrocles (Georges et 
al., 2006) were used to predict the effect of miRSNPs in the 3‟-UTR of CYP2D6 and 
HNF4A mRNA on the mRNA-miRNA interaction.   
RNA isolation: Fresh human hepatocytes were isolated by Vitacyte LLC, 
(Indianapolis, IN, USA) from liver specimens that were collected after Indiana 
University‟s Institutional Review Board (IRB) approval.  These hepatocytes were flash 
frozen until RNA isolation.  Total RNA, including the small RNA was isolated using the 
miRNeasy kit (Qiagen, Valencia, CA, USA) following the manufacturer‟s instructions, 
except, the phase separation step was done using the maXtract tubes (Qiagen, Valencia, 
CA, USA).  The on-column DNase treatment step was included in the RNA isolation 
procedure and was done using the DNase set (Qiagen, Valencia, CA, USA).  The RNA 
yield was determined using the Quant-iT RNA Broad Range assay kit (Invitrogen, 
Carlsbad, CA, USA) in the Qubit fluorometer (Invitrogen, Carlsbad, CA, USA).  RNA 
quality/integrity was assessed using RNA 6000 Nano Labchip in the BioAnalyzer 2100 
(Agilent Technologies, Palo Alto, CA, USA). 
Quantification of miRNAs: The expression of miRNAs was analyzed using 
specific TaqMan MicroRNA Assays (ABI, Forest City, CA, USA) following the 
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manufacturer‟s instructions in a StepOne Plus real time PCR instrument (ABI, Forest 
City, CA, USA).  Briefly, total RNA, including the small RNA, was analyzed for specific 
miRNA expression in a two-step protocol.  The first step, reverse transcription, was 
performed using a miRNA specific primer which confers both specificity and sensitivity.  
In the second step, Real-Time PCR was performed with TaqMan probes that amplify 
only the target mature miRNA.  The PCR steps included a 10 min
 
polymerase enzyme 
activation at 95ºC, 50 cycles each of denaturation
 
at 95ºC for 15 s, and 
annealing/extension at 60ºC for
 
1 min.  Relative quantities of miRNA were calculated 
using the ∆CT method using U6 snRNA as endogenous control.  That is, the relative 
miRNA expression was calculated as 2
–(∆CT)
 and was multiplied by 10
3
 to simplify
 
data 
presentation.  
Genotyping of HNF4A 3’-UTR SNP: A custom TaqMan SNP genotyping assay 
(ABI, Forest City, CA, USA) was developed for
 HNF4A 3‟-UTR SNP (rs11574744).  
The primer and probe sequences were: CCCGAGAACATGGCCTAAGG as forward 
primer, CCAGAGCAGGGCGTCAA as reverse primer, VIC-ATCCCACAGCCACCC 
as probe 1 and FAM-ATCCCACTGCCACCC as probe 2 (variant sequence is 
underlined).  Genotyping was performed with the Coriell DNA Diversity panel genomic 
DNA samples (African American, Caucasian and Asian) in a StepOne Plus Real-Time 
PCR System (ABI, Forest City, CA, USA) using the recommended genotyping PCR 
conditions i.e., an initial denaturation for 10 min at 95ºC, followed by 40 cycles of 
denaturation for 15 s at 92ºC and annealing/extension for 1 min at 60ºC.  The genotyping 
assay results were confirmed by resequencing 96 DNA samples (48 Caucasian and 48 
African American) from the Coriell biorepository.  DNA resequencing was performed 
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using the commercial DNA sequencing services of Polymorphic DNA Technologies Inc 
(Alameda, CA, USA).  
Resequencing of CYP2D6 3’-UTR: In order to resequence the CYP2D6 3‟-
UTR, CYP2D6 PCR amplicon was generated using a forward primer (2D6 int6x2F: 
5‟AGGAGGCAAGAAGGAGTGTCAGG) that binds to intron 6 and a reverse primer 
(2D6 R/2: 5‟ACTGAGCCCTGGGAGGTAGGTAG) that binds downstream of the 
CYP2D6 gene (Gaedigk et al., 2007).  These primers specifically amplify 1668 bp of the 
CYP2D6 gene and not the CYP2D7 or CYP2D8 gene sequences.  To sequence the 3‟-
UTR in the long template PCR fragment, a forward primer (E9seq: 
5‟CTTCCGTGGAGTCTTGCAGG; Gaedigk, A., personal communication) that binds to 
exon 9, and/or a reverse primer (UTR Seq RP: 5‟CTCAGCCTCAACATACCCCT) that 
binds downstream of the 3‟-UTR were used.  Resequencing was performed using DNA 
from the Coriell Diversity Panels, including 48 Caucasian and 48 African American 
samples.  All sequencing of the CYP2D6 gene was done at the DNA Sequencing Core 
Facility of Indiana University.  
Quantification of HNF4A protein and mRNA: In a 6-well plate, 1x10
6
 HepG2 
cells/ml were reverse transfected with 100 nM of synthetic miRNA Mimics (hsa-miR-
34a, hsa-miR-449a, hsa-miR-493* and control cel-miR-67; miRIDIAN microRNA 
Mimics from Dharmacon, Lafayette, CO, USA) using siPORT NeoFX transfection 
reagent (Ambion, Austin, TX, USA) following the manufacturer‟s specifications.  As 
described previously (Iwazaki et al., 2008), a Genome-Wide siRNA for human HNF4A 
(Hs_HNF4A_9) and an AllStars Negative Control siRNA (Qiagen, Valencia, CA, USA) 
were also used as process controls.  At 72 hours of transfection, the cells were harvested 
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for HNF4A protein and RNA analyses.  The transfections were repeated on three separate 
days.   
For protein analyses, nuclear protein extract was isolated using NucBuster protein 
extraction kit (Novagen, Madison, WI, USA).  Protein concentrations were determined 
using bicinchoninic acid (BCA) reagent protein assay kit (Pierce, Bradford, IL, USA).  
The nuclear protein lysate (20 µg) was electrophoresed using a 4-20% Tris-Glycine gel 
(Invitrogen, Carlsbad, CA, USA) and transferred to a Immobilon polyvinylidene fluoride 
(PVDF) transfer membrane (Millipore, Bedford, MA, USA) using Novex semi-dry blotter 
(Invitrogen, Carlsbad, CA, USA).  The membranes were blocked using 3% milk and then 
incubated overnight at 4ºC with mouse anti-human HNF4A primary antibody (Perseus 
Proteomics, Tokyo, Japan) at a dilution of 1:5000, followed by horseradish peroxidase 
(HRP) conjugated ImmunoPure goat anti-mouse secondary antibody (Pierce, Bradford, 
IL, USA) at a dilution of 1:10000 for 1 hour.  HRP conjugated beta-actin antibody 
(Abcam, Cambridge, MA, USA) at a dilution of 1:5000 was used as the loading control.  
All the three antibodies were diluted in Starting Block (T20) blocking buffer (Pierce, 
Bradford, IL, USA).  Protein bands were developed using a SuperSignal enhanced 
chemiluminescence kit (Pierce, Rockford, IL, USA).  The protein bands were visualized 
using a LAS-1000 plus system (Fujifilm, Tokyo, Japan) and quantified using the Multi 
Gauge software (Fujifilm, Tokyo, Japan). 
For RNA analyses, total RNA, including the small RNA, was isolated as 
described above.  The RNA yield was determined using the Quant-iT RNA Broad Range 
assay kit (Invitrogen, Carlsbad, CA, USA) in the Qubit fluorometer (Invitrogen, 
Carlsbad, CA, USA).  The cDNA was generated from 1 µg of total RNA using Reverse 
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Transcription System (Promega, Madison, WI, USA) following the manufacturer‟s 
instructions.  The expression of HNF4A and GAPDH (endogenous control) mRNAs was 
analyzed using specific TaqMan Gene Expression Assays (ABI, Forest City, CA, USA) 
following the manufacturer‟s instructions in a StepOne Plus real time PCR instrument 
(ABI, Forest City, CA, USA).  Relative quantity of HNF4A mRNA was calculated using 
the ∆∆CT method using GAPDH and negative controls (cel-miR-67 and negative control 
siRNA) as reference controls.  The RT-PCR was done in triplicate for each of the three 
transfections.   
Statistical analysis: Statistical analyses were carried out as described in the 
figure legends, by ANOVA using SPSS software (version 13.0; SPSS Inc, Chicago, IL, 
USA).  A p-value of p ≤ 0.05 was considered statistically significant. 
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CHAPTER FIVE 
Conclusion and Future Directions 
 Cytochrome P450 2D6 (CYP2D6) is an important drug metabolizing enzyme that 
is involved in the metabolism of ~20-25% of commonly prescribed drugs (Ingelman-
Sundberg, 2004).  There is considerable interindividual variability in CYP2D6 mediated 
enzyme activity and consequently, there is variability in both drug metabolism and 
response (Ingelman-Sundberg, 2004).  Only a part of this interindividual variability is 
explained by environmental and genetic factors (Ingelman-Sundberg, 2001; Eichelbaum 
et al., 2006); the cause of much of the variability is still unknown.  Hence, it becomes 
important to study the endogenous and exogenous factors that regulate CYP2D6 enzyme 
activity.   
 The overall goal of this research was to gain insight into the contribution of 
genetic and epigenetic factors that drive the interindividual variability seen in CYP2D6 
mediated drug metabolism and response.  The specific objective of this research was to 
determine the role of CYP2D6 genotype, copy number variations and microRNA that 
result in the variability seen in CYP2D6 mediated drug metabolism.   
 
Effect of CYP2D6 gene polymorphisms on tamoxifen metabolism 
 CYP2D6 is a highly polymorphic gene (Ingelman-Sundberg, 2005).  These 
polymorphisms lead to interindividual variability in CYP2D6 enzyme activity (Ingelman-
Sundberg, 2005).  This variability in enzyme activity results in the creation of extreme 
phenotype groups [poor metabolizers (PM) and ultrarapid metabolizers (UM)]; these 
groups have an increased risk for either therapeutic failure or adverse drug reaction.  The 
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cost of treating patients with these extreme CYP2D6 phenotypes (UM and PM) is 
estimated to be on an average, $4,000-6,000 greater than the cost of treating patients in 
the extensive metabolizer (EM) and intermediate metabolizer (IM) groups (Chou et al., 
2000).  Hence, prospective CYP2D6 genotyping can help predict therapy outcome and 
the occurrences of adverse events (Zanger et al., 2004).  Prospective CYP2D6 genotyping 
is estimated to be beneficial in the treatment of  ~10% of all clinically used drugs 
(Ingelman-Sundberg, 2005).   
 One of the important drug that is biotransformed by CYP2D6 is tamoxifen.  
Tamoxifen is used globally as a selective estrogen receptor modulator in the hormonal 
therapy of estrogen receptor (ER) positive breast cancers in both pre- and post-
menopausal women.  However, there is considerable interindividual variability in 
response to tamoxifen (Lonning et al., 1992; Ingle et al., 1999).   
 CYP2D6 is primarily responsible for the sequential generation of the active 
tamoxifen metabolite, endoxifen (Desta et al., 2004).  Endoxifen concentration is 
influenced by polymorphisms in the CYP2D6 gene (Stearns et al., 2003; Jin et al., 2005; 
Borges et al., 2006).  CYP2D6 gene polymorphisms are also associated with clinical 
outcomes of tamoxifen therapy (Goetz et al., 2005; Bonanni et al., 2006; Goetz et al., 
2007; Gonzalez-Santiago et al., 2007; Lim et al., 2007; Schroth et al., 2007; Kiyotani et 
al., 2008; Xu et al., 2008).  Published data on CYP2D6 genotype-endoxifen concentration 
or CYP2D6 genotype-outcome is largely from Caucasian women in the US and Europe.  
To date, three studies have been reported from Asia; these studies performed in Korea 
(Lim et al., 2007), Japan (Kiyotani et al., 2008) and China (Xu et al., 2008) have 
suggested that CYP2D6*10 allele is associated with poorer clinical outcome.  However, 
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not all studies have confirmed this association between CYP2D6 variant genotype and 
clinical outcomes (Nowell et al., 2005; Wegman et al., 2005; Wegman et al., 2007; 
Okishiro et al., 2009).  Hence, prospective trials are needed to understand the association 
between CYP2D6 gene variants, endoxifen concentration and clinical outcome. 
 In this study (Chapter Two), an association between CYP2D6 genetic variants and 
the concentration of tamoxifen and its metabolites was analyzed in breast cancer patients 
undergoing adjuvant tamoxifen therapy in two Asian countries - Vietnam (N = 93) and 
the Philippines (N = 144).  In both these Asian populations, CYP2D6*10 was the most 
frequent CYP2D6 allele with a frequency of 59.1% and 53.6% in the Vietnamese and 
Filipino populations, respectively.  The CYP2D6 alleles that are frequent in Caucasians 
(CYP2D6*4, *3, *6 and *41) were present in less than 3% in both the populations.  The 
CYP2D6 allelic frequencies in the Vietnamese and Filipino populations were comparable 
to that of other Asian populations previously reported (Kubota et al., 2000; Cai et al., 
2007; Kiyotani et al., 2008; Lee et al., 2009; Veiga et al., 2009; Figure 5.1).   
 These CYP2D6 polymorphisms that result in CYP2D6 IM or PM status were 
significantly associated with impaired metabolism of tamoxifen; both endoxifen 
concentration and endoxifen/N-desmethyltamoxifen ratio were significantly different (p < 
.01) when compared to the wildtype CYP2D6 allele.  These results are consistent with 
previous results from our group (Stearns et al., 2003; Jin et al., 2005; Borges et al., 2006) 
and also results reported by others in Caucasian (Gjerde et al., 2008) and Asian women 
(Lim et al., 2007).  In these Vietnamese and Filipino women, the primary allele that was 
involved in decreased endoxifen concentration was the CYP2D6*10 allele.  It is an 
intermediate metabolizer (IM) allele with reduced function.  This allele is primarily 
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characterized by the „tag‟ SNP 100C>T which results in an amino acid change P34C 
(Johansson et al., 1994).  This amino acid change occurs in the conserved tetrapeptide, 
PPGP sequence (a proline rich region) that is important for folding the CYP450 enzymes.  
As a result, the CYP2D6*10 enzyme becomes less stable and also decreases the affinity 
to CYP2D6 substrate drugs (Yu et al., 2002).  
 
Figure 5.1: CYP2D6 allele frequencies in the current Vietnamese and Filipino study 
are comparable to other Asian populations but not to Caucasian or African 
populations.  
 
Source: Veiga, S., et al., 2009; Sachse, C., et al.,1997; Wennerholm, A., et al., 1999; 
current study involving Vietnamese and Filipino breast cancer patients (Chapter Two). 
  
In summary, this study provides the first comprehensive analysis of the 
association between CYP2D6 polymorphisms and the concentration of endoxifen in the 
Vietnamese and Filipino population.  Like other ethnicities, the CYP2D6 genetic 
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polymorphisms appear to affect endoxifen concentrations in these two Asian populations.  
In both the Vietnamese and Filipino populations, the CYP2D6*10 allele is the primarily 
responsible for the reduced plasma endoxifen concentration.  Since several studies have 
shown that endoxifen appears to contribute to the activity of tamoxifen, these results 
indicate that CYP2D6 genotyping may be useful predicting the efficacy of tamoxifen in 
Vietnamese and Filipino women.  Furthermore, because CYP2D6 inhibiting drugs create 
a phenocopy of the CYP2D6 poor metabolizer phenotype, they also would likely reduce 
endoxifen concentrations and ultimately increase breast cancer recurrence in these 
women.  Although the final conclusions will depend on the recurrence outcomes from the 
ongoing clinical trial, the conclusion based on the current results is that it would be 
prudent for these women avoid CYP2D6 inhibitor drugs. 
 Even though the CYP2D6 gene polymorphisms were significantly associated with 
endoxifen concentrations, considerable interindividual variability exists even after 
correcting for this factor (Figure 2.1 D and E).  For example, within CYP2D6*10 group, 
there is over a 10-fold difference in plasma endoxifen concentration and endoxifen/NDM 
ratio.  In the combined Vietnamese and Filipino cohort, the CYP2D6 variants explain 
about 10% of the variability in the endoxifen concentration and 4% of the variability in 
the endoxifen/NDM concentration ratio (Figure 5.2 A and B).   
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Figure 5.2: Association of CYP2D6 genetic variants with tamoxifen metabolism in 
the combined Vietnamese and Filipino cohort based on regression analysis. 
(A) Endoxifen concentration 
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(B) Endoxifen/NDM ratio  
 
Note: The association of CYP2D6 gene variants with (A) endoxifen concentration and 
(B) endoxifen/NDM ratio in combined Vietnamese and Filipino cohort was measured by 
regression analysis.  Individuals were classified into the different score groups based on 
their CYP2D6 genotype (data in Chapter Two).  The endoxifen concentrations and 
endoxifen/NDM ratios were log transformed for normalization. 
 
 A part of this interindividual variability may be explained by other CYP2D6 rare 
alleles that were not tested (e.g., *14, *21, *27, *39, *47, etc.).  This variability may also 
be due differences in enzyme activity because of CYP2D6 gene copy number variations.  
Hence, the next specific aim (Chapter Three) was designed to assess the association of 
CYP2D6 gene copy numbers on plasma endoxifen concentrations.   
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Effect of CYP2D6 gene copy number variations on enzyme activity 
 One of the primary sources of variation in the human genome is the copy number 
variations (CNV) involving deletion or multiplication of DNA segments (Sebat et al., 
2004).  Recent studies have suggested an increasing role for CNVs in many diseases 
including cancer, developmental diseases, mental illness, autoimmune diseases and 
infectious diseases (Shrestha et al., 2009; Wain et al., 2009).  A number of drug 
metabolizing enzymes also to exhibit gene copy number variations.  These include 
UGT2B17, UGT2B28 (McCarroll et al., 2006), SULTA1 (Hebbring et al., 2007), GSTT1, 
GSTM1 (Bolt and Thier, 2006) and CYP2D6 (Bradford, 2002; Sistonen et al., 2007).   
 The CYP2D6 gene CNVs affect CYP2D6 enzyme activity and consequently, alter 
drug metabolism and response, including both safety and efficacy.  These CYP2D6 CNVs 
can either lead to reduced metabolism (gene deletion) or increased metabolism (>2 
functional copies).  This phenotypic variability in CYP2D6 enzyme activity arises from 
the variety of CYP2D6 alleles that exist in CNVs.  For example, (a) the carriers of 
CYP2D6*5 (gene deletion) have no enzyme activity and are considered to be PMs; (b) 
the carriers of multiple copies of functional CYP2D6 alleles (*1xN, *2xN) have increased 
enzyme activity and are classified as UMs; (c) the carriers of *10x2 do not have 
increased enzyme activity when compared to *10 and are still considered to be IMs; and 
(d) carriers of CYP2D6*36x2 and CYP2D6*4x2 have negligible enzyme activity and are 
still considered to be PMs.  However, little is known about the phenotypic consequence 
of other complex multiple copy arrangements including *36-*10-*10 or *36-*36-*10, 
etc.   
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 In different ethnic populations (Caucasians, Asians and Africans), different 
CYP2D6 alleles are involved in gene multiplication and there is also variability in the 
frequencies of these CYP2D6 CNVs (Bradford, 2002; Sistonen et al., 2007).  For 
example, CNVs involving the *36-*10 allele are frequent in Japanese and Chinese 
population, but not in Caucasians or Africans (Gaedigk et al., 2006; Hosono et al., 2009).  
To date, not much is known about the presence of CYP2D6 gene CNVs in the 
Vietnamese and Filipino populations.  Hence, in the prospective clinical trial involving 
the Vietnamese and Filipino breast cancer patients, quantitative RT-PCR assays were 
performed to identify the CYP2D6 gene CNVs and the presence of CYP2D6*36 alleles.  
The objective was to investigate the association of CYP2D6 CNVs with the steady-state 
concentrations of tamoxifen and its metabolites.   
 The results of this study indicated that in the combined cohort, only 39% of the 
individuals carried 2 copies of the CYP2D6 gene.  Approximately 61% of the individuals 
had a genomic imbalance for CYP2D6: 3.8% had a CYP2D6 gene deletion (CYP2D6*5) 
and 57.2% of the individuals had more than two copies of the CYP2D6 gene.  These 
results are comparable to the CYP2D6 CNVs reported in the Japanese and Chinese 
populations (Hosono et al., 2009).  The CNV phaser program (Kato et al., 2008) was used 
to estimate the CYP2D6 diplotypes.  The results indicated that 34.2% of the individuals 
had CNVs involving one or more copies of CYP2D6*36 allele along with a copy of 
CYP2D6*10 allele, i.e., CYP2D6(*36)n-*10 allelic arrangement.  In most of these 
individuals (99.8% of the cases), the CYP2D6(*36)n allele was present along with a copy 
of a CYP2D6*10 allele (Figure 5.3).  Approximately 50% of the diplotypes in the 
combined populations involved CYP2D6(*36)n allelic CNVs.  
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In order to determine the phenotypic consequence of the CNVs involving the 
CYP2D6(*36)n allele, tamoxifen and its metabolite concentration were compared 
between following: *10 vs. *36-*10 vs. *36-*36-*10 and also *10 vs. (*36)n-*10.  The 
results indicated that, based on the endoxifen concentration, there is a trend of decreased 
enzyme activity with an increase in the number of CYP2D6*36 copies.  However, both 
plasma endoxifen concentration and endoxifen/NDM ratio were not significantly 
different between these groups.  Thus, multiple copies of the CYP2D6(*36)n CNV alleles 
do not appear to increase the CYP2D6 activity.  Further studies with larger sample 
numbers will be required to confirm the possible effect of the CYP2D6*36 multiple 
copies on the adjacent CYP2D6*10 allele.   
 In summary, this study is the first comprehensive study to analyze: (1) the 
CYP2D6 CNVs in the Vietnamese and Filipino population and (2) the functional 
consequence of CNVs involving the CYP2D6*36 allele.  Like the other two Asian 
populations, Japanese and Chinese (Hosono et al., 2009), the Vietnamese and Filipino 
populations also have frequent CYP2D6 gene CNVs.  This specifically involves the 
CYP2D6(*36)n-*10 allele.  These CYP2D6 gene CNVs involving the CYP2D6(*36)n 
allele neither increases nor decreases the CYP2D6 enzyme activity.  That is, the enzyme 
activities of CYP2D6*36-*10 and CYP2D6*36-*36-*10 alleles are comparable to that of 
CYP2D6*10.  Based on tamoxifen metabolism, these CYP2D6(*36)n CNV alleles are still 
null alleles and consequently, can be considered as poor metabolizers.   
 These results suggest that multiple copies of a gene do not always translate to 
additive effects.  Even though CNVs are frequent in the human genome, the phenotypic 
consequence may depend on the sequence of the DNA that is duplicated.  In case of the 
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CYP2D6*36 allele, the gene polymorphisms, rather than the gene copy number 
variations, appear to be associated with CYP2D6 enzyme activity.  Thus, in the Asian 
populations where CNVs involving the CYP2D6*36 allele is frequent, in order to 
estimate the phenotypic consequence, it is not enough to estimate just the total number of 
copies of the CYP2D6 gene; it is necessary to identify the CYP2D6 alleles involved in 
gene multiplication.   
 There was considerable interindividual variability even after correcting for 
CYP2D6 copy number variations (Figure 3.2).  Some of the variability may be explained 
by genes that were not analyzed (eg. other genes involved in drug metabolism).  Plasma 
endoxifen concentration is dependent not only on its formation by CYP2D6 enzyme but 
also on its clearance by phase II enzymes including UDP-glucuronosyltransferase 2B7 
(UGT2B7; Blevins-Primeau et al., 2009).  Hence, it is conceivable that UGT2B7 alone or 
in combination with CYP2D6 contributes to the interindividual variability in tamoxifen 
metabolism.  A part of this interindividual variability may also be due other additional 
factors like epigenetic mechanisms; however, little is known about which factors are 
important.  Hence, the next specific aim (Chapter Four) was designed to assess the role of 
microRNAs (miRNA) in the direct and indirect regulation of CYP2D6 expression. 
 
Direct and indirect regulation of CYP2D6 by microRNAs 
In this study, the specific aim was to identify microRNAs (miRNAs) that are 
predicted to target CYP2D6.  The working hypothesis is that the variability in CYP2D6 
enzyme activity within a genotype group may be due to direct miRNA regulation of 
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CYP2D6 or indirect miRNA regulation of hepatic nuclear factor 4α (HNF4A), a 
transcriptional factor that regulates CYP2D6.   
MicroRNAs are small (18-25 nucleotides), noncoding RNAs that post-
transcriptionally regulate gene expression.  These miRNAs are predicted to regulate the 
expression of 20-90% of human transcripts (Lewis et al., 2005; Xie et al., 2005; Miranda 
et al., 2006).  In animals, miRNAs typically bind to the 3‟-untranslated region (3‟-UTR) 
of the mRNAs and negatively regulate gene expression by blocking protein translation or 
by degrading the mRNA (Olsen and Ambros, 1999; Ambros et al., 2003).  As more 
miRNAs are identified and studied, newer target sites and functions are being recognized, 
including coding region, promoter and 5‟-UTR.  
MicroRNAs are involved in the regulation of a number of genes involved in drug 
disposition - the ATP-binding cassette xenobiotic transporter (ABCG2; To et al., 2008), 
Pregnane X Receptor (PXR; Takagi et al., 2008), Cytochrome P450 1B1 (CYP1B1; 
Tsuchiya et al., 2006) and Cytochrome P450 3A4 (CYP3A4; Pan et al., 2009).  Others 
have also speculated that interindividual variability in CYP450 expression and drug 
response may be due to the action of miRNAs (Ingelman-Sundberg et al., 2007).   
 In this study, bioinformatic analyses were first performed to predict the miRNAs 
that target CYP2D6.  The results suggested that CYP2D6 is likely to be regulated by 
miRNAs (Table 4.1).  However, the results of the in vitro luciferase functional validation 
studies suggested that none of the five miRNAs tested (hsa-miR-493*, hsa-miR-137, hsa-
miR-140-3p, hsa-miR-149 and hsa-miR-323-3p) interacted with CYP2D6 3‟-UTR.  
Bioinformatic analyses of the CYP2D6 5‟-UTR and coding region using RNA22 
algorithm predicted that a number of miRNAs target these regions.  It is conceivable that 
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the miRNAs regulate CYP2D6 expression by targeting these regions.  Further in vitro 
experiments are needed to validate these predictions. 
MicroRNAs can regulate transcription factors (e.g., PXR, VDR) and thus, 
indirectly regulate the expression of CYP450 enzymes (Takagi et al., 2008; Pan et al., 
2009).  Hence, in the next step of the study, the miRNA regulation of an important 
transcriptional regulator of CYP2D6 -- HNF4A was investigated (Figure 5.4).  HNF4A is 
transcriptional „master regulator‟ that regulates the expression of a number of drug 
metabolizing genes including phase I enzymes, phase II enzymes, transporters and 
transcriptional factors that regulate the CYP450 genes (Kamiyama et al., 2007; Figure 
1.4).  Thus, regulation of HNF4A by miRNAs would likely affect many genes that are 
involved in drug disposition.   
Bioinformatic analyses were performed to predict miRNAs that target HNF4A.  
The results indicated that many miRNAs may be involved in the regulation of HNF4A 
expression (Table 4.1).  Based on these predictions, in vitro studies were performed in 
HeLa and HepG2 cell lines.  Five of the miRNAs (hsa-miR-34a, hsa-miR-34b*, hsa-miR-
34c-5p, hsa-miR-449a and hsa-miR-765) regulated the expression of pIS-HNF4A 
luciferase plasmids.  Based on the expression of these miRNAs in primary human 
hepatocytes, two of these miRNAs (hsa-miR-34a and hsa-miR-449a) were selected for 
further in vitro studies.  Both these miRNAs down-regulated HNF4A protein expression.  
HNF4A mRNA expression was not affected, suggesting that they are most likely 
regulating the HNF4A expression by blocking HNF4A protein synthesis rather than 
degrading HNF4A mRNA. 
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Figure 5.4: Schematic representation of possible indirect regulation of CYP2D6 by 
microRNAs targeting HNF4A. 
 
Note: microRNAs can regulate the expression of HNF4A.  This can in turn lead to 
indirect regulation of the expression of CYP2D6 mRNA, protein and enzyme activity. 
 
Since CYP2D6 is strongly regulated by HNF4A, the miRNAs that target HNF4A 
likely also affect its expression.  There was no observable effect of those miRNAs on 
CYP2D6, however, this was likely because CYP2D6 is expressed at basal levels in the 
HepG2 cell line and consequently, these cells are not a good model for studying the 
down-regulation of CYP2D6 expression.  In contrast, the expression level of PXR, 
another downstream target of HNF4A which is expressed highly in the HepG2 cells, was 
suppressed by the HNF4A miRNA.   
MicroRNA functions can be altered by miRSNPs that affect the miRNA binding 
to the target mRNA (Mishra et al., 2007).  These miRSNPs have been shown to alter the 
enzyme activity of dihydrofolate reductase (Mishra et al., 2007) and estrogen receptor α 
(Adams et al., 2007).  Hence, if miRSNPs are identified for HNF4A, these would serve as 
novel biomarkers of CYP2D6 activity.  These biomarkers would help predict adverse 
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drug reactions and improve drug efficacy.  The bioinformatic analyses predicted that 
miRSNPs do exist in HNF4A 3‟-UTR.  Furthermore, the luciferase activity was 
significantly higher (p < .05) in the variant (rs11574744) plasmid when compared to the 
wildtype HNF4A 3‟-UTR (Figure 4.12).  Similarly, the luciferase activity of the variant 
plasmid was significantly higher (p < .05) when either the hsa-miR-34a or the hsa-miR-
449a were also cotransfected, suggesting that the miRSNP was interfering with the 
normal mRNA-miRNA activity.  Further functional studies will be required to determine 
the phenotypic consequences of the miRSNPs.  Genetic variants in the 3‟-UTRs of drug 
metabolizing genes have not typically been given high priority in functional studies; 
however, based on these analyses, they may contribute to interindividual variability in the 
expression of the drug metabolizing enzymes.   
Recent studies have shown that other proteins involved in drug metabolism 
(Tsuchiya et al., 2006; Takagi et al., 2008; To et al., 2008; Pan et al., 2009) are subject to 
miRNA regulation.  The results of this study taken together with previous findings, 
suggest a complex regulatory mechanism for drug metabolizing enzymes by miRNAs. 
In conclusion, these findings provide the first direct evidence that HNF4A and 
consequently, its downstream targets are regulated by miRNAs.  This miRNA regulation 
of HNF4A can be important for the indirect regulation of CYP2D6.  Thus, some of the 
interindividual variability seen in CYP2D6 mRNA expression and enzyme activity may 
be due to direct or indirect regulation by miRNAs.  Since HNF4A also regulates the 
expression of a number of genes involved in drug metabolism (including phase II 
enzymes, drug transporters, transcription factors, etc.) these results have a broader 
implication.  Thus, these miRNAs and miRSNPs may be useful as additional biomarkers 
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to refine the predicted metabolic phenotype an individual.  These novel biomarkers 
would help improve the efficacy and reduce the side effects of many commonly 
prescribed drugs. 
 
Clinical significance  
 In breast cancer therapeutics, tamoxifen remains an important endocrine agent.  
Especially in many developing countries, including Vietnam and the Philippines, 
tamoxifen is preferred over aromatase inhibitors (AI) because of its low cost.  Hence, it 
becomes important to understand the factors that lead to interindividual variability in 
tamoxifen response.  A better understanding of this variability would help to improve the 
effectiveness and compliance of this life saving drug.   
 In both Vietnamese and Filipino populations, the most frequent (>50%) CYP2D6 
allele is the reduced functional allele, CYP2D6*10.  The polymorphisms that lead to 
reduced enzyme activity interfere with the metabolism of tamoxifen into endoxifen.  
Thus, in Vietnamese and Filipino women, CYP2D6 genotyping may be useful in 
predicting the efficacy of tamoxifen therapy: that is, homozygous carriers of the 
CYP2D6*10 allele may derive reduced benefit from tamoxifen therapy.  Prospective 
genotyping for CYP2D6 variants may help identify a group of women who may 
experience greater benefit from tamoxifen therapy and a group that should consider 
alternatives to tamoxifen therapy.  Furthermore, as CYP2D6 inhibiting drugs create a 
phenocopy of the CYP2D6 poor metabolizer phenotypes, they also would likely reduce 
endoxifen concentration and increase breast cancer recurrence in these women.  Although 
the final conclusions will depend on the prospective outcome studies, based on the 
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current results, it would be prudent for these women avoid any CYP2D6 inhibitors.  
Clinical recommendations on CYP2D6 genotype guided tamoxifen therapy await results 
from prospective clinical trials that show a direct correlation between endoxifen 
concentration and clinical outcomes; direct association between endoxifen concentration 
and clinical outcome has not been demonstrated yet. 
 These results presented here indicate the importance of conducting a prospective 
clinical trial to understand the association between endoxifen concentration and clinical 
outcome.  The ongoing clinical trial in Vietnam and the Philippines will be able to bridge 
the gap.  The prospective collection of both endoxifen concentrations and the recurrence 
outcomes in this study will for the first time, provide a direct assessment of the 
association of endoxifen with breast cancer recurrence outcomes.  The results from this 
study will likely help guide the personalization of tamoxifen therapy by adjusting doses 
or choosing other endocrine therapies  
 Like the CYP2D6 gene variants, CYP2D6 gene CNVs can also affect CYP2D6 
enzyme activity and consequently, alter drug metabolism and response.  The phenotypic 
consequence of CNVs will depend on the CYP2D6 allele involved in duplication.  In the 
Vietnamese and Filipino populations, CYP2D6 gene multiplications are frequent (>50%).  
Based on tamoxifen metabolism, the CNV alleles [CYP2D6(*36)n] are poor metabolizer 
(null) alleles, suggesting that increased copy numbers of a gene does not always result in 
a corresponding increase in the phenotype.  Thus, in the Vietnamese and Filipino 
populations, it is necessary to identify the CYP2D6 alleles involved in the CNV; simply 
estimating the total number of copies of the CYP2D6 gene without identifying the 
CYP2D6 alleles cannot reliably be used to estimate the phenotype of an individual. 
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There is interindividual variability in endoxifen concentration even after 
correcting for both CYP2D6 polymorphisms and CNVs.  Other factors like microRNAs 
may explain a part of this variability.  The results of this study suggest that miRNAs are 
likely to play an important role in the indirect regulation of CYP2D6 through the 
regulation of its transcriptional factor, HNF4A.  These endogenous hepatic miRNAs that 
regulate CYP2D6 directly or indirectly will help to understand the interindividual 
variability in therapeutic efficacy and toxicity.  Furthermore, polymorphisms that alter 
the mRNA-miRNA interactions can be used as biomarkers for guiding the clinically use 
of CYP2D6 substrate drugs.  Ultimately, these novel biomarkers will help improve the 
efficacy and reduce the side effects of commonly prescribed drugs.   
 
Future directions 
 Based on the results presented in this thesis, in the future, it would be valuable to 
further evaluate the following: 
(1) To determine the association between CYP2D6*10 and clinical outcome in the 
Vietnamese and Filipino populations.  The CYP2D6*10 allele is a very common allele in 
the Asians (40-60% frequency) and thus perhaps the most common CYP2D6 variant 
allele in the world.  Hence, demonstrating a clinically relevant relationship between 
CYP2D6*10 allele and clinical outcome will help to explore alternative therapies in the 
Vietnamese and Filipino patients with poorer outcomes.  These may include tamoxifen 
dose changes, exploration of use of alternative SERMs, and the use of AIs.   
(2) To determine the association between endoxifen concentrations and clinical outcome.  
A direct association between endoxifen concentration and clinical outcome has not been 
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studied yet.  In the future, this ongoing clinical trial in Vietnam and the Philippines will 
be able to bridge the gap by studying the association between these two factors.  
Demonstrating a clinically relevant relationship between endoxifen concentration and 
clinical outcome will help to personalize the tamoxifen therapy in the Vietnamese and 
Filipino patients with poorer outcomes.   
(3) To evaluate the CYP2D6*36 structure.  The CYP2D6*36 null allele is present in 
CNVs at a frequency of 30-50% in Japanese, Chinese, Filipino and Vietnamese 
populations, suggesting that this may be due to a „founder effect‟.  The CYP2D6*36 
allele should be sequenced to identify the specific break points that create the fusion 
allele in these populations.  This will be useful to understand the origin of these complex 
CYP2D6 CNVs and the mechanism of gene duplications.   
(4) To determine the association between HNF4A miRNA regulation and CYP2D6 
expression.  The results of the current study indicate that miRNAs regulate HNF4A in 
vitro.  Further in vitro and in vivo studies (e.g., nuclear run-on assays, enzyme activity 
measurement) should be performed to understand the functional significance of these 
miRNAs on the expression and activity of CYP2D6.  Also, the effect of the HNF4A 3‟-
UTR miRSNP on the CYP2D6 enzyme activity needs to be investigated.  Identification 
of miRNAs and miRSNPs that regulate CYP2D6 will help to explain some of the 
interindividual variability that is not explained by drug-drug interactions and gene 
polymorphisms. 
(5) To determine if the miRNAs regulate CYP2D6 expression by targeting the 5’-UTR or 
coding region.  The results of the bioinformatic analyses using RNA22 algorithm indicate 
that both 5‟-UTR and coding regions are a target of miRNAs.  Further laboratory 
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experiments (e.g., luciferase assays, mRNA and protein expression, enzyme activity 
measurements) are needed to validate these predictions.  Identification of such 
endogenous hepatic miRNAs that target regions other than the 3‟-UTR will explain the 
differential expression of CYP2D6 mRNA transcripts in the human liver. 
(6) To identify the microRNAs that are expressed differentially between fetal and adult 
livers.  A number of CYP450 proteins, including CYP2D6 are only expressed 
postnatally.  Hence, it is possible that post-transcriptional mechanisms like miRNAs may 
be developmentally regulating the expression of these CYP450s.  Hence, miRNAs that 
are differentially expressed between the fetal and adult livers need to be identified by 
using methods like quantitative PCR, deep resequencing, and microarrays.  Once the 
differentially expressed miRNAs are identified, the effect of these miRNAs on CYP450 
expression can be evaluated by both in vitro and in vivo experiments (e.g., luciferase 
assays, mRNA expression, western blot, and enzyme activity measurements).  These 
experiments will help to understand the developmental changes seen in CYP2D6 
expression and activity.  These results will also likely reveal miRNAs that are important 
in regulating CYP2D6 activity in adults. 
 
Summary 
Interindividual variability in drug metabolism remains a significant contributor to 
differences in drug efficacy and toxicity.  Some of this variability is due to known genetic 
variations and environmental factors that inhibit the enzymes or alter their expression 
levels.  The studies presented here emphasize on the role of CYP2D6 gene 
polymorphisms and copy number variations in the regulation of CYP2D6 enzyme 
activity and consequently, metabolism of tamoxifen in breast cancer patients.  
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Furthermore, in addition to the genetic factors, these results also show that miRNAs are 
involved in regulating HNF4A, a transcriptional regulator of CYP2D6.  Ultimately, all 
these three factors can contribute to the interindividual variability in CYP2D6 mediated 
drug metabolism and response (Figure 5.5).   
 
Figure 5.5: Genetic and epigenetic factors regulate the expression and activity of 
CYP2D6. 
 
Note: Cis-acting genetic (polymorphisms and copy number variations) and trans-acting 
epigenetic factors epigenetic (microRNA) factors regulate the expression of CYP2D6 
mRNA, protein and consequently interindividual variability in CYP2D6 enzyme activity, 
drug metabolism and response.  
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